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Abstract 
The discrepancy between HbA1c and fructosamine estimations in the assessment of 
glycaemia has frequently been observed and is referred to as the glycation gap (G-
gap). This could be explained by the higher activity of the fructosamine-3-kinase 
(FN3K) deglycating enzyme in the negative G-gap group (patients with lower than 
predicted HbA1c for their mean glycaemia) as compared to the positive G-gap group. 
This G-gap is linked with differences in complications in patients with diabetes and 
this potentially happens because of dissimilarities in deglycation. The difference in 
deglycation rate in turn leads to altered production of advanced glycation end 
products (AGEs). These AGEs are both receptor dependent and receptor 
independent. It was hypothesised that variations in the level of the deglycating 
enzyme fructosamine-3-kinase (FN3K) might be as a result of known Single 
Nucleotide Polymorphisms (SNPs): rs1056534, rs3848403 and rs1046896 in FN3K 
gene, SNP in ferroportin1/SLC40A1 gene (rs11568350 linked with FN3K activity), 
differentially expressed genes (DEGs), differentially expressed transcripts or 
alternatively spliced transcript variants. Previous studies reported accelerated 
telomere length shortening in patients with diabetes.  
 
In this study, 184 patients with diabetes were included as dichotomised groups with 
either a strongly negative or positive G-gap. This study was conducted to analyse 
the differences in genotype frequency of specific SNPs via real time 
qPCR,determine soluble receptors for AGE (sRAGE) concentration via ELISA, 
finding association of sRAGE concentration with SNPs genotype, and evaluate 
relative average telomere length ratio via real time qPCR. This study also aimed at 
the investigation of underlying mechanisms of G-gap via transcriptome study for the 
identification of the DEGs and differentially expressed transcripts and to 
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consequently identify pathways, biological processes and diseases linked to 
situations in which DEGs were enriched. The relative length of the telomere was 
normalised to the expression of a single copy gene (S). Chi-squared test was used 
for estimating the expected genotype frequencies in diabetic patients with negative 
and positive G-gap.  
 
Genotype frequencies of FN3K SNPs (rs1056534, rs3848403 and rs1046896) and 
SLC40A1/ferroportin1 SNP (rs11568350) polymorphisms within the studied groups 
were non-significant. With respect to genotypes, the rs1046896 genotype (CT) and 
rs11568350 genotype (AC) were only found in heterozygous state in all the 
investigated cohorts. No association between sRAGE concentration and FN3K 
SNPs (rs3848403 and rs1056534) was observed as the sRAGE concentration was 
also found not to be different between the groups. Similarly, the relative average 
telomere length was not different in both groups. Plasma sRAGE levels were not 
different in the cohort studied even though the Wolverhampton Diabetes Research 
Group (WDRG) previously reported that AGE is higher in positive G-gap. The latter 
is a more likely consequence of lower FN3K activities. In this study, it was found 
that SNPs in the FN3K/ferroportin1 gene are not responsible for the discrepancy in 
average glycaemia. The transcriptomic study via RNA-Seq mapped a total of 64451 
gene transcripts to the human transcriptome. The DEGs and differentially expressed 
transcripts were 103 and 342 respectively (p < 0.05, fold change > 1.5). Of 103 
DEGs, 61 were downregulated in G-gap positive and 42 were upregulated in 
positive G-gap individuals while 14 genes produced alternatively spliced transcript 
variants. Four pathways (Viral carcinogenesis, Ribosome, Phagosome and Dorso-
ventral axis) were identified in the bioinformatics analysis of samples in which DEGs 
were enriched. These DEGs were also found to be associated with raised blood 
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pressure and glycated haemoglobin (conditions that coexist with diabetes). Future 
analysis based on these results will be necessary to elucidate the significant drivers 
of gene expression leading to the G-gap in these patients.  
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1.1 Diabetes mellitus  
Diabetes mellitus is a group of metabolic disorders resulting in increased blood 
glucose level over a prolonged period because of defects in insulin secretion, insulin 
action, or both. Higher morbidity and mortality risk are present in diabetic individuals 
suffering from diabetes as compare to the general population. International Diabetes 
Federation study found that the number of adults with diabetes will be expected to 
rise from 415 million in 2015 to a projected 642 million by 2040 (Ogurtsova et al., 
2017).  
 
In developed countries, diabetes mellitus is more common and is, associated with 
increase in obesity and changes in the lifestyle. Two broad categories of diabetes 
are: type 1 diabetes (T1DM), also known as insulin-dependent diabetes or juvenile-
onset diabetes) which constitutes only 5-10% of diabetes cases (American Diabetes 
Association, 2014 and Atkinson and Eisenbarth, 2014) and type 2 diabetes (T2DM) 
which is more prevalent and accounts for 90-95% of diabetes cases worldwide (Wild 
et al., 2004). Insulin secretion stops in T1DM which leads to hyperglycaemia. This 
is a result of autoimmune destruction of the insulin-producing β-cells leading to an 
absolute insulin deficiency in the system (American Diabetes Association, 2014). 
Hereditary characteristics and the impact of environmental factors on the 
autoimmune destruction of pancreatic β-cells have been implicated in changes 
leading to the onset of the disease (Soleimanpour and Stoffers, 2013). Islet cell 
antibodies (ICA) and ketoacidosis are apparent in T1DM. Islet cell auto-antibodies 
(antibodies produced against proteins of islet cell cytoplasm), insulin auto-
antibodies, GAD65, and tyrosine phosphatases IA-2 and IA-2b are markers of 
immune destruction (Wesche et al., 2001). T1DM can be diagnosed with a 
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decreased level of circulating C-peptide with reasonable accuracy (American 
Diabetes Association, 2014 and Arvan et al., 2012).  
 
On the contrary, insulin resistance and inadequate insulin secretory response 
appear in T2DM, leading to raised circulating glucose levels (American Diabetes 
Association, 2014). Specific aetiologies of T2DM are not known but islet cell 
antibodies are absent in individuals with T2DM (Thomas and Philipson, 2015). 
Glucose provides carbon atoms for biosynthesis and fuel for the provision of energy 
in living organisms. However, long-term exposure to increased glucose 
concentrations can produce damaging effects. Type 2 diabetes for many years may 
remain undetected. During this period when patients show no appearance of 
symptoms, it is sufficient to cause pathological changes (American Diabetes 
Association, 2014). 
 
1.2. The economic impact of diabetes 
In the UK, diabetes is one of the chronic illnesses that has a significant economic 
impact.  There is not only direct cost associated with the treatment of illness and its 
associated complications, but indirect social and productivity costs involved with 
diabetes. Hex et al. (2012) reported that the total overall cost of diabetes was £23.7 
billion in 2010-2011. The direct cost was £9.8 billion, of which £1 billion was for Type 
1 and the remaining £8.8 billion for Type 2 diabetes. The indirect cost was £13.9 
billion, of which £0.9 billion was for T1D and the remaining £13.0 billion was for T2D. 
Hex et al. (2012) estimated that the cost is expected to rise to £39.8 billion by 2035-
2036 for this disease. Comprising direct cost of £16.9 billion: of this £1.8 billion will 
be for Type 1 and the remaining £15.1 billion will be for Type 2 diabetes. Whilst the 
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£22.9 billion will be indirect cost: of this £2.4 billion will be for T1D and the remaining 
£20.5 billion will be for T2D. 
 
1.3. Diagnostic criteria for diabetes 
After several years of debate and modification, the diagnostic criteria for diabetes 
and pre-diabetes (intermediate hyperglycaemia such as impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT)) was set. The cut-off level for fasting 
glucose was 7.0 mmol/l (Kumar et al., 2016 and World Health Organization, 2006) 
and the threshold for IFG was changed from 6.1 to 5.6 mmol/l by the American 
Diabetes Association (ADA) (Expert Committee on the Diagnosis and Classification 
of Diabetes Mellitus, 2003). In addition, for the diagnosis of diabetes and to identify 
the increased risk for future diabetes, ADA introduced the use of glycated 
haemoglobin (HbA1c) (American Diabetes Association, 2010) with a diagnostic cut-
off point ≥ 6.5% (48mmol/mol) for diabetes (Farmer, 2012). HbA1c levels are thought 
to better predict the development of long-term complications in type 1 and type 2 
diabetes. 
 
1.4. Glycation of protein/Maillard reaction  
Glucose or other reducing sugars react with proteins and this process is called 
glycation of proteins. Protein glycation/Maillard reaction provides an association 
between chronic hyperglycaemia and a series of pathophysiological alterations that 
are critical in the development of the chronic complications of diabetes (Fournet, 
Bonte and Desmouliere, 2018). Enhanced development of dicarbonyl species (such 
as glyoxal, methylglyoxal, and 3-deoxyglucosone) leads to the production of AGEs 
during protein glycation. During hyperglycemia and oxidative stress, the carbonyl 
group of glucose non-enzymatically react with amino groups of proteins leading to 
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the formation of a Schiff base. This thermodynamically unstable base after 
rearrangement converts into a stable ketoamine, the Amadori product. During the 
intermediate stage of the Maillard reaction oxidation, fragmentation and dehydration 
reactions occur that result in the degradation of the Amadori product into more 
reactive carbonyl species than the sugars from which they are derived (Amore et 
al., 2004). The carbonyl species are formed not only through the non-oxidative 
rearrangement and hydrolysis of the Amadori product, but also through the fructose-
3-phosphate which is an intermediate of the polyol pathway.  
 
Auto-oxidation of carbohydrates, decomposition of triose phosphates and lipid 
peroxidation result in methylglyoxal production, whilst glyoxal formation occurs via 
fructose-phosphate fragmentation, lipid peroxidation and oxidative fragmentation of 
the Schiff base. In addition, these carbonyl compounds can also be formed by 
glucose degradation in vitro (Thornalley, Langborg and Minhas,1999). 
Methylglyoxal is a very reactive alpha-oxoaldehyde (Nemet, Varga and Turk, 2006). 
Oxidation, dehydration, fragmentation and cyclisation reactions take place in the 
late stage of the Maillard reaction and carbonyl species react with free amino groups 
of proteins very rapidly and form insoluble, irreversible compounds, usually called 
Advanced Glycation End-Products (AGEs) (Figure 1.1).  
25 
 
 
 
Figure 1. 1 Three stages of non-enzymatic glycation reaction/Maillard 
reaction. (Adapted and modified from Lapolla, Trald and Fedele, 2005). 
 
1.4.1. Glycation of haemoglobin 
The non-enzymatic reaction between glucose and amino groups in lysine and 
arginine residues or in the amino-terminal position leads to the glycation of proteins. 
A minor fraction of adult haemoglobin (HbA1c) is glycated slowly. Erythrocytes are 
considered to be freely permeable to glucose because of the presence of glucose 
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transporter protein 1 (GLUT1) (Hajjawi, 2013). The non-enzymatic glycation 
reaction takes place within erythrocytes over the average life of red blood cells. The 
lifespan of red blood cells is approximately 120 days. During non-enzymatic 
glycation glucose covalently binds to the haemoglobin molecule (Goldstein et al., 
2004). This is denoted as HbA1c and its rate of formation is directly proportional to 
the glucose concentration inside the cell. Following the formation of Schiff base and 
ketoamine, this glycation adduct produces advanced glycation end products (AGEs) 
(Boteva and Mironova, 2019) which are associated with diabetic complications. This 
provides a link between the deleterious effects of chronic hyperglycaemia and 
several complications (Stitt, Jenkins and Cooper, 2002 & Cohen et al., 1999). 
Glycation of proteins is an important process in terms of biomarkers for the 
diagnosis of diabetes. The estimation of glycated haemoglobin or other glycated 
blood proteins (indicators of average glycaemia) helps in monitoring the efficacy of 
diabetes treatment. The American Diabetes Association recommended the use of 
glycated haemoglobin in the diagnosis of diabetes because of the established 
association between glycated haemoglobin and microvascular disease (American 
Diabetes Association, 2010). 
 
Various molecular species of haemoglobin are present in human blood arising from 
the many potential glycation sites on haemoglobin which indicates that glycated 
haemoglobin is not a single molecular entity. Glycation of α- and β-chains in various 
species of HbA are collectively called the glycohaemoglobins (GHb). Total GHb 
includes all glycated subfractions of haemoglobin. Glycation reaction of 
haemoglobin takes place not only at the valine residues of N-terminal beta chain but 
this also occurs non-specifically at the epsilon amino groups on lysine residues 
along the alpha and beta chains and at the N-terminal valine of the alpha chains 
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(Little and Rohlfing, 2013). Consideration of all glycation sites makes total GHb 
value approximately 50% higher as compared to HbA1c alone. HbA1c makes about 
5% of the total haemoglobin in normoglycaemic subjects. HbA0, HbA2, HbF are 
different molecular forms of human haemoglobin. Haemoglobin variants and “minor 
components” HbA1a, HbA1b, and HbA1c in human blood were detected based on 
their elution from chromatography column (Makris and Spanou, 2011 & Weykamp, 
John and Mosca, 2009). HbA1c was used for estimating the risk of diabetes 
complications after the publication of Diabetes Control and Complications Trial 
(DCCT) results and the prospective diabetes study performed inside the UK 
(Kilpatrick, Rigby and Atkin, 2008) as well as International Committee and the ADA 
also recommended HbA1c as a diagnostic test for diabetes (International Expert 
Committee, 2009).  
 
1.4.2. Glycation gap and consistency of the glycation gap in diabetes 
Blood proteins are glycated in diabetes and in non-diabetes states. Protein glycation 
is important with respect to diabetes because the rate of reaction (covalent binding 
of glucose with protein) is slow. Moreover, and the level of protein glycation is 
directly proportional to glucose concentration (Ott et al., 2014 & Magalhaes, Appell, 
and Duarte, 2008). Protein glycation is an integrated measure of the blood glucose 
concentration over time. These are represented by the levels of glycated 
haemoglobin and serum fructosamines (glycated albumin) and they are commonly 
assayed to assess the efficacy of treatment (Vos, Schollum, and Walker, 2011 & 
Smaldone, 2008). Secondly, fructosamines may go through further spontaneous 
reactions, producing AGEs (advanced glycation end products). Both fructosamines 
and AGEs are thought to be involved in the development of diabetic complications 
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because they cross link with collagen and reduce vessel elasticity (Singh et al., 
2014). Vascular stiffness leads to vascular comlications. 
 
Fructosamine, a ketoamine, is a product of non-enzymatic mechanism in blood 
plasma derived from glycation between a sugar molecule and a protein (usually 
albumin). This process involves the labile Schiff base intermediate and the Amadori 
rearrangement. Different kinetics of interaction of glucose with valine of 
haemoglobin versus lysine of fructosamine are observed in research studies. 
 
In diabetic patients, the differences in HbA1c contrasted with fructosamine were 
compared by Cohen et al. (2003). The possible causes for such discrepancy have 
been described, and various erythrocytic factors may affect HbA1c independently of 
glycaemia (Beltran et al., 2016 & Jeffcoate, 2004 & Hare, Shaw and Zimmet, 2012). 
These include impacts on red cell life expectancy and glucose concentration across 
the red cell membrane (Cohen et al.,2008 and Khera et al., 2008).  
 
The glycation gap (G-gap), which is a variation between the actual HbA1c 
concentration and that predicted by the fructosamine concentration, could provide 
an explanation of inter-individual differences in HbA1c levels (Cohen et al., 2006). 
Within the intra-erythrocyte space, glycaemic control is measured by the 
haemoglobin A1C (HbA1c) level whereas serum proteins are glycated in the 
extracellular compartment. Thus, the G-gap might be linked with the complications 
associated with intracellular glucose metabolism. This might alter an individual's risk 
of vascular complications for any given level of long-term glycaemia by modification 
in one of the key pathological processes.  These included protein glycations and the 
formation of advanced glycation end products (Cohen et al., 2003, McCarter et al., 
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2004 & Gkogkolou, and Bohm, 2012 & and Goh & Cooper, 2008). The co-use of 
glycated haemoglobin and serum fructosamine is recommended as glycated HbA1c 
alone may not be suitable for calculating prevailing glycaemia because of the factors 
described above (life expectancy of red cell and glucose gradient). In a similar way 
serum fructosamine may itself be affected by variability in protein turnover and 
serum albumin concentration (Speeckaert et al., 2014 & Duran et al., 2015). This 
highlights the importance of determining the G-gap in any individual. The above-
mentioned factors affecting HbA1c and serum fructosamine might have an overall 
impact on G-gap but Nayak et al. (2011) provided evidence for the consistent G-gap 
in patients with diabetes. This suggested that there is a consistent underlying 
mechanism that could be a genetic or biochemical process. Other studies also 
demonstrated such consistency in people with diabetes.  
 
Considerable discrepancy in HbA1c levels between-individual diabetic patients 
despite similar preceding levels of mean blood glucose was observed (Monnier, 
Lapinski and Colette, 2003). This variation is not random, as evidence has been 
provided by several investigators for between-individual biological variation in HbA1c 
levels from populations of patients with diabetes (Hempe et al., 2002; Hudson et al., 
1999; Madsen, Kjasrgaard and Ditzel, 1982). Hempe et al. (2002) used the 
Haemoglobin Glycation Index (HGI) for measuring HbA1c variation between 
individuals with respect to mean blood glucose. HGI enabled the quantification of 
predictable and patterned differences in glycation level of an individual's intracellular 
haemoglobin relative to the rest of the population in response to a given level of 
MBG. However, the use of fructosamine instead of MBG for the comparison of the 
differences of HbA1c in diabetic patients leads to the computation of glycation gap 
(G- gap) (Cohen et al., 2003). Individuals show consistency in G-gap and HGI over 
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time that represents a constant underlying mechanism for variation in intracellular 
glycation compared to extracellular glycation or glycaemia that is estimated by 
serum fructosamine or MBG (Nayak et al., 2011, Cohen et al., 2003 and Hempe et 
al., 2002). 
 
Haemoglobin glycation index (HGI) and G-gap may be important in any individual 
as identification of the G-gap might direct safer therapeutics. HGI and G-gap are 
two indices of between-individual differences in glycated haemoglobin (HbA1c), 
adjusted for glycaemia that are based on a mean blood glucose level (MBG) and 
fructosamine measurement respectively.  
 
1.4.2.1. Mechanisms of glycation gap (G-gap)  
As described in the previous section (1.1.2 paragraph 3), glycated HbA1c 
concentration is affected by various factors. Haemolysis, sickle cell disease, 
transfusion, cystic fibrosis, iron deficiency (anaemia) are potential underlying 
mechanisms that affect the erythrocytes lifespan independent of glycaemia. 
Therefore, HbA1c can underestimate average glucose levels in some patients. 
Individuals may have a lower or higher HbA1c concentration than predicted from 
prevalent glycaemia (Macdonald et al., 2008, Hempe et al., 2002, Chan et al., 2018 
& Wei, Zheng, and Nathan, 2014). Dunmore et al. (2018) excluded mechanisms 
above which do not adequately account for the G-gap in many cases and focused 
on the factor of deglycation. Oxidases, isomerases, and kinases are three different 
types of enzymes involved in the metabolism of ketoamines (Wiame et al., 2002; 
Monnier and Wu, 2003). However, protein deglycation under physiological 
conditions is carried out by only the kinases. Fructosamine-3-kinase (FN3K) 
(Szwergold, Howell and Beisswenger, 2001 and Van Schaftingen et al., 2012) is 
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found to be involved in the deglycation pathway. Deglycation is suggested to be 
responsible for the systematic variation of the glycation phenotype within the human 
population with diabetes measured using the G-gap as a metric. Therefore, the 
determination of G-gap is important in an individual with diabetes.  
 
1.4.2.2. Clinical importance of G-gap 
There are potential limitations of the use of HbA1c in the monitoring of glycaemic 
control. There are different factors amongst others that affecting HbA1c level. 
Haemolytic anaemia and chronic kidney disease decrease the HbA1c level whilst 
splenectomy and reticulocytes increase the HbA1c level (Sodi et al., 2018). These 
and previously described factors are the reasons for potentially discrepant HbA1c 
values when compared with other measures of average glycaemia including plasma 
fructosamine or glycated albumin. Glycation gap is a biochemical phenomenon 
affecting glycation independent of the factors described above (Dunmore et al., 
2018). The misclassification of glycaemic control based on HbA1c alone (standard 
classifications of diabetes) could be avoided by considering another measure of 
glycaemic control, such as fructosamine alongside HbA1c. In addition, continuous 
glucose measurement or glycated albumin should at least be used alongside HbA1c 
in both diagnosis and monitoring treatment of diabetes. Different lifespans of 
haemoglobin and albumin do not affect the glycation gap. Individuals diagnosed with 
diabetes show fairly constant mean blood glucose (MBG) even if fluctuating over 
short periods, so fructosamine and HbA1c should give similar estimates of MBG if 
there is no G-gap (Nayak et al., 2011). 
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1.5. Fructosamine 3-kinase (FN3K)   
 
1.5.1. Properties 
FN3K is expressed at higher levels in the kidneys, heart, nervous tissue and 
erythrocytes (Mohas et al., 2010). This 35 kDa protein encoded by the FN3K gene 
which is located on chromosome 17q25.3 and ordered in six exons (Monnier, 2006). 
FN3K gene may have emerged during the duplication process of the gene, FN3K-
related protein (FN3K-RP), as the gene encoding FN3K-RP, is located proximal to 
the gene encoding FN3K and has 65% sequence homology with FN3K and an 
identical genome organisation (Collard et al., 2003 and Delplanque et al., 2004). 
FN3K and FN3K-RP both have 6 exons where starting ATG codon is present in 
exon 1 and a termination codon is present in exon 6. They have intron-exon 
junctions in homologous position and lack TATA or CCAAT sequence but with high 
GC content in promoter. Their promoter sequences are similar to the housekeeping 
genes which indicate that they are likely to be expressed in various tissues (Conner, 
Beisswenger and Szwergold, 2005). The level of expression of FN3K in different 
tissues remains unchanged regardless of starvation and diabetes. No regulation of 
FN3K expression in human fibroblasts treated with the similar condition as in the 
diabetic state. This provides the stronger evidence that FN3K is a housekeeping 
gene (Conner, Beisswenger and Szwergold, 2005). Both FN3K and FN3K-RP 
catalyse the phosphorylation of psicosamines and ribulosamines. However, only 
FN3K acts on fructosamines (Collard et al., 2003) and deglycates proteins under 
physiological conditions. FN3K is more active in those tissues that contain proteins 
with long half-lives, such as erythrocytes (Collard et al., 2003). It was discovered 
initially with the identification of F3P (fructose 3-phosphate) in human and animal 
tissues (Szwergold et al., 2007), where 3-phosphokinase enzyme phosphorylates 
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fructose into fructose-3-phosphate (F3P) in the lens and erythrocyte, leading to the 
development of 3-deoxyglucosone (Lal et al., 2005) in diabetes.   
 
FN3K is important in cellular defence and/or repair system where it deglycates 
proteins including HbA1c by a catalytic pathway (Szwergold, Howell and 
Beisswenger, 2001; Van Schaftingen et al., 2012). This involves ketoamines 
removal and prevention of AGE production. In addition to fructosamines, this 
enzyme also phosphorylates C3-epimers psicosamines, as well as ribulosamines 
and erythrulosamines. However, FN3K has a much lower affinity for psicosamines 
than the other ketoamines (Szwergold, Howell and Beisswenger, 2001). 
 
1.5.2. FN3K involvement in deglycation 
Delpierre et al. (2000) discovered, cloned and characterised FN3K enzyme in 
erythrocytes based on earlier NMR studies. They found that this enzyme deglycates 
both small molecular weight products as well as protein bound fructosamines. 
Erythrocytes of FN3K-knock out mouse were incubated with 200 mmol/L glucose 
leading to the increased formation of glycated haemoglobin alongside an increased 
level of inorganic phosphate. However, when this experiment was repeated with 
FN3K competitive inhibitor deoxymorpholinofructose (DMF), the concentration of 
DMF increased about two-fold the rate of accumulation of glycated haemoglobin 
with the decreased concentration of inorganic phosphate. This indicated the 
involvement of FN3K in deglycation (Delpierre et al., 2002).  
 
FN3K is involved in the deglycation of glycated haemoglobin in erythrocytes as well 
as other glycated proteins that are present in other tissues. The difference in FN3K 
activity could result in an apparent difference in glycated haemoglobin levels. In 
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some individuals FN3K activity is high: then carry out deglycation at a higher rate 
and this results in a lower level of glycation, whilst those with low FN3K activity have 
a low rate of deglycation and results in high level of glycation (Mohas et al., 2010).  
The FN3K enzyme is involved in the control of intrinsic toxicity of glucose due to 
intracellular non-enzymatic glycation, this is a complex process that involves many 
stages as it proceeds and leads to the formation of irreversible end products known 
as advanced glycation end products (AGEs) (Figure 1.1).  
 
The FN3K enzyme catalyses the phosphorylation of fructosamines with high affinity 
and leads to the development of F3P (fructosamine-3-phosphate) at the expense of 
ATP (Szwergold and Beisswenger, 2003). This phosphorylation destabilises the 
fructosamine linkage, which causes the breakdown of F3P (fructosamine-3-
phosphate) to lysine, 3-deoxyglucosone, and inorganic phosphate (Conner, 
Beisswenger and Szwergold, 2004), thereby reversing the non- enzymatic glycation 
process at an early stage (Figure 1.2). The reduction or oxidation of 3-
deoxyglucosone to 3-deoxyfructose (Sakiyama et al., 2006) or 2-keto-3-
deoxygluconic acid respectively neutralises its potential toxic effects (Ruckriemen 
et al., 2018). The discovery of the FN3K deglycating enzyme increased the 
understanding of cellular metabolism and its role in protein deglycation in the 
aetiology of diabetes. 
 
Research study demonstrated the phosphorylation of glycated haemoglobin by 
FN3K in intact cells to prove partial deglycation. The aim was the identification of 
fructosamines removal from haemoglobin in intact erythrocytes by action of the 
FN3K (Delpierrre et al., 2004). Study indicated that lysines bound fructosamines are 
relevant substrates for FN3K in addition to other low-molecular-mass glycated 
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substrates due to the high affinity of FN3K for FL (Fructoslysine, Amadori product) 
that was detected in vivo (Avemaria et al., 2015). Krause et al. (2006) used reverse-
phase high-performance liquid chromatography (RP-HPLC) to estimate FN3K 
activity within human erythrocytes. Krause et al. (2006) used erythrocyte lysate and 
measured the product Nα hippuryl-Nε-(phosphofructosyl) lysine (BzGpFruK) that 
was formed by the transformation of the synthetic substrate Nα-hippuryl-Nε-(1-
deoxy-D-fructosyl) lysine (BzGFruK) by FN3K. FN3K is constitutively expressed in 
human cells, previous studies found a correlation between FN3K activity and the 
levels of HbA1c in patients with diabetes (Delpierre et al., 2002) where certain single 
nucleotide polymorphisms were found in FN3K gene. FN3K`s involvement in 
deglycation of intracellular proteins such as haemoglobin may provide a logical 
reason behind the variation in the glycation (measured as G-gap) because 
haemoglobin is intracellular as is FN3K which therefore does not affect fructosamine 
(albumin) that reflects extracellular circulating protein. The International Federation 
of Clinical Chemistry working group (IFCC) defined haemoglobin A1c (HbA1c) as 
haemoglobin that undergoes irreversible glycation at one or both N-terminal valines 
of the beta chains (Nasir, Thevarajah and Yean, 2010) as well as epsilon amino 
group of lysine residue on both α and β chains and form fructosylvaline and 
fructosylysine respectively. Fructosvaline is a low-affinity substrate for FN3K as 
compare to fructoslysine that is an excellent substrate. 
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Figure 1. 2 FN3K role as a catalyst in deglycation of Fructosyl amino-acid 
Fructoselysine-3-phosphate (FL3P) is the unstable product formed from the 
phosphorylation of fructose-lysine. This phosphorylation destabilises fructose-lysine 
linkage and FL3P breaks down to unmodified lysine by β-elimination with the 
accompanied formation of inorganic phosphate (Pi) and 3-deoxyglucosone (3DG) 
(Szwergold et al., 2001). 
 
 
1.5.3. Genetic variants of FN3K 
The consistent FN3K activity in human erythrocytes within an individual is highly 
variable between individuals regardless of the blood glucose levels or the type of 
diabetes (Delpierre et al., 2006). Previous study demonstrated the contribution of 
the FN3K enzyme in the development of diabetic complications by the comparison 
of the patients with complications with low and high FN3K activities (Delpierre et al., 
2006). Dunmore et al. (2018) reported a remarkable difference in the activity 
between individuals despite similar blood glucose levels after the application of 
HPLC method (Krause et al., 2006) and introduced the term high deglycator group 
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(with high FN3K activity) and low deglycator group (with low FN3K activity). An 
alternative approach to understanding the possible role of FN3K in diabetic 
complications would be to analyse the presence of different SNPs in the FN3K gene 
that previously linked to FN3K enzymatic activity and HbA1c level.  
 
Genome-wide association studies (GWAS) of glucose and Insulin have identified 
variants at various genomic loci that affected HbA1c through glycaemic, non-
glycaemic (erythrocytic) and unclassified pathways. Glycaemic pathways involve 
factors that affect the blood glucose level whilst non-glycaemic, i.e. erythrocytic 
pathways include factors that affect the red blood cell (Leong and Wheeler, 2018). 
The FN3K locus identified through GWAS is an example of unclassified variants that 
affect the HbA1c through the unclassified pathway (neither glycaemic nor 
erythrocytic) e.g. deglycation of glycated proteins (Wheeler et al., 2017). These 
unclassified genetic variants might act through mechanisms that are neither initiated 
through between-person variation in erythrocytes lifespan, erythrocyte biology or 
glycaemia. 
 
In diabetic humans, certain single nucleotide polymorphisms (SNPs) of the FN3K 
gene i.e. C/G (rs1056534) alter its activity (Avemaria et al., 2015), C/G (rs1056534) 
influence sRAGE and glycated haemoglobin levels (Škrha et al., 2014 and Mohás 
et al., 2010), C/T (rs1046896) responsible for variability in glycated haemoglobin 
level (Soranzo et al., 2010), and C/T (rs3848403) affecting sRAGE concentration 
and linked with some diabetic complications (Škrha et al., 2014). Previous study 
also showed an association between FN3K enzymatic activity in red cells and some 
polymorphisms in the FN3K gene (Delpierre et al., 2006), where the SNP C/G 
(rs1056534) in exon 6 was connected with reduced enzymatic activity measured in 
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erythrocytes. However, no correlation has so far been detected between FN3K 
SNPs and HbA1c levels (Delpierre et al., 2006). The study by Dunmore et al., (2018) 
showed a notable correlation between erythrocyte FN3K and the G-gap. The study 
reported that FN3K enzyme activity and protein levels were both notably elevated 
(3-fold) in the negative G-gap group (lower HbA1c levels than average glycaemia). 
These differences may arise through the single nucleotide polymorphisms in the 
FN3K gene (Avemaria et al., 2015, Tanhauserova et al., 2014 and Soranzo et al., 
2010), leading to the potential differences in enzyme activity or differentially 
expressed genes and transcript variants that are enriched in different biological 
processes, pathways and diseases that might give rise to the G-gap.   
 
In this thesis, the correlation between FN3K SNPs and the glycation gap was 
investigated in patients with diabetes. Mohas. (2010) reported that the C allele of 
rs1056534 was linked with lower HbA1c concentration and with later development of 
T2D. However, this variant was independent of diabetic complications, such as 
nephropathy, neuropathy or retinopathy during the investigation. In 2014, to verify 
the influence of genetic variability in FN3K genes on diabetic nephropathy 
progression, the correlation was reported between SNPs C/G (rs1056534) and 
diabetic nephropathy progression and cardiovascular morbidity and mortality in 
T2DM subjects (Tanhauserová et al., 2014). Skrha and co-workers also evaluated 
the genetic variability of FN3K and GLO1 with parameters of endothelial dysfunction 
and soluble receptor for AGEs (sRAGE) in patients with diabetes (Skrha et al., 
2014). In diabetic patients, a significant relationship between the rs1056534 and 
rs3848403 of FN3K gene polymorphisms was proved with circulating sRAGE 
concentration.  
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1.6.  Q248H ferroportin1 polymorphism 
SLC40A1 gene encodes cellular ferroportin, a transmembrane protein that exports 
iron from the cells to the bloodstream (Girelli et al., 2008). Research evidence 
indicate an association between ferroportin polymorphism SLC40A1 Q248H 
(localized in exon 6), and high levels of serum ferritin. It has been demonstrated that 
it may be responsible for primarily high iron levels in sub-Saharan African population 
(Beutler et al., 2003; Gordeuk et al., 2003; Kasvosve et al., 2005; McNamara et al., 
2005; Barton et al., 2007 and Rivers et al., 2007).  Ferroportin Q248H mutations 
(rs11568350) in gene leading to African iron overload disease (hemochromatosis 
type IV) or hyperferritinaemia as a result of increased duodenal iron absorption 
(Katchunga el al., 2013, Kasvosve et al., 2015 and Rivers et al., 2007). Cikomola et 
al. (2017) found the correlation between FN3K activity and Q248H genotypes 
(rs11568350) in subjects. Research also indicate that serum ferritin is associated 
with the risk of developing diabetes mellitus (Sun et al., 2008).  Furthermore, 
ferroportin (encoded bySLC40A1 gene) Q248H mutation is prevalent in Africa 
(Albuquerque et al., 2011).  
 
1.7. Single nucleotide polymorphisms (SNPs) genotyping 
The single nucleotide polymorphisms (SNPs) are genetic signatures and caused by 
variation of a single nucleotide (A, T, C and G) in the DNA sequence. These are 
used for the study of predisposition to certain traits including disease (Chanock, 
2001).  Generally, SNPs (which do not always modify gene function) are important 
for the dynamics evaluation of the studied population. However, SNPs presence 
may lead to alternatively spliced transcript variants and may affect the transcription 
factor`s binding capacity (Uppu, Krishna and Gopalan, 2016). The SNPs may 
present in the coding/noncoding regions of genes. These are used for the 
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investigation of phenotypic characteristics based on their genotypes and they also 
play a role in diagnostic assays development (Karki et al., 2015). The TaqMan 
method is commonly used for SNP studies. This method is based on 5′ exonuclease 
chemistry. TaqMan assay use two fluorescently labelled probes to detect target 
amplicons which are accumulated during the PCR reaction. These target specific 
probes are highly sensitive (Martino, Mancuso and Rossi, 2010). The probes are 
non-fluorescent because of the close proximity between fluorophore and quencher. 
Once the Probe/target hybridisation occurs during each PCR cycle Taq DNA 
polymerase cleaves the probe which results in an increase in fluorescence 
(proportional to the accumulated target amplicon) because of conformational 
changes where the close proximity between fluorophore and quencher no longer 
exists. Fluorescent signals are detected using sequence detection software installed 
into the real-time PCR machine (Malkki and Petersdorf, 2012). 
 
1.8. Diabetic complications and vascular diseases 
Diabetic complications arise from chronic hyperglycaemia, including microvascular 
and macrovascular complications (Naess et al., 2003 and Skyler & Oddo, 2002). 
Atherosclerotic cardiovascular, peripheral arterial and cerebrovascular diseases are 
examples of main macrovascular complications. Microvascular complications 
include retinopathy with potentially affecting the vision; nephropathy leading to renal 
damage; peripheral neuropathy with the potential risk of foot ulcers and amputations 
(Bailes, 2002). Macrovascular and microvascular complications in diabetes are 
caused by extended exposure to hyperglycaemia together with arterial 
hypertension, dyslipidaemia as well as genetic susceptibility, considered as risk 
factors (Krentz, Clough and Byrne, 2007). Obesity in T2D, insulin insensitivity or 
damage to insulin secretion leads to early glycaemia, responsible for variation in 
41 
 
structure and function of vessel wall reaching a climax with diabetic vascular 
complications. The disproportion between nitric oxide (NO) bioavailability and 
production of reactive oxygen species (ROS) is stimulated by high glucose 
concentrations leading to the alterations of vascular function (Creager et al., 2003). 
 
To explain the association between the increased concentration of glucose and the 
development of complications “Non-enzymatic Glycation Hypothesis” was 
suggested. The “Non-enzymatic Glycation Hypothesis” hypothesises that 
immoderate non-enzymatic alteration of proteins and some phospholipids by 
glucose and its by-products are due to the detrimental effects of chronic 
hyperglycaemia (Stitt, Jenkins and Cooper, 2002). Diabetic complications 
dependent on several factors. The biochemical process of advanced glycation has 
been demonstrated to play a key role in the pathogenicity of long-term vascular 
complications in patients with diabetes (Brownlee, 2005, Genuth et al., 2005, 
Vlassara & Striker, 2013).  Pentosidine and carboxymethyl-lysine (CML) are some 
important chemically characterised AGEs in humans, of which pentosidine has 
intrinsic fluorescence. It can also be used as a marker of AGE accumulation. AGEs 
are also originated from exogenous sources such as tobacco smoke and diet and 
they contribute to renal and vascular complications (Vlassara et al., 2002 and Zheng 
et al., 2002) and participate in insulin resistance and diabetes progression (Cai et 
al., 2012). Both fructosamines and AGEs can alter the biological and functional 
properties of proteins in living organisms (Ulrich and Cerami, 2001 & Chilelli, Burlina, 
and Lapolla, 2013). This highlights the importance of deglycation processes for 
retardation of vascular damage progression.  
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1.8.1. The function of advanced glycation end products (AGEs) and their 
receptors in diabetes 
Spontaneous damage to proteins occurs due to the glycation. Many studies not only 
confirmed the traditional role of glycation in diabetes complications but also brought 
new insights. This is evident from AGEs that are involved in the pathogenesis of 
diabetes complications and in morbidity and mortality of diabetic patients. 
Nevertheless, it is critically important to identify proteins and their significant active 
sites vulnerable to glycation. These directed targets will help to develop inducers of 
enzymatic defence against the glycation of proteins (Schmidt and Stern, 2000; 
Ahmed and Thornalley, 2007) such as FN3K. 
 
AGEs are generated from glucose-derived dicarbonyl precursors as well as 
glycation of proteins. These accumulate intracellularly and act as a stimulus for 
activating intracellular signalling pathways as well as altering the function of 
intracellular proteins (Brownlee, 2001 & Singh et al., 2014). AGEs are also present 
in the extracellular matrix and thus lead to the modification of matrix proteins and 
diminish matrix-matrix as well as matrix cell interactions. This may lead to cell death, 
cell differentiation or reduced cell resistance and relocation (Monnier et al., 2005). 
AGEs form cross-links with collagen and other proteins and leading to decreased 
vessel elasticity (Zieman et al., 2007). AGEs directly change protein structures and 
functions or cross-link which is potentially damaging (Singh et al., 2001). Chronic 
hyperglycaemia in a diabetic condition not only elevates the generation and 
accumulation of AGEs is also associated with impaired renal function because the 
kidney is the major site for clearing AGEs. AGE-modified proteins may be less 
susceptible to enzymatic degradation (Singh et al., 2014). AGE formation, AGE 
precursors and oxidative stress are accelerated with a high concentration of 
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circulating glucose in diabetic patients. High concentrations of AGEs have been 
found in serum and tissues of patients with diabetes, and accumulated AGE in 
diabetic tissue found to be correlated with diabetic complications (Monnier et al., 
2005). Dunmore et al. (2018) identified differences in AGE levels and associated 
diabetic complications between the G-gap groups. In addition to direct impairing 
protein structures and functions, AGEs bind to the receptor of advanced glycation 
end products (RAGE) and have damaging effects (Sessa et al., 2014), which 
includes chronic inflammation, stimulating oxidative stress and playing an important 
role in cardiovascular disease and diabetic complications (Coughlan et al., 2009 and 
Yan, Ramasamy and Schmid., 2010). RAGEs are involved in the pathogenesis of 
diabetes angiopathy (Yan, Ramasamy, and Schmidt, 2007, Lindsey et al., 2009 & 
Skrha et al., 2012), atherosclerosis, cardiovascular disease, and other diabetes 
complications.  
 
Total sRAGE is comprised of extracellular domain of wild-type full-length RAGE 
(cleaved from cell membrane) and an endogenously secreted isoform (esRAGE). 
The sRAGE is a potentially a useful biomarker for cardiovascular disease (CVD) in 
diabetes. It is possible to measure full-length RAGE and esRAGE separately 
(Zhang, Postina and Wang, 2009 & Hudson et al., 2008). RAGE antagonists are in 
the developmental phase as therapeutics for diabetes complication. Alongside this, 
there is a need for therapy focusing on total sRAGE and esRAGE as potential 
biomarkers for diabetes complications. RAGE is a multi-ligand receptor as it 
interacts with a wide range of AGEs and belongs to the immunoglobulin superfamily. 
In vitro studies showed that binding of AGEs with RAGE activates NAPDH oxidases 
and leads to the increased formation of intracellular ROS (Wautier et al., 2001 and 
Zhang et al., 2006), which in turn leads to AGE formation. In addition to these 
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damaging mechanisms, AGEs also participate in the activation of the transcription 
factor, nuclear factor kappa B (NFκB) (Bierhaus et al., 2001). Expression of pro-
inflammatory cytokines such as interleukin 6 (Sessa et al., 2014) and RAGE itself 
increases because of NFκB activation (Tobon, Cuevas and Torres, 2014), thus 
escalating the inflammatory response.  
 
1.9. The nature of transcriptome 
Examining specific SNPs may not provide a comprehensive view of the reasons for 
the differences in glycation in the G-gap whereas a transcriptomic approach has the 
potential to identify novel differences in transcription of a broader range of genes. 
Gene expression, or the transcription of DNA into RNA, can be used to determine 
the phenotype at the cellular level and the set of RNAs expressed in a given cell. In 
the process of transcription, DNA strands act as templates for the synthesis of 
single-stranded RNA molecules (i.e. transcripts) which are complementary to DNA. 
This process requires the presence of RNA polymerases. RNA polymerase II plays 
a key role in the transcription reaction because, in its presence, the binding of 
proteins (transcription factors) to a regulatory region located upstream of the gene, 
known as the promoter takes place (Fuda et al., 2009). After the assembly step and 
other conformational rearrangements (i.e. RNA releases from the transcription 
initiation complex and leads to promoter clearance), the elongation phase starts 
(Kwak and Lis, 2013). In the elongation phase, complementary RNA synthesis in 5’ 
to 3’ direction takes place from the transcription start site (TSS).  The study of RNA 
produced in the cells, in terms of characterisation and quantification, is critical for 
the in-depth understanding of biological pathways. The term transcriptome is used 
for all RNA molecules, which is a complete set of transcripts present in a cell, tissue 
or in an organism at a particular time point. Transcriptomic studies provide a better 
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understanding of how different cell type exist in an organism from a genome and 
how genes are regulated during the development stages and in response to 
condition associated with diseases (Pertea, 2012). In contrast to DNA, RNA is 
single-stranded, backbone consists of ribose, and uracil (U) nucleotide is present 
instead of thymine (T). Diversity in human transcriptome has been revealed (Martin 
et al., 2014). The data published by Encyclopaedia of DNA elements (ENCODE) 
showed that more than 60% of the human genome consists of transcribed regions 
(Djebali et al., 2012), which include protein-coding RNA and processed non-coding 
RNA. The majority of 55000 genes in the human genome do not encode proteins 
whilst only approximately 20000 are protein coding genes.  
 
Several RNA variants exist including messenger RNA (mRNA) (encodes protein) 
and non‐protein coding RNA (ncRNA), such as transfer RNA (tRNA), ribosomal 
RNA (rRNA) and regulatory RNAs including micro RNA (miRNA), small nuclear 
RNA (snRNA), short interfering RNA (siRNA) and long non‐coding RNA (lncRNA). 
Cytoplasm contains protein-coding transcripts whilst the nucleus contains non- 
protein-coding transcripts (Djebali et al., 2012). Total RNA in the cell contains a 
small part (<5%) of protein-coding mRNA whilst the majority of the total RNA is 
rRNA (International Human Genome Sequencing Consortium, 2004). mRNA 
contains all information that is necessary for protein synthesis. The mRNAs derived 
from protein-coding genes are translated into polypeptides. Expression of the 
polyadenylated (poly--‐A) mRNAs is of great interest in today’s research. A 
precursor mRNA molecule is formed during transcription which undergoes several 
modifications, including 5’ capping, the polyadenylation of the 3’ end and the 
removal of introns by splicing (Darnell, 2013). In 5’ capping, methylated guanine is 
ligated to its 5’ end via an enzymatic reaction. Such capping makes mRNA distinct 
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from other RNA species, makes it more stable and helps in the initiation of the 
translation process by enabling ribosome binding to mRNA. During the 
polyadenylation process, poly--‐A--‐tail of about 200 nucleotides is ligated at the 
3’end of the transcript which extends the half-life of mRNA. While in splicing event 
introns are removed from pre-mRNA and exons come together. These exons are 
stretches of sequence that contain the necessary information for protein 
synthesis. After various steps and the association of numerous RNA-binding and 
processing proteins this precursor mRNA is processed into mature mRNA (Maniatis 
and Reed, 2002). By changing the exon composition of the same mRNA and 
alternative inclusion or exclusion of exons a range of unique transcripts (isoforms) 
as well as proteins can be produced.  
 
Alternative splicing is almost common for all human multiexon genes and on 
average around six transcripts per protein-coding gene were found and the majority 
of transcripts contained four exons, whilst 1.6 transcripts per gene were found for 
long non-coding RNA and the majority of them contain two exons (Consortium, 2012 
& Harrow et al., 2012). The nucleus is the prime location for alternative splicing, after 
that the molecule moves to the rough endoplasmic reticulum, where protein 
synthesis takes place. This process is called translation. The nucleus is also the 
place for another regulatory mechanism i.e. RNA editing, where small changes in 
nucleotide sequence occur by insertion, deletion or nucleotide replacement. These 
changes lead to amino acid substitutions, altering splice patterns and thus directly 
or indirectly can change the expression and function of many genes (Farajollahi and 
Maas, 2010; Gott and Emeson, 2000) as well as information stored in the 
RNA.  In humans, A to I editing is common, where adenosine is replaced with 
inosine in RNAs (Valente and Nishikura, 2005). For the regulation of gene 
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expression, cells use different mechanisms, including binding of transcription factors 
to the promoter and enhancer regions. These transcription factors activate 
transcription. Other important gene expression regulators are epigenetic factors i.e. 
DNA methylation where a methyl group is added to the cytosine bases of the DNA 
sequence of the gene, resulting in cell suppressing the initiation of gene expression. 
Gene expression is also influenced by histone modifications (epigenetic factor), 
leading to a change in chromatin structure. Its importance appears in cell 
development (Smith and Meissner, 2013), cancer (Kulis and Esteller, 2010) and 
ageing (Horvath, 2013). In a human cell, RNA expression level is regulated at 
various levels and used as a surrogate to phenotypes such as disease (Vogel and 
Marcotte, 2012). Multiple technologies are available to measure RNA in a high-
throughput manner (Marioni et al., 2008). 
 
1.9.1. Transcriptomic analysis of gene expression   
The transcriptome is a complete set of transcripts in a cell where transcription of the 
genetic code to RNA molecules takes place during a specific developmental stage 
or physiological condition. These polyadenylated products are formed as a result of 
RNA polymerase II activity (Tang et al., 2010 & Wang, Gerstein and Snyder, 2009). 
Despite the fact that the same genome is present within an organism or tissue, 
diverse phenotypes exist. This happens potentially because of mRNA transcripts 
variants that have varying types and amounts (Kalisky et al., 2011 & Tang, Lao and 
Surani, 2011) or divergence of cis-regulatory regions (Stern and Orgogozo, 2008). 
These cis-regulatory regions are the part of DNA sequence that regulates gene 
expression and divergence can also arise from epigenetic changes that alter 
chromatin structure (Wittkopp, 2005) and may alter transcription rate and/or 
transcript stability.  Transcriptomic analysis (of mRNAs, non-coding RNAs and small 
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RNAs) in this sense provides an understanding of the transcriptional structure of 
genes with regards of their start sites, 5′ and 3′ ends, splicing patterns and other 
post-transcriptional modifications. This is therefore relevant in the quantification of 
the changing expression levels of each transcript during development and under 
different environmental conditions (Wang, Gerstein and Snyder, 2009). It also allows 
the identification of all genes with different expression patterns across various 
conditions. RNA-Seq allows the sequencing of a cell’s entire transcriptome. The 
technique also allows the researcher to study this with unprecedented detail as only 
1-2% of transcribed genes codes for and are translated to proteins. Often, 80-90% 
of the processed genes that did not translate to proteins are involved in the process 
of epigenetic and gene expression regulation (Elgar and Vavouri, 2008 & Shabalina 
and Spiridonov, 2004).  
 
Regulation of a complex gene expression process occurred at transcription, post-
transcriptional modifications, and translational level. Gene expression is a complex 
process. During transcription process multiple transcripts may be produced from a 
single gene as a result of multiple Transcription Start Sites (TSSs) (Davuluri et al., 
2008). Alongside this, alternative splicing of the pre-RNA may produce several 
transcripts from the same gene (Chen and Manley, 2009 & Tian and Manley, 2013). 
 
  
49 
 
1.9.2. Methods for transcriptome analysis 
For gene expression measurement many technologies have been in use over the 
years. These include Northern blots and qPCR, hybridisation-based microarray and 
more recently RNA-sequencing (RNA-Seq) technology.  
 
1.9.2.1. Northern blots and qPCR 
These techniques were initially used for measuring mRNA abundance and were 
suitable to investigate a limited number of genes at a time and provide insight into 
a few candidate genes. However, to measure the entire transcriptome these 
techniques were found to be impractical.  
 
1.9.2.2. Microarray 
Microarray (hybridisation-based) is a traditional method that was used to study gene 
expression and quantify RNA in a global manner (Lowe et al., 2017). It involves the 
incubation of fluorescently labelled complementary DNA (cDNA) fragments with 
microarray chips. The microarray chips are fixed with oligonucleotide probes 
containing a perfect match with target sequences. Laser scan for fluorescent 
detection of the probe-target pair quantifies gene expression levels. Useful 
information can be obtained from microarray results such as how gene expression 
changes during developmental states and how it varies between and among spaces 
(Zhang et al., 2007). 
 
Although microarray is a relatively low-cost method, potential cross-hybridisation, 
reliability on existing knowledge of genome sequence and limited ability to fully 
detect and quantify the diverse RNA molecule that are expressed at various levels 
made it of limited use for RNA analysis (Okoniewski and Miller, 2006 & Pan et al., 
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2004). Therefore, microarray has a limited interrogating capacity and is useful for 
only specific genes for which probes are designed.  
 
1.9.2.3. RNA-Seq 
RNA-Seq, a high- throughput sequencing approach is a relatively new technique. 
This technique is more sensitive for detecting genes at low expression level and it 
overcomes many weaknesses of hybridisation-based method. 
 
In today’s age, RNA sequencing has become a tool of choice for transcriptome 
analysis. It can detect all coding and non-coding transcripts in a cell as well as 
determine their sequence and abundance. It can also identify alternative splicing 
(Pan et al., 2008), novel transcript (Guttman et al., 2010), gene fusion events 
(Edgren et al., 2011), RNA editing products, mutations in the expressed coding 
sequence and allele-specific expression (Borodina, Adjaye and Sultan, 2011).  
 
RNA-Seq does not rely on the prior knowledge of a gene to identify and quantify the 
novel transcripts. This shows that RNA-Seq can directly perform whole-genome 
transcriptome profiling in a high-throughput manner (Mortazavi et al., 2008 and Mutz 
et al., 2013). However, specialised algorithms and more powerful servers are 
needed for bioinformatic analysis of the big volume of data generated from this 
method (Pop and Salzberg, 2008). 
 
1.9.3. Roadmap of an RNA sequencing experiment 
Next generation or high throughput sequencing of RNA molecules is used to 
describe several sequencing technologies, including the one developed by Roche 
(454), Illumina (Hiseq 4000) and Applied Biosystems (ABI SOLiD). These 
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technologies require different experimental protocols and differ by sequencing 
chemistry, length of the read produced, running time for the experiment, throughput 
per run and reads produced per run (Di Bella et al., 2013). The most commonly used 
one, which is adopted with Illumina’s machines because it is cost effective and it 
accommodates the samples with lower accuracy (Mardis, 2013), usually follow 
these steps (Figure 1.3): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 3 Diagrammatic representation of RNA-Seq. Total RNA was isolated; 
enrichment and fragmentation of mRNA were performed. After that, the mRNA 
molecules were reverse transcribed into cDNA, which is then used to prepare a DNA 
library and for sequencing. (Zeng and Mortazavi, 2012). 
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1.9.3.1. Enrichment of protein-coding mRNAs from a larger pool of total RNA 
More than 80% of the total RNA consists of rRNA transcripts. To avoid, the 
correspondence of sequencing reads with these transcripts, enrichment of protein-
coding mRNAs of the transcriptome is performed for sequencing purposes via two 
methods which include poly-A enrichment of mRNA and depletion of rRNA. Poly-A 
enrichment process briefly involves, hybridisation of polyadenylated 3´-end of RNA 
transcripts to poly-d (T) probes, while ribosomal deletion involves hybridisation of 
abundant rRNA molecules to specific probes and subsequent deletion (Braasch and 
Corey, 2001). 
 
1.9.3.2. Fragmentation of RNA 
Next step involves the fragmentation of enriched RNA molecules (Illumina 
sequencing technology is only able to use DNA fragments of a specific length i.e. 
150-200 bp) via RNA hydrolysis or nebulisation or uridine digestion to obtain a 
uniform sampling of sequences along the transcripts (Mortazavi et al., 2008).  
Alternatively, the cDNA (described below) may be fragmented instead of enriched 
RNA molecules via DNase I treatment or sonication (Wang, Gerstein and Snyder, 
2009).  
 
1.9.3.3. Synthesis of cDNA 
DNA molecules are more stable in contrast to RNA. Reverse transcription process 
is used for the synthesis of cDNA molecules by using RNA molecules as templates. 
To start this process a random hexamers primer (sequence of the obtained 
fragments is unknown at this point) hybridises to the random positions of RNA 
sequence and synthesise single-stranded cDNA molecule. The hairpin loop at the 
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3’ end of single-stranded cDNA molecule act as a primer for the synthesis of a 
second DNA strand that is complementary to the first strand. 
 
1.9.3.4. Adapter ligation and PCR amplification 
Adaptors are ligated at both ends of cDNA molecules to satisfy two purposes. The 
first purpose is to enable the sequencing machine to recognise the 
fragments/hybridise the fragments into a flow cell where sequencing occurs and the 
second purpose to act as a primer for sequencing. Next step is the PCR 
amplification of cDNA molecules. 
 
1.9.3.5. Size selection 
To ensure that all molecules are of similar length, gel electrophoresis is performed 
to select the correct size of cDNA molecules, as a sequencing machine can 
sequence typically 150-200 bp fragments. After verification of cDNA library 
concentration and its fragment length samples are ready to load into a flow cell for 
sequencing (Mardis, 2013).  
 
1.9.3.6. Sequencing-by-synthesis 
In the initial step of sequencing, the double-stranded molecules are separated into 
single strands by denaturing and loaded into the flow cell. Adapters at both ends of 
cDNA molecules are complementary to the surface-bound oligonucleotide in the 
flow cell. Bridge amplification takes place after fragments hybridise to the surface-
bound oligonucleotide in the flow cell. Synthesis of the new strand (complementary 
to the original strand) from the 3′ end of the flow cell oligonucleotide takes place in 
the elongation phase. The original strand is then removed by denaturation. Bridge 
formation and generation of a new site for the synthesis of a second strand occurs 
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by the hybridisation of the adaptor sequence at the 3′ end of the newly synthesised 
strand to a new surface-bound complementary oligonucleotide. In the end, after 
several hybridisations, extension and denaturation cycles many clusters originate 
from the same template with identical sequences. (Figure 1.4) (Bentley et al., 2008).  
 
In each sequencing step, the Illumina system uses ‘cyclic reversible termination’ 
strategy. Under this strategy reversibly terminated fluorescently labelled nucleotides 
(specific for each nucleotide type) are incorporated into the growing complementary 
strand.  Fluorescence image is captured via laser to identify which nucleotide was 
incorporated, and cleavage cycles are repeated (Bentley et al., 2008 and Metzker, 
2005). The reaction begins with the use of a modified nucleotide containing a 
reversible terminator that terminates DNA synthesis after successful incorporation 
of a single base. The modified nucleotide also contains fluorescent dye. The 
fluorescent dye and terminal group are then removed from the new nucleotides and 
the process is repeated. Fluorescence imaging measurement helps to identify the 
incorporated single base. This process is repeated to produce the set of images. 
These images are interpreted with a base calling software and are converted into 
the set of sequences/reads (Das and Vikalo, 2013). These set of sequences/reads 
represent the set of molecules express in the initial samples. The length of that reads 
represents the number of cycles performed during the sequencing reaction. The 
sequence information and the quality of the identification of a base call at each given 
position of the read are stored as a plain text file in FASTQ format (Cock et al., 
2010).  
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Figure 1.4 Hybridisation and bridge amplification. A. The single strand is 
hybridised to complementary adapter sequence on the flow cell surface. A new 
complementary strand (dotted) is synthesised in elongation reaction from the 3´end 
of the surface-bound adapter; B. Denaturation removes the master strand C. The 
adaptor sequence at the 3´end of the newly synthesized strand is hybridized to a 
new surface bound adapter, resulting a bridge formation and creating a site of 
synthesis of a new strand (dotted). Cluster formation takes place after multiple 
cycles of hybridisation, elongation, and denaturation. (Bentle et al., 2008). 
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1.9.4. Software for RNA-Seq data analysis 
 
RNA-Seq studies have a number of objectives. These are commonly used for 
studies of specific genomic regions expression. These genomic regions include 
genes, isoforms, exons, splice junctions or novel transcribed regions. To study their 
expression, the identification of the features in the sequencing library is the prime 
requirement. Aligning short reads to these features is a challenge because of 
genome size (Trapnell and Salzberg, 2009). An efficient and accurate software is 
required for the analysis of data from RNA-Seq experiments. This software must 
have the ability to handle a large volume of sequencing reads produced from the 
experiment. Typically, analysis stage consists of the following stages:  alignment of 
the reads to the reference, assembling the alignments into full-length transcripts, 
quantifying the expression level of each gene/transcript and calculating the 
differences in expression for all genes in different experimental groups/ conditions. 
 
1.9.4.1. Alignment to the reference 
Reads can be aligned to reference which can either be a genome or a transcriptome 
for quantification and differential expression of genes. The advantage of 
transcriptome alignment is simplification as no intronic sequences exist. On the 
other hand, it limits the downstream analysis because of its incompatibility with the 
identification of novel expressed regions, the study of intronic expression levels and 
splice junctions (Zhao, 2014). TopHat2 was a splice aware aligner package tool 
(Trapnell, Pachter and Salzberg, 2009) that generated spliced alignments and it was 
used at the beginning of RNA-Seq era, whilst Bowtie and BWA (Degner et al., 2009) 
were used for the alignment of short reads contiguously to a reference.  
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1.9.4.1.1. Alignment to the genome  
RNA sequencing reads are aligned to a reference genome by a spliced alignment 
program HISAT2 (hierarchical indexing for spliced alignment of transcripts 2) that is 
a fast, sensitive and splice aligner program (Pertea et al., 2016). HISAT2 can identify 
splice sites by mapping RNA-Seq reads to a reference and it needs much less 
computer memory. HISAT2 is advanced version of the spliced alignment program 
HISAT (hierarchical indexing for spliced alignment of transcripts) (Kim, Langmead 
and Salzberg, 2015) and Bowtie 2 (Langmead and Salzberg, 2012). An independent 
algorithm Bowtie2 was able to align short reads and detect exon-exon junctions 
without the need for any advance information on the annotation. HISAT2 is a 
replacement of TopHat2. HISAT2 creates a global index (for the entire reference 
sequence) and lots of small local indexes (for regions of the reference). Small local 
indexes not only cover the entire reference but also cover the overlapping 
boundaries where overlapping boundaries simplify mapping of reads that span over 
exon-exon junction by covering two indexes. Kim et al. (2015) split exon spanning 
reads into three groups including long-anchored reads, where reads align across 
two exons with at least 16 bp aligning into one exon; intermediate-anchored reads, 
where reads align across two exons with 8–15bp aligning in one exon; and short-
anchored reads, where reads align across two exons with 1–7bp in to one exon. 
Each group correlates to a different alignment strategy based on global and local 
indexes. For example a gene on human chromosome 22 consists of two exons and 
three introns (Figure 1.5) and after transcription and splicing of the genomic region 
there are three 100bp error-free reads including a reading mapped to exon, a read 
that spans over an exon-exon junction with an 8-bp sequence in one of these exons 
and a read that spans over two exons with 50bp anchored in each exon. Strategies 
(hierarchical indexing) for the alignment depend on two conditions that reads are at 
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least 28bp long and these align exactly onto one location. Firstly, global index is 
used Figure 1.5a: the 28bp long end of reading maps exactly, therefore, the global 
search is stopped and extended the partial alignment by using the mapped 
alignment as an index. The remaining 72bp sequence is aligned within one exon, 
the alignment of this read is completed. With the 2nd type of reading, the 28bp long 
end maps exactly whilst the read has an 8bp anchor as well, therefore, the alignment 
is extended until a mismatch occurs (Figure 1.5a), this mismatch appears when the 
extended alignment reaches an intron.  
 
The local compressed full-text data structure FM index (Ferragina-Manzini index) is 
used for the alignment of 8bp. In the end, 8bp and 92bp are combined to generate 
a spliced alignment (Figure 1.5b). The process of alignment of 3rd (Figure 1.5c) read 
starts as described before where 28bp long end uniquely mapped, alignment 
extension continues which aligns further 22bp and stops when a mismatch appears. 
The local FM index is then selected to find 8bp anchor alignment. Once 8bp is found, 
the HISAT2 extension operation is used to align the rest of the read. If the 8bp prefix 
maps to too many locations within the local index than HISAT2 would use a longer 
prefix to reduce the number of potential locations. HISAT2 produce outputs in SAM 
(Sequence Alignment Map) format. 
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Figure 1. 5 HISAT2. The application of hierarchical indexing for fast and sensitive 
alignment with three different strategies. (Kim et al., 2015). 
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TopHat2 
TopHat2 aligns reads contiguously to the genome with Bowtie (Langmead and 
Salzberg, 2012). However, to simplify this process, TopHat2 aligns the reads to the 
transcriptome first and the nonaligned reads will subsequently be mapped to the 
genome. Initially aligned reads are assembled into exons, which might become 
connected via spliced alignment. Nonaligned reads and aligned reads with low 
alignment scores in the initial step, are split into the smaller segments and 
independently aligned again to get information of possible splice junction when two 
consecutive segments from the same read do not align contiguously on a given 
genomic locus. In the next phase, identified splice sites and their flanking sequences 
are linked into a novel transcriptome to re-align the set of unmapped reads. Each 
read is processed separately where paired-end data is available and the alignments 
from genome and transcriptome are evaluated at the end phase by considering 
other sources of information such as fragment length and orientation of the reads. 
At the final stage, all the obtained information during the mapping process is 
reported in the SAM (sequence alignment map) format (Li et al., 2009). 
 
1.9.4.2. Assemble the alignments into full-length transcripts 
Around 30% of non-coding RNA genes (ncRNAs) and greater than 90% of 
transcripts produced from multi-exon protein-coding genes are subject to alternative 
splicing (Wang et al., 2008 & Cabili et al., 2011). Previous procedures for the 
assembly of genes de novo as well as coding regions have been replaced with 
highly accurate method such as StringTie (Pertea et al., 2016). These new methods 
use RNA-Seq data as a starting point. A research study for the reconstruction of 
transcript found that previous method such as Cufflinks (for the transcript 
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identification and expression quantification) though identified all exons of a transcript 
but failed to assemble the exons into complete isoforms (Pertea et al., 2015). 
 
For the assembly of alignments into full and partial transcripts, producing multiple 
isoforms, and for the estimation of the expression levels of all genes and transcripts, 
StringTie was used (Pertea et al., 2015). StringTie was based on genome-guided 
transcriptome assembly and de novo genome assembly concept for the 
improvement of transcript assembly. Therefore, it used spliced read alignments as 
well as alignments of contigs that it pre-assembles from reading pairs. 
 
1.9.4.3. Quantification of expression level 
Once the alignment assembly and identification of the specific location of reads in 
the genome and transcriptome is completed, the next step in the analysis involves 
computing the level of expression for genes and transcripts. Expression level can 
be quantified based on existing information by counting how many reads align to 
each of the features i.e. genome and transcriptome. 
 
1.9.4.3.1. Quantification of gene/transcript expression 
At the gene level, quantification was achieved previously by the number of counts 
of the reads covering the locus. Many downstream analysis algorithms such as 
DESeq (Love, Huber, and Anders, 2014), DEXSeq (Anders, Reyes and Huber, 
2012) and the count (Anders, Pyl and Huber, 2015) start the process by counting 
the number of reads aligned to the features. To avoid the double counts which 
results in an overestimation of expression level of the reads (multi-mapping reads) 
that map to the multiple locations in the genome htseq-count discards them, but this 
may result in a significant loss of information (Turro et al., 2011). Another problem 
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was that individual transcripts complicate the estimation of expression level because 
of the overlapping of reads with exons which are shared across multiple isoforms of 
the same gene. In this case, various algorithms are required. Some of them depend 
on various pools of information to randomly estimated transcript expression levels. 
But the reads aligned to one of the annotated transcripts within the loci are more 
important. However, reads (split reads) provide useful information when they span 
two different exons. This information could be about splice junctions that involve 
cassette exons such as during a splicing event an inclusion and exclusion of an 
exon between two other exons to form two distinct protein isoforms. In this case, 
sequencing from both sides of the initial cDNA fragment in paired-end form is 
important because it covers larger genomic regions where it is highly probable that 
a given read pair is aligned across different exons (i.e. spliced reads).  
 
Various tools were available for the estimation of expression levels of the transcripts 
including MISO (Mixture-of-Isoforms) (Katz et al., 2010), Cufflinks (Trapnell et al., 
2010) and MMSEQ (Minimum Mean Square Error Quantizer) (Turro et al., 2011). 
MISO and Cufflinks require that the reads need to be mapped to a reference 
genome whilst MMSEQ based on mapping reads to the transcriptome, which limits 
the scope of the downstream analysis. To overcome this, StringTie performs 
quantification. StringTie uses a NetFlow algorithm to perform both functions 
simultaneously such as assembly and quantification for the highly expressed 
transcripts and separate reads associated with that transcript and leads to the 
repetition of the process until all the reads are used. With the use of an algorithm, 
StringTie runs faster and use less memory. By using the reference annotation file 
StringTie can construct assembly for low abundance genes i.e. novel genes and 
transcripts and able to reflect the expression of rare or novel genes and alternative 
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splicing isoforms. StringTie-merger is able to merge the transcript assemblies 
obtained from G-gap negative and G-gap positive samples into a consolidated 
annotation set. This function was previously performed with the Cufflinks-merger. 
Full length of the transcript can be restored especially those transcripts assembled 
with low coverage with this merger step. StringTie store the transcript assembly as 
GTF (Gene Transfer format) file format.  
 
1.9.4.3.2. Computing the differences in gene expression levels  
Ballgown helps the visualisation of transcript assembly on a gene-by-gene basis, 
estimation of abundance for exons, introns, transcripts or genes and the 
performance of linear model-based differential expression analysis. Ballgown is 
based on the output of StringTie merger. It collects all the transcripts and 
abundances and converts them into groups based on experimental condition. 
Therefore, it is thus able to find which genes and transcripts were differentially 
expressed between conditions. Ballgown software consists of plotting tools as part 
of the R/Bioconductor package that helps in the visualisation of results (Pertea et 
al., 2016). Ballgown acts as a link between the assembly of the transcriptome and 
the fast, flexible differential expression analysis. Ballgown software links the HISAT2 
and StringTie software to R/Bioconductor package. 
 
1.9.5. Normalisation of expression 
Regardless of the quantification approach used it is necessary to ensure that the 
results are comparable across different libraries/features within a sample. 
Normalisation is important because the number of reads/counts not only are 
proportional to the expression levels of the feature of interest, but this also depend 
on the length of the feature such as base pairs and the sequencing depth of the 
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experiment. Sequencing depth represents the total number of mapped reads in a 
sample that are mapped to any regions within a genome. Different length of the 
feature produces within-sample bias (Hansen, Irizarry and Wu, 2012; Risso et al., 
2011 and Pickrell et al., 2010) because long features produce more reads (Garber 
et al., 2011 and Oshlack and Wakefield, 2009). Whilst sequencing depth is a source 
of between- sample bias (Mortazavi et al., 2008; Marioni et al., 2008). This 
normalisation concludes the meaningful expression values between the same or 
different features in different or the same samples respectively under different 
biological conditions or deals with biases within-sample and between-samples 
(Risso et al., 2014) as count data obtained from RNA-Seq are subject to certain 
biases (Garber et al., 2011; Mortazavi et al., 2008; Nagalakshmi et al., 2008 and 
Wang, Gerstein and Snyder, 2009). 
 
Commonly used normalization strategies in RNA-Seq are the reads per kilobase of 
transcripts per million reads mapped (RPKM) (Mortazavi et al., 2008) and fragments 
per kilobase of transcripts per million reads mapped (FPKM) (Trapnell et al., 2010). 
RPKM is used when the mapped reads are single end whilst FPKM is used when 
the mapped reads are paired-end (Mortazavi et al., 2008). FPKM showed that if one 
million fragments are sequenced, the FPKM value for a certain feature represents 
the expected number of fragments identified per thousand bases in that feature. 
This method assumes that across all libraries total RNA levels are similar. Ballgown 
used FPKM for normalisation. 
 
1.9.6. Challenges for RNA sequencing technology 
   
RNA-Seq technology has some challenges such as during library preparation, the 
random hexamer priming step has some specificity to sequence composition 
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leading to the preferential conversion of some fragments to cDNA (Hansen, Brenner 
and Dudoit, 2010). Cufflinks (Trapnell et al., 2010), MMSEQ (Turro et al., 2011) are 
some examples from several algorithms that cope with the biases derived from the 
random hexamer amplification step. Another challenge is that fragments with higher 
or lower GC content undergo differential amplification during PCR (Benjamini and 
Speed, 2012), and during sequencing step wrong base calls is possibly due to the 
failure to stop the elongation phase or to remove the fluorescent dye (Metzker, 
2010). To overcome amplification bias alternative library preparation methods are 
recommended where random barcodes i.e. molecular identifiers quantify the 
absolute number of molecules (Shiroguchi et al., 2012) whilst to account for wrong 
base call bias some downstream analysis algorithms are used that include 
information on the quality of the identification of a base call at each given position 
of the read, as reported by the Phred score (Kim et al., 2013). 
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1.10. The Telomere 
 
1.10.1. Telomere biology 
Telomeres are nucleoprotein positioned at the end of chromosomes. They 
themselves do not encode proteins but perform various biological functions, 
including maintenance of chromosomal structure and stability, and eventually the 
determination of the lifespan of cells (Lu et al., 2013). Telomere plays an important 
role in the process of the cell’s ageing alongside the protection of chromosome ends 
from degradation or fusion (Blackburn, Greider, and Szostak, 2006). They contain 
stretches of repetitive DNA sequence of six nucleotide bases (TTAGGG) ending in 
a short single-stranded G-rich overhang, thus the 5′ to 3′ strand of double-stranded 
telomeric DNA is G rich. Figure 1.6 illustrates the structure and position of the 
telomeres.  
 
In humans, the average telomere length is approximately 2-20 kilobase pairs.  The 
double- and single-stranded telomeric DNA is associated with the shelterin complex. 
The shelterin complex consists of six proteins which help in the organisation and 
stabilisation of telomeric DNA into a loop structure (Diotti and Loayza, 2011). 
Telomeres are functionally active when these proteins interact with telomeric DNA 
sequences. Two telomeric sequence-specific binding proteins among others include 
repeat-binding factor 1 and 2 (TRF1 and TRF2). TRF2 protects the telomeric 
structure in vivo by the formation of a T-loop. Without T-loop formation telomeres 
are prone to non-homologous end-joining and fusion (Blackburn, 2001 and De 
Boeck et al., 2009).  
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TRF1 binds to double-stranded DNA and blocks replication by DNA polymerases 
(Smucker and Turchi, 2001). DNA polymerases will not replicate chromosomes 
completely because one primer presents on each daughter DNA strand. 5’-3’ 
exonuclease activity removes the last primers, but gaps remain unfilled by DNA 
polymerases because of the absence of 3’-OH to which a nucleotide can be added. 
Because of this, the telomere, which is a small region at the end is left unreplicated 
due to the end-replication problem and absence of telomerase expression in 
somatic cells (Wai, 2004). The end of the replication process results in chromosome 
shortening with every round of cell division. After a period, length reduces below the 
Hayflick limit leading to the induction of replicative senescence (Sozou and 
Kirkwood, 2001) and elimination of the telomeres. This results in apoptosis (Buijsse 
et al., 2007) and triggers associated ageing disorders. For this reason, telomere 
length is considered as the life-clock of a cell. 
 
 
          
Figure 1. 6 Position and structure of telomere on the chromosome. (Zhu, 
Belcher and van, 2011). 
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1.10.1.1. End-replication problem 
End replication problem leads to the shortening of telomere length with each round 
of cell division. Therefore, telomere length is proposed as a biomarker of cell ageing 
(Kaszubowska, 2008). All eukaryotic chromosomes consist of double-stranded DNA 
molecules: helicase enzymes unwind these double strands, where each strand of 
the double-stranded DNA is used as the template for the new strand synthesis 
(Nandakumar, Pandey and Patel, 2015). DNA polymerase synthesises continuously 
a new DNA strand in 5’ to 3’ direction. This strand is called the leading strand. To 
initiate the replication process, DNA polymerase requires primer to provide a 3’ 
hydroxyl group. On the opposite side (3’ to 5’ direction) is the lagging strand. The 
DNA polymerase can only elongate from a 3’ hydroxyl group. Because of this, the 
lagging strand is synthesised in short fragments termed as Okazaki fragments (Lei 
et al., 2005 and Wang et al., 2007). The leading strand can be synthesised 5’-3’ 
completely and continuously to the end of the template. However, at the end of each 
round of DNA replication of the lagging strand, the last DNA primer is removed, 
leaving no 3’ hydroxyl for DNA polymerase to initiate DNA synthesis. This leaves a 
gap and is unable to completely replicate the end of the lagging strand that is up to 
500 nucleotides (mean value of 250 nucleotides) at the 5' end of the chromosome 
(Xin et al., 2007 and Yu et al., 2008). James Watson in 1972 identified this as the 
“end replication problem” (Herbert, 2011). The loss of terminal sequences 
continuously into the cell leads to cell death and cellular senescence. Therefore, the 
“end replication problem” provides the reason for the ability of the cultured cells to 
divide up to a certain number of generations (Palm and Lange, 2008) (also known 
as the Hayflick limit). 
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1.10.2. Relevance to disease  
The attrition of telomeres is not only the distinctive feature of mammalian ageing but 
also involves numerous metabolic dysfunctions. A previous study suggests that 
shorter telomeres length is a risk factor for age-related pathologies such as insulin 
resistance, overt diabetes mellitus, cardiovascular disease or neurological disorders 
such as Alzheimer’s disease (Kirchner et al., 2017). It is not clear whether the 
telomere shortening is a heritable feature, representing the cause of such chronic 
diseases or it is reflecting a disease consequence. But in either way, numerous 
cellular functions are compromised because of the loss of chromosomal DNA end-
protection. 
 
End replication problem (Maestroni, Matmati and Coulon, 2017) and oxidative stress 
(Von, 2002) have an impact on telomere length. The increased cellular 
concentration of free radicals can damage proteins, lipids and nucleic acids and 
their concentration increases because of cellular stress which is induced by chronic 
and autoimmune diseases as well as environmental factors (Rains and Jain, 2011). 
Telomere tandem repeats are guanine-rich which makes it more sensitive to react 
with reactive oxygen species (Fleming and Burrows, 2013) and leading to DNA 
breaks. In diabetes, oxidative stress is increased in leukocytes as well as in 
pancreatic β-cells. Oxidative stress in pancreatic β-cells could result in shortening 
of β-cell telomeres and subsequent dysfunction of insulin secretion (Tamura et al., 
2016). Oxidative stress can also stimulate inflammation, which leads to an increased 
proliferation of immune cells. Increased proliferation results in an increased rate of 
telomere shortening (Shalev, 2012). Inflammation appears in chronic and 
autoimmune diseases, such as cardiovascular diseases, rheumatoid arthritis, type 
1 and 2 diabetes (Shalev, 2012; Georgin et al, 2010).  Studies have reported that a 
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longer telomere is associated with better health status, protection from age-related 
diseases and lower mortality risk (Shalev, 2012).  
 
The proposed idea of the relationship between telomere length and the ageing 
process provided hindsight for the first association with telomeres and age-related 
diseases (Armanios, 2013). Cawthon et al., 2003 provided strong support that 
telomere length was linked to mortality. The study demonstrated that mortality rates 
from heart disease and infectious diseases were higher in elderly participants with 
telomere shortening as compared to participants with longer telomeres. This 
suggested that short telomeres could affect human health. Several studies showed 
that telomere length is apparently shorter in type 2 diabetes (T2D) 
(Adaikalakoteswari et al., 2007, Olivieri et al., 2009, Smart et al., 2009 and., 
Sampson et al., 2006) as T2D is considered an age-related disease in terms of its 
development and progression. Uziel et al. (2007) also reported shorter telomeres in 
type 1 diabetes patients. Although there is paucity of data, inflammation leads to 
shortened telomere length in cultured proliferative cells (Von, 2000). Thus, in theory, 
replications, oxidative stress and inflammation have an impact on telomere length. 
Previous studies demonstrated that patients with diabetes mellitus have shorter 
white blood cell telomeres than normal individuals (Sampson et al., 2006 and Zee 
et al., 2010). 
 
1.10.2.1. Telomere length and type 2 diabetes 
Type 2 diabetes (T2D) is characterised by high levels of blood glucose 
(hyperglycaemia) due to the absence or reduced production of insulin by pancreatic 
beta-cells and resistance to insulin. Beta cell failure is caused by increased levels 
of both glucose and free fatty acids (glucolipotoxicity) (Poitout et al., 2010), and is 
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often observed as an important factor in the initiation and progression of T2D. 
Increased levels of glucose increase mitochondrial metabolism which leads to 
increased production of reactive oxygen species (ROS) (Muoio and Newgard, 
2008). Age is clearly a strong risk factor for T2D in terms of its onset and progression 
because the replication capacity of β-cells decreases with ageing (Meier et al., 2008 
and Mizukami et al., 2014), potentially as a result of telomere shortening. Premature 
cell senescence due to chronic exposure to hyperglycaemia and free fatty acids 
over time has been proposed as an important cause and consequence of T2D and 
its complications (Sampson and Hughes, 2006). The β cell senescence and 
apoptosis leads to the development of T2D. Given that complications of the disease 
are consequent to senescent phenotypes in kidneys, the eyes, the peripheral 
nerves, and the vascular vessels, it can be postulated that telomere shortening may 
play a mediating role in inducing senescence of beta cells and the onset of the 
disease by affecting pancreatic β-cell metabolism directly (Guo et al., 2011), 
providing a link between telomere length and T2D. 
 
1.10.2.2. Telomere length and type 1 diabetes 
Telomeres in WBCs may be associated with the pathophysiology of T1D. T1D 
(IDDM) is mediated via autoimmune destruction of insulin-producing β cells by 
subsets of WBCs, primarily subsets of T-cells that express CD4 and CD8 surface 
markers (Graham et al., 2012). Wang et al. (2016) determined that the WBC 
telomere length in patients with Type 1 diabetes was shorter than in healthy 
individuals. 
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1.11. Research gaps in previous studies 
HbA1c estimation is widely recognised for the monitoring and control of glycaemic 
level. American Diabetes Association (2010) recommended the use of HbA1c for 
diagnosing diabetes. Within-individuals variation in HbA1c values are consistent in 
non-diabetics (Rohlfing et al., 2002), in contrast to between-individuals (Cohen and 
Smith, 2008; Saaddine et al., 2002). Macdonald et al. (2008) developed a 
methodology for measuring G-gap (a difference between glycated haemoglobin 
levels and other measures of average glycaemia such as fructosamine). Nayak et 
al. (2011) demonstrated that a glycation gap is found to be consistent in with-in 
diabetic individuals and also reported that G-gap is associated with the diabetic 
complications like retinopathy and nephropathy (Nayak et al., 2013).  
 
Among multiple factors that were involved in the variation of non-enzymatic 
haemoglobin (Hb) glycation (Leslie and Cohen, 2009; Cohen and Lindsell, 2012), 
this study focused on deglycation (fructosamine-3-kinase (FN3K)-catalyzed 
pathway). No previous study has explored the correlation between Single 
Nucleotide Polymorphisms (SNPs) of FN3K and Glycation gap status.  Previous 
studies neglected to look at pathway/isoforms which are linked with the G-gap status 
at the transcriptome level. No study had been conducted to study the sRAGE level 
within consistent G-gap diabetic patients. There are no previous studies that have 
examined the telomere length in relation to the G-gap. 
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1.12. Research Questions, Aims, and Objectives 
 
1.12.1. Research questions 
Following are the questions that developed on the basis of research gaps in the 
previous studies;  
1. Are SNPs in FN3K gene responsible for the underlying mechanism of the 
discrepancies in FN3K activity among individuals?  
2. Are the sRAGE levels consistent with the AGE level in diabetic individuals 
according to their G-gap values? 
3. Is FN3K the only enzyme involved in deglycation of glycated haemoglobin in 
erythrocytes or Are there other DEGs and differentially expressed transcripts and 
their associated pathways/biological processes involved in deglycation?  
4. Do the different G-gap values influence the telomere length?  
5. Are FN3K SNPs associated with the sRAGE in patients with different G-gap 
values? 
6. Is Ferroportin1 SNP responsible for the variation of G-gap values in diabetic 
patients? 
7. Can transcriptomic analysis provide novel information on the mechanisms 
causing the G-gap? 
  
74 
 
1.12.2. Research aims and objectives 
● A previous study demonstrated shorter telomeres in T1D and T2D (Tamura et al., 
2016). The first aim of this thesis was to test the hypothesis that the average 
telomere length ratio (T/S) is altered in G-gap negative and G-gap positive patients 
with diabetes.  
 
● The second aim was to explore the relationship between specific FN3K 
polymorphisms (SNPs rs1056534, rs1046896, rs3848403) and G-gap in diabetic 
patients. The iron overload plays an important role in diabetes mellitus in sub-
Saharan African (Katchunga et al.,2013) and this is linked with FN3K activity as well 
as with the glycation gap. In this thesis the Q248H ferroportin polymorphism A/C 
(rs11568350) (linked with FN3K activity) was studied in G-gap negative and G-gap 
positive patients.   
 
● The third aim was to evaluate circulating levels of receptor for AGEs (RAGE) in 
G-gap groups. The association of rs3848403 SNPs of the FN3K gene was analysed 
with G-gap negative and G-gap positive patients. In this thesis, the correlation 
between FN3K SNPs and the glycation gap in patients with diabetes was examined. 
 
● The final aim was to investigate DEGs and differentially expressed transcripts and 
alternatively spliced transcript variants in G-gap groups via RNA-Sequencing (RNA-
Seq) technology.  
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Chapter 2 
 
 
Material and Methods 
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2.1. Methods 
 
2.1.1. Ethical committee approval  
The UK National Health Service Research Ethical Committee (ref. no. 11/WM/0224) 
approved the genetic and transcriptomic studies. The study was also approved by 
the University Life Sciences Ethics Committee. 
 
2.1.2. Selection of patients and data collection  
Selection of appropriate patients for the study was critical after ethical approval. All 
simultaneous HbA1c and fructosamine values measured over 10 years were 
identified from laboratory records at New Cross Hospital Wolverhampton, yielding 
31,119 results amongst 12,253 people with diabetes. 
 
From amongst those with at least 3 estimations, whose average G-gap was either 
<= -0.5 or >= +0.5, who were confirmed as having a long-term over 10 years 
consistent negative or positive G-gap status and who were alive (n=1663), 150 each 
of G-gap negative or positive subjects were invited by post to participate according 
to the ethical committee approved research protocol of whom in total 184 attended 
and had complete data. Pregnant women, participants with creatinine>200 μmol/L, 
with known haemoglobinopathy, or those with an unusual electrophoretic pattern on 
HbA1c testing were excluded from this study. No other demographic or clinical 
selection criteria were used.  
 
The 184 selected patients had 2 pairs of simultaneous estimations of HbA1c and 
fructosamine and 3 calculated G-gaps that were consistently greater than +0.5% or 
lower than -0.5% in a positive or negative direction respectively. 
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2.1.2.1. Blood glucose analysis 
All subjects were confirmed with diabetes using standard diagnostic tests as carried 
out in pathology lab of New Cross Hospital.  
 
2.1.3. Blood collection 
Venous blood was collected from all volunteers (refer to section 2.1.2) by 
venepuncture into heparin-based S-Monovette system (9 ml, Sarstedt), EDTA 
coated blood collection tubes (sterile 9 ml, Vacutainer, Becton Dickinson, UK) and 
Tempus Blood RNA tubes (Thermo Fisher Scientific). Plasma was separated by 
centrifugation (2000g for 10 minutes at 4°C), aliquoted into 200µl aliquots and stored 
at -80°C until needed.   
 
2.1.3.1. Study participants  
A total of 184 participants, distinguished according to their G-gap status (102 
negatives and 82 positive groups), age 60.4±13 and 65±10 and with a body mass 
index (BMI) of 28.5±5.1 and 36±7.2 kg/m2 respectively), were invited from the local 
community in Wolverhampton, UK (Table 2.1). Participants in this study were obese 
(BMI>30). Participants suffered from T1D and T2D. However, most of them had T2D 
(63% in negative G-gap and 91% in positive G-gap). After ethical approval, the 
written informed consent was given by all participants. Every patient was allocated 
a unique code, and volunteer specific data were recorded in the subject information 
sheet. 
 
 
 
78 
 
  Negative G-gap Positive G-gap 
Number 102 82 
Age (years) 60±13 65±10 
Gender (% male) 77% 61% 
Ethnicity (% White, Asian, 
Black) 
70%, 18%, 12% 73%, 23%, 4% 
Body Mass Index (kg/m2) 30.2±5.2 36.0±7.2 
  
Table 2.1 The baseline characteristcs in the cohort in each glycation gap 
group 
 
2.1.3.2. Analysis methods 
Diabetes Control and Complications Trial (DCCT) presented HbA1c aligned values. 
These were used in the analysis because HbA1c values in mmol/mol were not 
available before 1 June 2009 as recommended by the International Federation of 
Clinical Chemistry and Laboratory Medicine (IFCC). HbA1c was measured by High-
performance liquid chromatography (Tosoh G7 analyzer, Bioscience Ltd, U.K.). In 
the U.K. National External Quality Assurance Scheme (NEQAS), the performance 
scores as A (accuracy) score <100 and B (bias) score <2% reported by Nayak et al. 
(2013). These scores were within the acceptable range (maximum limits: A score 
<200 and B score less than 7.5%) for glycated haemoglobins. Between-batch the 
coefficient of variation was found to be 1.8 and 1.4 for an HbA1c of 5.7% (39 
mmol/mol) and 9.5% (80 mmol/mol), respectively. Fructosamine was estimated by 
using a Cobas kit (based on Nitrotetrazolium-blue reduction method) and coefficient 
of variation of between batches was 3.1 (at a level of 263 mmol/L) and 2.2 (at a level 
of 518 mmol/L) (Nayak et al., 2013). 
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2.1.3.3.  Predicted HbA1c (FHbA1c) and the G-gap calculations 
G-gap was determined by the method of Nayak et al. (2013), who calculated the 
predicted HbA1c (FHbA1c) from simultaneously measured HbA1c, and fructosamine 
values from fructosamine estimation, where fructosamine was converted to an 
HbA1c equivalent measure (F_HbA1c) using the Standardised Normal Deviate 
approach:FHbA1c =  [{(actual Fructosamine value –  mean Fructosamine) /
 SD Fructosamine} x SD HbA1c]  +  mean HbA1c where SD = standard deviation. G-
gap was calculated when the predicted HbA1c (FHbA1c) was subtracted to the true 
HbA1c (𝐺 − 𝑔𝑎𝑝 = 𝐻𝑏𝐴1𝑐 − 𝐹𝐻𝑏𝐴1𝑐). Importantly correlation/regression methods 
were not used to derive the FHbA1c from HbA1c. A negative G-gap is indicated when 
the true HbA1c reading is lower than the FHbA1c, and a positive G-gap denoted when 
the true HbA1c reading exceeds the value predicted by fructosamine. The 
consistency of G-gap status was determined by the positivity of the product of the 
minimum and maximum G-gap value. To identify consistent G-gap among those 
with a second paired HbA1c-fructosamine estimation, the product of two G-gaps was 
calculated. The G-gap would be consistent when the product of two G-gaps is 
positive (positive × positive = positive; negative × negative = positive) whilst any 
discrepancy in two paired readings of G-gaps would yield a negative G-gap product 
(negative × positive = negative) (Nayak et al., 2013).  
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2.1.3.4. Classification of the G-gap and statistical analysis 
 
For simplification, the G-gap was categorised as negative when HbA1c represented 
in % was less than or equal to 0.5 (i.e., <= -0.5), or positive when greater than or 
equal to 0.5 (i.e., >= +0.5). 
 
In this study, the sRAGE level, SNPs genotyping, telomere length, and 
transcriptome level were compared between negative and positive G-gap patients. 
To analyse the data statistically t-tests and Chi-square tests were used, and charts 
drawn to represent these associations. All statistical tests were considered 
statistically significant if P value is < 0.05.   
 
2.1.4. Study 1: Plasma sample analysis for sRAGE level 
The plasma samples from G-gap negative and G-gap positive cohorts were 
prepared by collecting blood in plasma separator tubes and centrifuging at 2000g 
for 10 min at 4°C. To protect from repeated freeze-thaw cycles, the plasma samples 
were stored at -20°C after aliquoting and were then assayed for the levels of 
circulating soluble Receptor-AGE using the sRAGE immunoassay kit (R&D System, 
Minneapolis, MN 55413, USA) according to the instruction of the manufacturer. This 
assay is quantitative and is based on a sandwich enzyme-linked immunosorbent 
assay (ELISA) technique. The coefficient of variation (CV%) value is used to reflect 
the precision of an assay or how repeatable this assay is for producing these results 
(refer section 3.4.5). Full detail of assay parameters is provided in manufacturer`s 
leaflet. 
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2.1.4.1. Enzyme-linked immunosorbent assay (ELISA)   
Plasma level of circulating soluble Receptors for AGE (sRAGE) for 146 patients was 
estimated by the use of a commercial ELISA kit (DuoSet® ELISA; R&D Systems, 
Minneapolis, MN 55413, USA) according to the manufacturer’s instructions. In 
summary, the working concentration of the appropriate capture antibody was used 
to coat the 96-well microtiter plates overnight at room temperature and then next 
day washing was performed using wash buffer (0.05% Tween® 20 in PBS, pH 7.2 
- 7.4. After that reagent diluent contains 1% BSA in PBS at pH 7.2 - 7.4 was used 
to block the plates for one hour at room temperature. Seven standard concentrations 
were prepared including 2000pg/ml, 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 
62.5pg/ml and 0pg/ml by using standards provided in the kit. Dilutions of plasma 
samples (1:4) in reagent diluent were carried out. Standards and diluted samples 
(100µl) were added to respective wells of the plates. After 2 hours incubation period 
at room temperature, the washing of microtiter plates was performed 3 times with 
the wash buffer (0.05% Tween® 20 in PBS) and incubated with the working 
concentration of 100µl biotinylated goat anti-human sRAGE detection antibody for 
2 hours. The washing of plates was performed again, and streptavidin conjugated 
to horseradish peroxidase was added (100µl) to each well for 20 minutes. After 
washing, substrate solution carrying equal parts of reagent A (H2O2) and reagent B 
[tetramethylbenzidine (TMB)] was added into each well to quantify the HRP by the 
colourimetric reaction, and after 20 minutes the colour formation was terminated by 
adding 2N sulphuric acid stop solution (R&D Systems, # DY994), the colour that 
develops is directly proportional to the amount of antigen present in the initial step.  
 
All ELISA reactions were in duplicate in neighbouring wells of the same 96 well plate 
for the assay of sRAGE within plasma samples. The mean was calculated for the 
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duplicate ELISA results. Each plate contained seven standard concentrations in 
duplicate. These standard concentrations were prepared by the serial dilutions 
method and represented the known concentration of the analyte that was present in 
the kit. The optical density of these wells was used to draw a standard curve. Optical 
density values of all wells were measured at 450nm on a microplate plate reader 
(Thermo Labsystems, Multiskan Ascent).  
 
2.1.5. Study 2: SNPs Analysis 
 
2.1.5.1. DNA extraction 
Genomic DNA was isolated from aliquots (200µl) of whole blood of 125 patients with 
diabetes with consistent negative and positive G-gap using the QIAamp DNA Blood 
Mini Kit (QIAGEN, # 51104). The QIAamp based DNA extraction was performed 
according to the manufacturer`s instructions using QIAamp Mini spin columns in a 
standard microcentrifuge.  
 
In summary, 20μl proteinase K (100mg/ml, Qiagen) was pipetted into the bottom of 
a 1.5ml microcentrifuge tube and then 200μl blood sample was added into it. In the 
next step 200μl Buffer AL (contains guanidine hydrochloride) was mixed to lyse the 
cells.  The incubation time was 10 minutes at 56°C. The samples were briefly 
centrifuged to remove drops from inside the lid of microcentrifuge. Two hundred 
microlitres (200 μl) of 100% ethanol was added to the samples and mixed by pulse-
vortexing for 15 seconds. The mixture was then carefully added to the QIAamp Mini 
Spin column. The caps were closed, and the samples centrifuged 8000 rpm for 1 
min. Buffer AW1 (comprising of guanidine hydrochloride and chaotropic salts) (500 
μl) was added to the QIAamp Mini spin columns, the caps were closed, and the 
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samples were centrifuged at 8000rpm for 1 minute. The QIAamp Mini spin column 
was then placed in a clean collection tube. Then 500 μl buffer AW2 (contains sodium 
azide) was added and centrifuged at 14000 rpm for 3 minutes. The samples were 
then centrifuged for an additional 1 minute at 14000 rpm to remove possible AW2 
carryover. Buffer AW1 and AW2 were washing buffers that ensured complete 
removal of any residual contaminants without affecting DNA binding and 
significantly improving the purity of eluted DNA. The QIAamp Mini spin column was 
then placed in a clean 1.5 ml microcentrifuge tube and 100μl buffer AE (contains 10 
mM Tris·Cl; 0.5 mM EDTA) was added and the sample was incubated for 5 minutes 
at room temperature before it was centrifuged at 8000 rpm for 1 minute. After 
centrifugation the concentration of DNA, eluted in Buffer AE was checked by 
Thermo Scientific 2000c/2000 nanodrop spectrophotometer; DNA purity was 
assessed through 260/280 ratio. The procedure involved was to first clean the UV 
spectrophotometer and then blanked the spectrophotometer by putting 1µl of elution 
fluid on the nanodrop window and then placing 1µl of samples to be quantified on 
the nanodrop window and each sample was quantified three times on the nanodrop. 
Nanodrop calculated the DNA concentration based on absorbance values obtained. 
Extracted genomic DNA was kept at -20°C until its use for the study of SNPs and 
telomere length. 
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2.1.5.2. DNA Amplification 
 
2.1.5.2.1. Real-time qPCR 
TaqMan (used for SNPs study) and SYBR-Green (used for telomere study) assays 
are two commonly used qPCR assays. They use TaqMan assay primers and a 
fluorescent probe that are complementary to template bind to the respective 
sequence while in SYBR-Green assay primers and a fluorescent dye sandwich 
between dsDNA (Figure 2.1). Despite the method used, targeting specific DNA 
sequences that are unique can provide a sensitive and specific way to test for the 
presence of SNPs and telomeric DNA. Primers (short synthetic oligo sequences) 
bind specifically to a DNA strand and act as an initiation site for DNA polymerase to 
synthesise a new DNA strand.  
 
 
 
Figure 2. 1 SYBR-Green Vs TaqMan qPCR assays. (Kim et al., 2013). 
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2.1.5.2.2. Single nucleotide polymorphism (SNPs) assay 
In this thesis, SNPs were detected using the TaqMan SNP Genotyping Assays 
technology. The SNP genotyping was carried out using the Stratagene 
Mx3000PTM, PikoReal and ABI 7500 FAST Real-Time PCR System. 
 
2.1.5.2.2.1. TaqMan SNP genotyping assay  
The TaqMan SNP genotyping assay is a single-tube PCR assay that utilises the 5ʹ 
nuclease chemistry for amplification and detection of specific polymorphisms in 
purified genomic DNA samples. Specific forward and reverse primers and two allele-
specific oligonucleotide probes (designed to target the polymorphism) were used for 
the amplification of wild-type SNP Allele “A” and the mutated Allele “B”. Allele-
specific oligonucleotide probes were labelled with a fluorescent reporter dye (VIC 
specific for allele “A” and FAM specific for allele “B”) attached to its 5′ end and a 
non-fluorescent quencher (NFQ) at its 3′ end (Applied Biosystems 2010a) (Figure 
2.2). During real-time PCR amplification, each labelled probe binds specifically to 
one of the two alleles of the SNP of interest with different affinity. Once the 
amplification process starts the Taq polymerase enzyme cuts the bound probe and 
a fluorescent signal is generated, the strength of which is dependent on the 
accumulation of PCR product. Fluorescent signals were measured and interpreted 
automatically by using ABI 7500 FAST Real-Time PCR system. Homozygosity for 
Allele “A” and homozygosity for Allele “B” will be interpreted when only VIC dye 
fluorescence and only FAM dye fluorescence signals appeared respectively. Allele 
“A”/Allele “B” heterozygosity was interpreted by the presence of both fluorescence 
signals (VIC and FAM). This technique was suitable for the discrimination of alleles 
that differed by a single base change: this technique was robust, accurate and cost-
effective. 
86 
 
 
 
 
Figure 2. 2 Allelic discrimination is determined by the selective annealing of 
TaqMan MGB probes. (Applied Biosystems, 2010a). 
 
 
2.1.5.2.3. Preparation of genomic DNA  
DNA samples of 15 ng/μl concentrations were prepared in nuclease-free water. All 
samples should preferably have the same DNA concentration for genotyping so that 
a wide range of fluorescence activity within a genotype group would be avoided. 
The occurrence of SNPs C/G (rs1056534), C/T (rs1046896) and C/T (rs3848403) 
in FN3K gene and A/C (rs11568350) in the SLC40A1 gene were analysed using the 
TaqMan Assay (ThermoFisher Scientific) with provided primers and probes by real 
time qPCR.   
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2.1.5.2.3.1. Sample preparation   
TaqMan Genotyping Assay mix was supplied at 40x concentration. The assay was 
diluted to a 20x working concentration by adding one volume of PCR grade water 
(Thermofisher). For one well, a basic volume was 24μl containing 12.5μl 2× TaqMan 
universal PCR master mix (contains AmpliTaq Gold DNA Polymerase, 
deoxyribonucleotide triphosphate (dNTPs) and ROX Passive Reference), 1.25μl 
20× SNP assay mix, and 10.25μL of nuclease-free water. The reaction mix was 
added into each well of a reaction plate. Then, 1μl of 15 ng/μl of the individual DNA 
sample was added into the bottom of wells, changing the tip between every DNA 
sample. Two wells in each plate were left free from template DNA as negative 
controls: for these wells, 1μl of water was added in place of DNA. The 8-strip cap 
seals were used to cover the plate and then centrifuged at 1,500 rpm for 1 min to 
collect reagents at the bottom of the wells and to remove any air bubbles. The plate 
was loaded into a Real-time PCR machine.  For SNPs the thermal cycling conditions 
were 10 minutes at 95°C, followed by 40 cycles of 92°C for 15 seconds and 60°C 
for 60 seconds. The 92°C reads provided the cycle threshold (Ct) values for the 
amplification of the target sequence. The reagents used for the assay are 
summarised in Table 2.1. Results were transferred into Microsoft Excel spreadsheet 
for analysis. The 5’ nuclease activity may produce false positive amplifications 
because of the repetitive nature and high throughput (Drosten, Seifried and Roth, 
2001), but in general TaqMan® genotyping assays are considered to be highly 
accurate (Martino, Mancuso and Rossi, 2010).  
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A) Reagents used for the TaqMan genotyping assay for SNPs 
Reagents Concentration Volume 
TaqMan genotyping assay 20x 1.25 µl 
TaqMan Universal PCR 
MasterMix 
2x 12.5 µl 
Nuclease-free water NA 10.25 µl 
DNA template  15ng/µl 1.0 µl 
Total  25 µl 
 
Table 2.1 Table showing the composition of the mixture for TaqMan 
genotyping assay. 
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2.1.6. Study 3: Telomere length (TL)   
 
2.1.6.1. Extraction of DNA 
DNA was extracted as described in section 2.1.5.1. 
 
2.1.6.2. Real-time polymerase chain assay for telomere length (TL)   
Average telomere length was estimated from total genomic DNA (15 ng/μl) samples 
of 125 diabetic patients with consistent negative and positive G-gap using real-time 
quantitative PCR using Cawthon's method (Telomere/Single Copy Gene ratio, T/S 
method) (Cawthon, 2002). The theory of this assay is to measure an average 
telomere length ratio by calculating telomeric DNA quantity with specially designed 
primer sequences and divide that quantity by the amount of a single-copy gene. The 
factor by which the ratio of telomere to single copy gene differs between G-gap 
negative samples and G-gap positive samples was measured. For each DNA 
sample 2 PCR reactions were designed using previously published telomere 
forward and reverse primers (Telomere forward: 
CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT and Telomere 
reverse: GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCC; final 
concentrations 100nM each) (Cawthon, 2002 & Callicott and Womack, 2006) and 
RPLP0 forward and reverse primers (RPLP0 forward: 
CAGCAAGTGGGAAGGTGTAATCC and RPLP0 reverse: 
CCCATTCTATCATCAACGGGTACAA; final concentrations 100nM each) 
(O'Callaghan et al., 2008). RPLP0 represents a single copy gene (SCG) and 
encodes 60S acidic ribosomal protein P0. The 60S acidic ribosomal protein P0 is a 
human ribosomal protein and this is a component of the 60S ribosomal subunit. 
SCG was used as a control and to standardise the assay, as described in Cawthon 
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(2002). Each 20 μl reaction performed consists of 15 ng DNA, Precision FAST 2 × 
qPCR master mix (with Syber Green), 100 nM telomere primers or 100 nM Rplp0 
primers on the 7500 FAST qPCR system (Applied Biosystem). The telomere assay 
uses SYBR Green to detect the PCR amplification product at 492nm-516nm 
wavelength indicating that only telomere/SCG is being amplified by the PCR. Both 
the telomere and SCG amplifications were performed in triplicates, whilst in each 
run duplicates of a non-template control included. Cawthon (2002) method was used 
to calculate the T/S ratio, based on the amplification of a telomere fragment (T) and 
an SCG (S) fragment. The thermal cycling conditions for both telomere and RPLP0 
consisted 20 seconds at 95°C. For telomere 40 cycles of 5 seconds at 95°C, 30 
seconds at 65°C. For RPLP0 40 cycles of 30 seconds at 95°C, 30 seconds at 60°C.  
Followed by 30 seconds at 72°C for both telomere and RPLP0. The 95°C reads 
provided the cycle threshold value (Ct) values for the amplification of the target 
sequence. After completion, the data were transferred from PCR software to a 
Microsoft Excel spreadsheet for analysis. “T” represented the experimental DNA 
sample that was calculated by taking the average of the cycle threshold value for 
the telomere product whilst “S” represented the average of the cycle threshold value 
for the SCG product and the T/S ratio was calculated in the negative and positive 
G-gap groups by dividing the relative average input amount of the telomere PCR by 
the relative average input amount of the RPLP0 PCR of the same sample.  The 
cycle threshold (Ct) value represented the number of cycles required for the 
fluorescent signal to cross background level to exceed the threshold level. The 
results were reported as the relative average telomere length ratio. 
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B) Reagents used for the Telomere Length Assay 
Reagents Concentration Volume 
TaqMan genotyping assay 20x 2.0 µl 
FAST qPCR Master Mix 2x 10.0 µl 
Nuclease-free water NA 7.0 µl 
DNA template  15ng/µl 1.0 µl 
Total  20 µl 
 
Table 2. 2 Telomere length assay. (A): Thermal cycling program. (B): Reagents 
used for the telomere length assay on 7500 FAST qPCR System (Applied 
Biosystem). 
 
  
A) Telomere length assay 
Steps Temperature Time Cycles PCR 
Initial denature 95 20 seconds 1 Telomere and RPLP0 
Denature 95 5 seconds  
 
40 
 
Telomere 
95 30 seconds RPLP0 
Annealing 65 30 seconds Telomere 
60 30 seconds             RPLP0 
Extension 72 30 seconds Telomere and RPLP0 
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2.1.7. Study 4: RNA extraction 
Tempus Blood RNA tubes (ThermoFisher) contains 6ml of stabilising reagents. 
These tubes were used to collect 3ml peripheral venous blood samples from 32 
diabetic patients with G-gap negative and G-gap positive, immediately mixed 
vigorously after collection, incubated at room temperature for 2 hours, and kept at -
80˚C until processing.  
 
A commercial kit from Norgen Biotek RNA purification Kit I (Norgen, Thorold, ON, 
Canada) was utilised to extract RNA. Samples were thawed and left for 2 hours at 
room temperature before extracting RNA. RNA extraction was performed according 
to the manufacturers’ instructions briefly described here. Blood samples were 
transferred to 50ml conical tubes marked respectively with sample numbers and 
filled with Tempus Blood RNA tube diluent (contains phosphate-buffered saline) to 
make up a final volume of 12 ml. Tubes were mixed by vortexing vigorously for 30 
seconds. Mixed samples were centrifuged at 4°C for 30 min at 4500rpm. After 
discarding supernatant, the pellet was dried by inverting the tube on a paper towel 
for 2 minutes. The dried pellet was re-suspended with 600μl lysis solution 
(comprising of Tris and EDTA) by vortexing for a few seconds. Pure ethanol 100% 
(300μl) was added to the samples and mixed. Afterwards, the solutions were 
transferred to the RNA isolation spin columns where a column was assembled with 
one of the provided collection tubes. Centrifugation for 1 min at 14,000 rpm was 
performed to make sure that the entire lysate volume had passed through the 
column. After that samples were washed with washing buffer (contains chaotropic 
salts). DNA may affect the sensitive downstream application. Therefore, RNase-
Free DNase I Kit (Norgen, Thorold, ON, Canada) was used at this point to remove 
maximum residual DNA and 100μl RNase-free DNase 1 was applied to the sample 
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and centrifuged for 60 seconds at 14,000 rpm. Flow through solution was pipetted 
to the column again for maximum DNase activity and to get maximum RNA yields 
and centrifuged at 14000 rpm. DNA digestion was carried out by incubating the 
column assembly at room temperature for 15 min. Thereafter, 400μl of the washing 
solution was applied to the column and centrifuged for 1 min at 14,000rpm and then 
for 2 min at 14000 rpm to dry the column. RNA was eluted by adding 50μl nuclease-
free water to the samples and incubated for 1 min followed by centrifugation for 2 
min at 2000 rpm and 1 min at 14,000 rpm. The RNA elution step was repeated for 
maximum RNA recovery. NanoDrop spectrophotometer (Thermo Fisher Scientific) 
was used to determine the yield of isolated RNA. The samples were stored at -80˚C 
until RNA sequencing and library preparation by Oxford Genomic Centre. 
 
2.1.7.1. RNA quantification 
RNA quantification was performed using a RiboGreen assay (Invitrogen) according 
to manufacturer`s instruction. The RiboGreen assay utilises a fluorescent RNA stain 
that is 200-fold more sensitive than ethidium bromide. RiboGreen reagent binds 
RNA and fluoresces with the maximum emission wavelength of 525nm. 
Fluorescence can be detected at a wavelength with detection as low as 1 ng/ml 
RNA (McKiernan et al., 2018). Briefly, 200-fold RiboGreen reagent was prepared 
into TE buffer and kept away from light. Six standard concentrations were prepared 
including 50ng/ml, 25ng/ml, 12.5ng/ml, 6.25ng/ml, 3.12ng/ml and 1.5ng/ml by using 
standard provided in the kit (ribosomal RNA, 100 µg/ml). Dilution of samples (1:10) 
in TE buffer were carried out. Diluted standards and samples (100 µl) in TE buffer 
were added to respective wells of 96-well plate in triplicate. Finally, 100 µl of the 
prepared RiboGreen reagent was added to each well. Plates were incubated for 5–
30 min at room temperature, protected from light until reading at fluorescein 
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emission settings on a FLUOstar OPTIMA plate reader (BMG Labtech) at 
wavelength 525nm.  
 
2.1.7.2. Quality control checks  
Quality control checks were conducted pre- and post-alignment to ensure sufficient 
quantity and quality of RNA samples. Pre-alignment quality control checks (RNA 
abundance and quality) were performed by using 2200 or 4200 Tape Station 
software using the High Sensitivity RNA ScreenTape kit (Agilent Technologies) 
according to the manufacturer's protocol. Briefly, each sample was prepared for 
RNA screen tape assay by mixing 5μl of Agilent RNA Buffer with 1µl of RNA sample. 
Similarly, the Ladder was prepared by mixing 5μl of Agilent RNA Buffer with 1µl of 
RNA ladder (a molecular-weight size marker). Samples and ladder were vortexed 
using IKA vortexer followed by centrifugation at 2000 rpm for 1 minute. After this 
brief spin the samples/ladder were denatured by heating at 72ºC for 3 minutes and 
placed on ice for 2 minutes and then centrifuged again and then loaded into Tape 
station. The Tape station calculates an RNA integrity number (RIN) which on a scale 
of 1 to 10 provides an assessment of RNA quality with 1 being highly degraded RNA 
and 10 being the heavily intact RNA (Mueller, Lightfoot and Schroeder, 2004). If the 
sequence base quality of RNA is not satisfactory then it can affect the downstream 
analysis. Therefore, it is better to perform quality trimming of sequence reads before 
alignment (Kallio, et al., 2011).  
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2.1.7.3. RNA-Seq library preparation  
 
2.1.7.3.1. Ribosomal RNA removal 
Samples for RNA-Seq from 32 negative and positive G-gap patients with diabetes 
were sequenced as recommended by the manufacturer (Illumina). Input material 
(total RNA) was normalised to 1µg prior to library preparation. For the removal of 
ribosomal RNA (rRNA), the Ribo-Zero rRNA Removal Kit (Illumina, 
Human/Mouse/Rat) was used according to the manufacturer’s instructions. 
Ribosomal RNA (rRNA) removal is based on the hybridisation/bead capture 
procedure that selectively hybridises to rRNA species using biotinylated capture 
probes. The hybridised compound (probe-rRNA) is then arrested by magnetic beads 
and then removed. RNA 1µg was used to deplete ribosomal RNA.  Ribosomal RNA 
(rRNA) depleted samples were purified using an ethanol precipitation method. Ribo-
Zero-treated RNA was quantified by using a fluorometric method and the size profile 
was assessed on 2200 Agilent TapeStation system.  
 
 2.1.7.3.2. TruSeq stranded total RNA (Illumina) library preparation  
After rRNA depletion, whole RNA libraries were prepared using TruSeq Stranded 
Total RNA kit (Illumina) following the manufacturer’s instructions. Elute, Prime and 
Fragment High Mix were added to fragment RNA. ERCC (Synthetic Spiking 
Standards) (1:1000) (LifeTechnologies) was added before incubation at 94˚C for 
8min. First and second cDNA strands were synthesised by two consecutive 
steps.For the first step (first strand synthesis), Act D (Actinomycin D) and 
SuperScript II, Reverse Transcriptase and random hexamer primer were added to 
fragment RNA before the thermocycler incubation at 25˚C for 10 minutes, at 42˚C 
for 15 minutes and at 70˚C for 15 minutes, while in the second step second strand 
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marking master mix was added and incubated at 16˚C for sixty minutes. The purified 
double-stranded cDNA was obtained by AMPure XP beads (Beckman Coulter), 
according to manufacturer’s instructions. The indexing adaptors were ligated to the 
end of double-stranded cDNA strands by incubation for 10 mins at 30°C. Additional 
adaptors were removed with the help of AMPure XP beads (Beckman Coulter), 
following manufacturer’s instructions. The amplification of cDNA libraries was 
performed on a Tetrad (Bio-Rad) using in-house unique dual indexing primers 
(Lamble et al., 2013) with this thermal cycler programme: 98°C for 30 seconds,15 
cycles of 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds and finally 
72°C for 5 minutes. The purification of amplified libraries was carried out by AMPure 
XP Beads (Beckman Coulter), according to manufacturer’s instructions, before 
analysing quality and size profile on Agilent 2200 TapeStation and quantified using 
Qubit 2.0 Fluorometer, under standard operating procedures. 
 
2.1.7.3.3. Libraries quantification and normalisation  
The quantification of libraries was conducted by Qubit Kit Assay (Invitrogen, Life 
Technologies). This quantification method is fluorometric-based and uses DNA 
binding dyes. Briefly, samples and standards were kept on ice whereas the Qubit 
buffer and reagent were kept at room temperature. The working concentration of 
Qubit reagent 1:200 was prepared in Qubit buffer. The standard tube contained 190 
μl of Qubit working solution and 10μl of Qubit standard whilst the sample tube 
included 199 μl of Qubit working solution (contains Quant-iT reagent and Quant-iT 
buffer) and 1μl of the sample. Each tube had a final volume of 200 μl. The tubes 
were vortexed briefly and incubated for 2 minutes at room temperature. Finally, 
tubes were inserted in the Qubit 2.0 Fluorometer and quantification was conducted. 
The Qubit readings were used for library normalisation. Individual libraries were 
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normalised to 10 nM before being pooled for processing. Each cDNA library was 
denatured and further diluted in resuspension buffer (10 mM Tris-HCl, 10% Tween-
20) to 2 nM prior to loading on the sequencer. Paired-end sequencing of the libraries 
was performed at Oxford Genomic Centre using a HiSeq4000 75bp platform after 
preparation with Illumina, HiSeq 3000/4000 PE Cluster kit and 150 cycles SBS kit, 
generating a raw read count of >45 million reads per sample. 
 
2.1.7.4. Roadmap from data to results 
Raw data were obtained for analysis in FASTQ format from the sequencing 
machine. In this format, four lines represents one sequence read; where the first line 
consists of the name or ID of the sequence and starts with the sign “@", the second 
line contains actual sequence, the third line starts with + sign and has no specific 
function whilst the fourth line indicates the quality of each base present in the 
sequence. FastQC (v 0.11.5) software acts as a quality control tool for data 
sequence (Andrews, 2010), check GC content for each base as well as adapter 
content (Cock et al., 2009) by using the FASTQ files as a starting point and produce 
a report about the statistics of the data. These reports also contain a Phred quality 
score per base. Base Callers set the Phred quality scores [Q = −10log10(P)], where 
P represents the likelihood of the base call being incorrect (Cock et al., 2009).  
Filtration of garbage reads i.e. reads with low-quality base call/reads with low-quality 
scores (Andrews, 2010) or trimming of the sequence to remove low-quality bases 
can be performed before reading alignment. Trim Galore tool can be easily applied 
to paired-end reads to remove low-quality base calls and adapters from raw 
sequences (Krueger, 2015). Trimming not only improves the mapping yield but also 
improves mapping speed. In paired-end reads experiments, two ordered files are 
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prepared, one with the first end and the other with the second. FastQC reports help 
in qualitative judgment about the quality of the data.  
 
Next step of the analysis includes the mapping of reads to the reference genome 
for the identification of their origin for the transcription process. Reference genomes 
are commonly available as FASTA/GTF file format and can be downloaded from the 
Ensembl FTP site (ftp://ftp.ensembl.org/pub/).  
 
2.1.7.5. RNA-Seq read mapping 
The reference genome, as well as gene annotations, exist for human. Therefore, 
sequenced reads were directly mapped to the reference genome. Data on human 
genome (GRCh38 human assembly) was downloaded from Ensembl FTP site that 
was used for all the steps of analysis. This assembly was used as a base to produce 
other files and results. HISAT2 was used to map the results with the reference 
genome and for the discovery of transcript splice sites. StringTie was used for the 
creation of multiple isoforms through the assembly of the alignments into full and 
partial transcripts, and for estimating the expression levels of all genes and 
transcripts. Ballgown takes the output (transcripts and expression levels) from 
StringTie and uses rigorous statistical methods to identify which transcripts were 
differentially expressed between G-gap negative and G-gap positive groups. 
 
2.1.7.6. Bioinformatics tools/ RNA sequencing mapper 
Bioinformatics tools were used to perform various activities including sequence 
mapping, identification of gene expression, identification of differential expression 
and aligning RNA-Seq reads (Luscombe, Greenbaum and Gerstein, 2001). High 
throughput sequencing of mRNA (RNA-Seq) was used for the measurement and 
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comparison of gene expression in negative and positive G-gap groups. RNA-Seq 
experiments generated large and complex data sets. HISAT2, String Tie, and 
Ballgown which provide fast, accurate and flexible software, were used to reduce 
the raw read data to comprehensive results and provide a comprehensive analysis 
of the RNA-Seq experiments. Together these were used for the alignment of reads 
to the genome, assembly of transcripts including novel splice variant and computing 
the abundance of these transcripts in each sample. These software packages were 
used to compare G-gap negative and G-gap positive groups to identify differentially 
expressed genes and transcripts.  
  
2.1.7.6.1. HISAT2  
For the downstream analysis of RNA sequencing, reads were mapped to a 
reference genome. Previously used TopHat2 programme was replaced with 
HISAT2 (hierarchical indexing for spliced alignment of transcripts) that is a faster, 
accurate and which uses a sensitive mapping programme for the alignment of RNA 
sequencing reads (Kim, Langmead and Salzberg, 2015). It is different in the sense 
that it maps the spliced reads that span over exon-exon junctions by using the 
indexing approach. The indexing approach is based on the FM index. In this tool, 
the algorithms use two types of indexes: one global FM index (denoting the whole 
genome) and various small around 48000 local FM indexes (collectively cover the 
entire genome) where every local FM index shows a genomic region consist of 
64,000bp. HISAT2 aligns the reads to the reference genome first on the basis of the 
global index where it applies exonic alignments with selected segments obtained 
from reading sequences and identified the candidate mapping region. After this, 
alignment was finalised with the help of the local indexes of the candidate regions. 
The small indexes in combinations with other alignment approach made it possible 
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to effectively align the RNA-Seq reads particularly those that span exon-exon 
junctions.   
 
2.1.7.6.2. String Tie assembler 
Various approaches after sequencing of the transcriptome produce more than 200 
million short sequence reads consisting of 100-150bp/reads. Assembly of numerous 
transcripts with variable sequence coverage and alternative splicing transcripts from 
the same locus that share the exons is hard. String Tie ensured that a read was 
assembled correctly across the entire region where the introns have been retained. 
Therefore, it was able to assemble the alignments into transcripts, producing 
multiple isoforms and computing the expression level of all genes and transcripts. 
String Tie was used because it was accurate and faster to align the reads into 
potential transcripts (Pertea et al., 2015) as compared to Cufflinks and can evaluate 
expression level effectively and reconstruct the genes precisely and 
comprehensively. String Tie can assemble transcripts regardless of whether gene 
annotation was available and can assemble a larger number of splice variants per 
gene locus. Specialised software i.e. Ballgown can process the output of String Tie. 
To eliminate the gene length and sample biases, normalisation was performed by 
Ballgown software.  
 
2.1.7.6.3. Ballgown 
  
Ballgown takes the output i.e. gene and transcripts expression levels from String Tie 
to determine differentially expressed genes between the studied cohort. Ballgown 
software helps in RNA-Seq data analysis as it is the part of the R/Bioconductor 
package. It helps in the visualisation of expression level for transcriptome assembly. 
The Ballgown R package is dependent on pre-processing activities (carried out by 
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HISAT2 and String Tie) including alignment of RNA sequencing reads to the 
reference and assembly of aligned reads. The obtained expression level of 
transcript, intron, and exons for the evaluation purpose should be in Ballgown 
readable format. FPKM is used for normalisation. Normalisation is done using a 
stattest function in a Ballgown.  
 
2.1.7.7. Gene set enrichment and pathway analysis of differentially expressed 
genes 
Gene set enrichment (GSE) testing, also known as functional analysis of genes, 
was used to identify enriched functions of differentially expressed genes between 
G-gap groups. All expressed genes were ranked according to their fold changes 
with p<0.05. This analysis provides an understanding of which pathways are 
important targets and more affected in G-gap groups. This study has identified which 
diseases the G-gap may play a role. The computational tool Database for 
Annotation, Visualization and Integrated Discovery (DAVID) 
(www.david.ncifcrf.gov/) v 6.8, which provides meaningful insight on biological 
meanings of large gene lists derived from genomic studies, was used for gene set 
enrichment and pathway analysis. Disease and gene ontology for functional 
annotation and KEGG for pathway analyses were applied using DAVID.  
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Chapter 3 
 
 
“Do SNPs in FN3K and Ferroportin1 explain G-gap variation and 
potentially associate with sRAGE?” 
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3.1. Introduction 
Research has demonstrated that FN3K and SLC40A1/Ferroportin1 SNPs were 
linked with FN3K activity, HbA1c levels and diabetes complications (Mohas et al., 
2010; Tanhauserova et al., 2014). The discrepant HbA1c values in comparison with 
other measures of average glycaemia including plasma fructosamine or glycated 
albumin could shift the glycation gap (G-gap) in the negative or positive direction. 
The study reported that a positive G-gap is associated with increased diabetes 
complications in patients compared with those with a negative G-gap as well as 
being associated with differences in mortality (Nayak et al., 2013). Dunmore et al. 
(2018) reported that the individually consistent glycation gap may be the result of 
differences in activity of a deglycating enzyme FN3K, which is highly expressed 
intracellularly in the erythrocyte. FN3K can only affect the HbA1c level without 
affecting glycated circulating protein. Glycation of circulating proteins is estimated 
by fructosamines.  
 
The study of FN3K gene is an approach in the dissection of the genetic basis of 
FN3K 3-fold higher activity in the negative G-gap group in patients with diabetes. 
Dunmore et al. (2018) also reported a low level of AGEs in negative G-gap group 
whilst in the positive G-gap group the high AGEs level was reported. Advanced 
glycation end products (AGEs) plays a key role in the development of diabetic 
vascular disease (Peppa and Vlassara, 2005, Genuth et al., 2005 and Monnier, Sell 
and Genuth, 2005) and are used as biomarkers because they are supposed to 
provide a link between hyperglycaemia and diabetes complications (Monnier, Sell 
and Genuth, 2005). AGEs are involved in pro-oxidant activities. Through these 
activities, AGEs might be involved in the progression of vascular disease in people 
with diabetes (Brownlee, 2005 and Peppa, Uribarri and Vlassara, 2008).  AGEs-
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RAGEs interaction induces inflammation and oxidative stress and is thought to 
nurture disease progression. RAGE as multi ligands is involved in several 
physiological processes (neural growth, acute inflammation) and disease 
pathologies (diabetes, tumour growth/metastasis, Alzheimer’s disease, chronic 
inflammation), implicating RAGE as a promising lead for therapeutic intervention 
(Schmidt et al., 2000 & Stern, 2002). N‐terminal truncated RAGE, produced from 
alternative splicing of RAGE mRNA, and C‐terminal truncated RAGE, formed by 
proteolytic cleavage of membrane-bound RAGE protein, are two other forms of 
RAGE, expressed in human endothelial cells of diabetic patients (Yonekura et al., 
2003). Endogenous factors like glucose, inflammation and exogenous factors such 
as smoking, and diet affect the circulating levels of AGE receptors (Selvin et al., 
2013).  
 
The extracellular surface of the RAGE consists of COOH terminus whilst the amine 
(NH) terminus of RAGE is important for the activation of the proinflammatory nuclear 
factor (NF)-KB-mediated signalling. RAGE induces inflammation after stimulation by 
AGEs and contributes to tissue injury. RAGE is also involved in the stimulus of 
progression of the chronic disease through NFkB-mediated signalling (Yan et al., 
2008, Yan, Ramasamy and Schmidt, 2009, Yan et al., 2007 and Ramasamy et al., 
2005). Previous studies reported the role of RAGE and soluble RAGE (sRAGE) in 
the pathophysiology of diabetes angiopathy (Ramasamy et al., 2007, Lindsey et al., 
2009, Skrha et al., 2012). COOH terminal and transmembrane domains are absent 
in plasma sRAGE.  sRAGE competes with RAGE to bind with the ligands. In type 2 
diabetes, the sRAGE level was directly proportional to urinary albumin excretion 
(Humpert et al., 2006). Considering the role of sRAGE in the pathogenesis of 
diabetes complication, this study examined the relative expression of soluble RAGE 
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(sRAGE) protein in G-gap negative and G-gap positive groups. This study was 
conducted to evaluate the sRAGE levels in 146 plasma samples collected from 
diabetic patients with negative and positive G-gaps and single nucleotide 
polymorphisms of genes encode FN3K/Ferroportin1 in the studied cohort. The 
relationship of FN3K polymorphisms (rs3848403 and rs1056534) with the sRAGE 
concentration was also explored in those cohorts.  
 
3.2. The rationale of the study 
The aim of the present study was investigating the genetic variation affecting FN3K 
activity in diabetic patients with negative and positive G-gap. This study, focused on 
the variant of FN3K gene, whose product is involved in non-enzymatic glycation 
reaction, in mixed populations with diabetes. The purpose was to identify the 
relationship between SNPs within the FN3K gene (with their known functional 
effects) and sRAGE levels in negative and positive G-gap. This may offer a better 
comprehension of the glycaemic control and provide a predictive role in the middle 
and long period of the disease.  
 
3.3. Materials and methods 
 
3.3.1. SNPs study for FN3K/Ferroportin1 
 
3.3.1.1. DNA extraction 
DNA was extracted according to the method described in Chapter 2 from whole 
blood that had been kept frozen at -20° C.  
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3.3.1.2. SNP selection and genotyping 
The SNPs in FN3K and SLC40A1/Ferroportin1 genes, according to their known 
functional effects were selected. The features of analysed SNPs are provided in 
Table 3.1. PCR with the fluorescent-based chemistry was used to determine FN3K 
and SLC40A1/Ferroportin1 SNPs (TaqMan® SNP Genotyping Assay, Applied 
Biosystems). Preparation of genomic DNA and PCR mixture can be found in 
Chapter 2 (2.1.6.2.3.1. Sample preparation). 
 
 
 
Chromosome rs number Nucleotide Substitution 
FN3K 17q25.3 1056534 C/G 
  1046896 C/T 
  3848403 C/T 
SLC40A1/Ferroportin1   2q32.2 11568350 A/C 
 
Table 3. 1 Characteristics of studied SNPs for FN3K/Ferroportin1 gene. The 
table shows FN3K, fructosamine 3-kinase; SLC40A1/Ferroportin1; SNPs, Single 
Nucleotide Polymorphism. 
 
3.3.1.3. TaqMan assay 
The TaqMan assay was used for genotyping polymorphisms of the 
FN3K/Ferroportin1 gene with a view to discriminate between two alleles of a specific 
SNP of FN3K/Ferroportin1 gene (refer to Chapter 2, TaqMan genotyping assay for 
details). 
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3.3.2. sRAGE study 
 
3.3.2.1 Materials 
Details of materials including equipment (microplate reader), reagents (phosphate 
buffer saline, wash buffer, reagent diluent, substrate solution and stop solution) and 
kit (Duoset ELISA kit for Human sRAGE) used for the (soluble Receptor-AGE) 
sRAGE assay can be found in Appendix 1. 
 
3.3.2.2. sRAGE assay  
Plasma sRAGE expression was measured by immunoassay (R&D Systems, 
Minneapolis, MN 55413, USA) with a detection range (1:4 diluted samples) of 0– 
2000 pg/ml. Details can be found in chapter 2 (2.1.5.1. Enzyme-linked 
immunosorbent assay (ELISA)). 
 
3.3.3. Statistical analysis 
 
3.3.3.1.  SNPs for FN3K/Ferroportin1 
Data were analysed on SPSS v 24. The comparison of means between the groups 
was done by Student`s t-tests for 2 independent measures or otherwise one-way 
analysis of variance. The comparison of proportions was by Chi-Square. Binary 
regression was used to compare the association of dichotomised variables with 
other factors and univariate analysis for continuous variables. Results of statistical 
testing were considered significant at p≤0.05. 
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3.3.3.2. sRAGE 
Data were analysed using SPSS/ Excel. Values were expressed in pg/ml. Student`s 
t-test (Two-Sample Assuming Unequal Variances) on Excel was then used to find 
the statistical significance (p ≤0.05) an association between the negative/positiveve 
G-gap and sRAGE values. sRAGE plasma concentration in relation to the genotype 
of FN3K was expressed as the mean ± standard deviation (SD). Differences 
between the genotype of FN3K SNPs rs3848403 and rs1056534 in relation to 
sRAGE concentration were analysed by one-way analysis of variance (ANOVA). P-
values ≤0.05 show statistically significant results.  
 
3.4. Results 
 
3.4.1. Patients 
A total of 184 diabetic subjects were recruited at different times at New Cross 
Hospital in Wolverhampton and divided into two different glycation gap categories 
i.e. negative and positive (see Chapter 2 for details) This cohort was previously 
analysed for the FN3K activity (Dunmore et al., 2018). The baseline characteristics 
of patients are reported in Table 3.2. Negative G-gap and positive G-gap subjects 
differed significantly (p<0.05) in age (60±13 and 65±10 respectively), BMI (30.2±5.2 
and 36.0±7.2 respectively) and type of diabetes (63% T2D and 91% T2D 
respectively) but not gender, ethnicity, duration of diabetes (p>0.05). As expected 
from the selection criteria, negative G-gap and positive G-gap subjects differed for 
HbA1c, fructosamine and the G-gap (all p<0.001). All clinical and biochemical data 
for the negative G-gap and positive G-gap groups are shown in Table 3.2. Glycated 
HbA1c level was 7.6% ±1.3 and 9.4%±1.3 in G-gap negative and G-gap positive 
groups respectively. While the fructosamine level was 347±62 and 293±43 µmol/l in 
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G-gap negative and G-gap positive groups respectively. Glycation gap in negative 
and positive groups was -1.5±0.6 and +1.6±0.6 respectively. 
  Negative G-gap Positive G-gap P value 
  
Number 102 82   
Age 60±13 65±10 p<0.001 
Body mass index (kg/m2) 30.2±5.2 36.0±7.2 p<0.001 
Type of diabetes (% Type 2)  63% 91% p<0.001 
Gender (% male) 77% 61% Ns 
Ethnicity (% white, Asian, 
Black) 
70%, 18%, 12% 73%, 23%, 4% Ns 
Duration of diabetes (years) 19±12 16±10 Ns 
Fructosamine derived HbA1c 
(% glycated HbA1c) 
9.1±1.9 7.8±1.3 p<0.05 
Average HbA1c (% glycated) 7.6±1.3 9.4±1.3 p<0.001 
Average Fructosamine (µmol/l) 347±62 293±43 p<0.001 
Average G-gap (% glycated 
HbA1c) 
-1.5±0.6 +1.6±0.6 p<0.001 
 
Table 3.2 Descriptive characteristics of patients involved in the study. Values 
are the mean± SD or otherwise percentages. 
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3.4.2. Nanodrop 
Nanodrop was used for the analysis of DNA sample purification. The absorbance at 
260nm provided a yield of DNA whilst proteins have an absorbance at 280 nm. The 
A260/A280 between 1.8 and 2.0 are acceptable as these indicate that the sample does 
not have any contamination. The average concentration of DNA samples was 
approximately 53.44ng/µl and 57.61ng/µl in G-gap negative and G-gap positive 
groups respectively. In this study the A260/A280 ratio for all studied DNA samples was 
≥1.7 in both studied groups. 
 
3.4.3. SNPs association with G-gap status 
Three polymorphisms in the FN3K gene and one polymorphism in 
SLC40A1/Ferroportin1 were studied. These were single nucleotide polymorphisms 
(SNPs), a c.141+246C>T (rs3848403) in intron region, a c.900C>G (rs1056534) in 
exon 6 and a C/T (rs1046896) in promoter region of FN3K gene whilst c.744G>T 
(rs11568350) in exon 6 of the SLC40A1 gene leading to Q248H amino acid 
substitution in the ferroportin-1 protein. In this study, A/C frequency that relates 
directly to G/T frequency was measured. G/T alleles were reported in reverse 
orientation to genome (rs11568350 in the NCBI database). The SNPs rs3848403, 
rs1056534, rs1046896, and rs11568350 were not significantly different between the 
negative G-gap and positive G-gap groups as the p>0.05.  
 
The FN3K SNPs rs3848403 had 3 allele combinations. Forty-eight percent of these 
were C/T, twenty-seven percent were T/T and twenty-five percent were C/C. 
rs1056534 had two allele combination C/G (73%) and G/G (27%), whilst rs1046896 
had only one allele combination C/T. The ferroportin1 SNP also had only one allele 
combination A/C.  These all were reallocated into heterozygous (C/T, C/G, A/C) and 
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homozygous (C/C, T/T, G/G or A/A) between G-gap negative and G-gap positive 
groups. Genotypes distributions of genetic variants of FN3K and the SLC40A1 gene 
in G-gap positive and G-gap negative patients and their relationship are shown in 
Table 3.3. 
 
 Genotypes Positive G-gap 
(%) 
 
Negative G-gap              
(%) 
χ2 test 
FN3K 
(3848403) 
N= 121 
CT 
 TT 
CC 
21.5 
11.6 
9.9 
26.4 
15.7 
14.9 
ns 
 
FN3K 
(1056534) 
N=124 
CG 
GG 
29.8 
11.3 
 
43.6 
15.3 
ns 
FN3K 
(1046896) 
N=125 
 
CT 
 
 
41.6 
 
58.4 
                           
ns 
SLC40A1 
(11568350) 
N=125 
 
AC 
 
41.6 
 
58.4 
 
 
ns 
 
Table 3.3 Table showing genotypes present in g-gap positive and g-gap 
negative patients. The table shows that SNPs rs3848403 and rs1056534 were 
present in heterozygous and homozygous state whilst SNPs rs1046896 and 
rs11568350 were present only in the heterozygous state. 
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3.4.4. Characterisation of SNPs 
 
3.4.4.1. c.141+246C>T 
The polymorphism c.141+246C>T has been described in literature (rs3848403 in 
the NCBI database). In the present study (Table 3.4), the polymorphism was 
detected in a heterozygous state in 58 patients. Of these, 32 were negative G-gap 
and 26 positive G-gap. The homozygous state was detected in 63 patients. of these, 
37 were negative G-gap and 26 positive G-gap. 
 
3.4.4.2. c.900 G>C 
In the present study (Table 3.4), this polymorphism was found in heterozygous state 
in 91 patients. These include 54 negative G-gap and 37 positive G-gap patients. 
The homozygous state was found in 33 patients, including 19 negative G-gap and 
14 positive G-gap. This polymorphism was already described in the literature 
(rs1056534 in the NCBI SNPs database). In this study, significant differences in 
heterozygous and homozygous state were not observed between negative and 
positive G-gap groups. 
 
3.4.4.3. c.486 C>T 
This polymorphism (Table 3.4) was found only in the heterozygous state in 125 
patients. These include 73 negative G-gap and 52 positive G-gap. This 
polymorphism was already described in the literature (rs1046896 in the NCBI SNPs 
database). 
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3.4.4.4. g.189565370 C>A/ c.744G → T mutation (G/T alleles in reverse 
orientation to the genome) 
This polymorphism (Table 3.4) was present as a heterozygous state in all 125 (73 
negative G-gap and 52 positive G-gap) patients in this study. Reference SNP of this 
polymorphism in NCBI SNPs database is rs11568350. 
 Genotypes Numbers Negative G-gap 
(n) 
Positive G-gap 
         (n)                    
FN3K 
(3848403) 
N= 121 
  
Heterozygous (CT) 
Homozygous  (TT/CC) 
 
58 
63 
 
32 
37 
 
 
26 
26 
 
FN3K 
(1056534) 
N=124 
 
Heterozygous (CG) 
Homozygous  (GG) 
 
91 
33 
 
54 
19 
 
 
37 
14 
FN3K 
(1046896) 
N=125 
 
Heterozygous (CT) 
 
 
125 
 
73 
 
52 
SLC40A1 
(11568350) 
N=125 
 
Heterozygous (AC) 
 
125 
 
73 
 
52 
 
 
Table 3.4 Table showing genotypes in heterozygous and homozygous state in 
G-gap negative and G-gap positive patients. The table shows that SNPs 
rs3848403 and rs1056534 were present in heterozygous and homozygous state 
whilst SNPs rs1046896 and rs11568350 were present only in the heterozygous 
state. 
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3.4.5. Plasma sRAGE in relation to G-gap 
Plasma sRAGE was assayed from sample collected studied cohort with negative 
(<-0.5%, n=79) and positive (>+0.5%, n=67) G-gaps using sandwich ELISA (R&D 
Systems, Bio-Techne Ltd). Linear regression analysis was performed in excel to 
create a standard curve (Figure 3.1) and used a line of the best-fit equation to 
calculate the concentration of the sRAGE in the plasma samples. The measurement 
of sRAGE in negative and positive G-gap heparinised-plasma samples revealed 
similar results p=0.16 (independent sample t-test) and the corresponding mean±SD 
values were 344.64±271.58 and 285.38±230.33 respectively (Figure 3.2). These 
results showed that the plasma sRAGE level is not correlated with differences in G-
gap values. Descriptive statistics indicated skewness of 1.3>1, indicating that data 
are very skewed. A normal distribution has a kurtosis of zero whilst in the present 
experiment, it is 1.61 indicating that data distribution has a heavier tail than a normal 
distribution (Figure 3.3). A non-parametric Mann–Whitney U test (Table 3.4) was 
performed using Excel, which showed a non-significant difference (P = 0.23), after 
adjustment for ties with 95% CI in sRAGE levels between subjects with the G-gap 
negative and G-gap positive. The reported intra-assay and inter-assay coefficient of 
the variant for the kit was 5.7% and 7.7% respectively. 
 
 
 
115 
 
 
Figure 3. 1 The standard curve created from the standard concentrations of 
human sRAGE in ELISA assay. The R2 value (0.9882) indicated data strong 
association between the variables used in constructing the standard curve and that 
unknown concentrations of sRAGE from plasma samples could be interpolated with 
accuracy from their optical density. 
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Figure 3. 2 Plasma sRAGE in relation to glycation gap. Values represent mean 
± SE. P>0.05 using the t-Test, G-gap positive (n=67) vs G-gap negative (n=79). 
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Figure 3. 3 RAGE data is positively skewed. Using the histogram. 
Mean±SD:317.44±254.36. 
 
 
Figure 3.3 sRAGE data are positively skewed. Using the histogram. 
Mean±SD:317.44±254.36. The data distribution has a tail i.e. kertosis: 1.61>0. 
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Table 3. 4 Mann–Whitney U (non-parametric) test of normality for sRAGE 
analysis for negative and positive G-gap groups p>0.05. 
 
 
3.4.6. Plasma sRAGE in relation to the genotype of FN3K SNPs rs3848403 
and rs1056534. 
In diabetic patients with G-gap negative and G-gap positive, statistically insignifcant 
association was observed in sRAGE concentrations according to their FN3K 
(rs3848403) and FN3K (rs1056534) genotype (Table 3.5). CT, TT and CC 
genotypes of FN3K (rs3848403) polymorphism were insignificantly associated with 
sRAGE concentration (C/T: 268.67±164.01, T/T: 312.69±332.46 and C/C 
393.37±150.94 pg/ml; p>0.05 in G-gap positive and C/T: 290.98±211.26, TT: 
383.02±359.84 and C/C: 180.9 pg/ml; p=0.5 in G-gap negative respectively). 
Moreover, statistically insignificant association was also observed between FN3K 
(rs1056534) genotype and sRAGE concentration in positive and negative G-gap 
groups (C/G: 284.19±248.20, G/G: 292.21±163.11 pg/ml; p=0.9 and C/G: 
342.48±275.40, G/G: 247.92±170.97 pg/ml; p>0.05 respectively). 
  
G-gap 
(n) 
Mean 
Ranks 
Sum of 
Ranks 
P Value 
(two-
tailed) 
Z Value Mann–
Whitney U 
Test 
Negative 
(79) 
 
77.34 
 
6110 
 
 
 
0.23/ns 
 
 
 
1.19 
 
 
 
2343 
Positive 
(67) 
 
68.97 
 
4621 
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Table 3.5 sRAGE concentration (pg/ml) in positive G-gap and negative G-gap 
diabetic patients with respect to their genotype. No significant association was 
observed between sRAGE concentration and FN3K genotypes (p>0.05). Data is 
shown as mean±SD. 
 
3.5. Discussion 
To understand the adverse effects of hyperglycaemia, previous studies have 
traditionally focused on the increased production of AGEs and activity of the 
receptor for AGEs (RAGE) produced because of its potentially harmful pathways 
(Wu, Xiao and Graves, 2015; Rhee and Kim, 2018). There was little focus on 
hypothetically protective mechanisms operating in parallel. These pathways have 
regulatory enzymes whose activities can lead to overall tolerance or intolerance of 
diabetes mellitus. For example, FN3K is involved in deglycation of proteins, control 
of AGE production and subsequently, the development of diabetes complications 
(Avemaria et al., 2015). The enzyme is highly expressed in erythrocytes 
(Delplanque et al., 2004) and is involved in HbA1c variation (Veiga et al., 2006). 
sRAGE 
(pg/ml) 
 Positive 
G-gap 
Negative 
G-gap 
FN3K 
(rs3848403) 
CT 
TT 
CC 
ANOVA 
268.67±164.01 
312.69±332.46  
393.37±150.94 
ns 
290.98±211.26 
383.02±359.84  
180.9 
Ns 
FN3K 
(rs1056534) 
CG 
GG 
ANOVA 
284.19±248.20 
292.21±163.11 
ns 
342.48±275.40 
247.92±170.97 
Ns 
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Dunmore et al. (2018) reported a significant relationship between erythrocyte FN3K 
and the G-gap and demonstrated that the negative G-gap group has significantly 
higher FN3K (3-fold difference) enzymatic activity and protein level. One of the 
factors affecting enzyme activity; contributing to the inter-individual differences in 
HbA1c, could be genetic variability in the FN3K gene (Avemaria et al., 2015, 
Tanhäuserová et al., 2014 and Soranzo et al., 2010). Single nucleotide 
polymorphisms (SNPs) may be possibly affecting FN3K enzyme activity among 
diabetic subjects with negative and positive G-gap. The combination of genes 
studied in this study encodes for enzymes that are linked with FN3K activity. 
Surprisingly no literature data exist on the effects of SNPs in these genes on the 
variability of the glycation gap. 
 
SNPs (rs3848403, rs1056534, rs1046896, and rs11568350) in FN3K and 
SLC40A1/Ferroportin1 genes did not reveal any significant associations with any of 
the studied endpoints (negative and positive G-gap groups) in this study. FN3K 
(rs1046896) and ferroportin1 (rs11568350) were both found only in the 
heterozygous state in the negative (58.4%) and positive (41.6%) G-gap groups and 
insignificantly distributed between the studied groups. Although FN3K SNPs 
(rs3848403 and rs1056534) were found both heterozygous and homozygous state 
in negative and positive G-gap groups, their distribution was still statistically 
insignificant in those groups. Previous studies found the association of SNPs with 
HbA1c (Mohás et al., 2010), sRAGE (Skrha et al., 2014), FN3K activity (Delpierre et 
al., 2006) and progression of diabetic nephropathy and cardiovascular morbidity and 
mortality (Avemaria et al., 2015).  
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It was hypothesised that the haemoglobin-level variant/iron homoeostasis may 
influence HbA1c, which in turn could affect the rate of haemoglobin that is glycated 
and impacting on measured HbA1c levels. This hypothesis requires further testing. 
The propensity of iron storage disease had a genetic basis (Gordeuk et al., 1992). 
Because ferroportin/SLC40A1 mutations are linked with iron overload as well as 
with FN3K activity, ferroportin/SLC40A1 gene may affect iron homeostasis which 
influencing HbA1c. Previous study reported a SLC40A1 (Ferroportin1) Q248H 
mutation (rs11568350) at rates ranging from 2.2 to 10% among sub-Saharan African 
natives (Albuquerque et al.,2011). A role for altered iron homeostasis influencing 
HbA1c is not suggested for SLC40A1 where no difference was observed at known 
functional variants in negative and positive G-gap groups (p>0.05). In this study, it 
was observed that the only the heterozygous state of this polymorphism 
(rs11568350) was found in both negative (58.4%) and positive (41.6%) G-gap 
groups. This present study does not establish a relationship between the 
ferroportin/SLC40A1 variant and G-gap groups. The possibility exists that the effect 
observed may be due to stratification with respect to the degree of Asian/European 
admixture without including the native people who resided in sub-Saharan Africa.  
 
FN3K and ferroportin/SLC40A1 have not been studied in relation to G-gap status. 
Results of this study indicated that selected SNPs in these genes are neither 
associated with G-gap status, nor with the difference in FN3K activity in the studied 
G-gap groups. Previously, it was suggested that the level of FN3K enzymatic activity 
in the deglycation process defines the G-gap (Dunmore et al., 2018). It is known 
that FN3K deglycates lysine residues more efficiently as compare to the HbA1c-
defining N-terminal valine. This is suggesting that FN3K might not contribute to G-
gap formation. Therefore, it might seem illogical to conclude that variation in FN3K 
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activity or the SNPs of FN3K gene accounts for the G-gap. The substrate (N-ε-
fructosyl-lysine and N-terminal” N-α-fructosyl amino acids) specificity of FN3K falls 
in the ranges of 100 times to 10 times lower affinity (Szwergold, Howell and 
Beisswenger 2001; Delpierrre et al., 2004). However, lower affinity does not imply a 
zero-rate reaction but indicates a slower reaction because the low range is ten (10) 
indicating some deglycation at the N-terminal valine. Studies reported the inverse 
relationship between HbA1c and FN3K activity when SNPs were found in the FN3K 
gene found (Mohas et al., 2010 and Delpierre et al., 2006). Other factors contributing 
to inter-individual differences in HbA1c could be transcript splice variants encoding 
products of differing activity.  
 
The significantly low FN3K activity in the positive G-gap group was associated with 
an increase in the AGE level in the same group (Dunmore et al., 2018). This 
potentially links with a G-gap associated with mortality and morbidity that typically 
links with high HbA1c levels (Nayak et al., 2013). Dunmore et al. (2018) found a 
fivefold change in PAI-1 (plasminogen activator inhibitor 1) (in positive G-gap 
patients, which would probably be a risk marker for cardiovascular disease (Grant, 
2007). With higher expression in erythrocytes (Delplanque et al., 2004), intracellular 
FN3K during the deglycation process provides a possible control mechanism for the 
production of AGEs and their associated complications (Avemaria et al., 2015). 
Dunmore et al. (2018) showed that the plasma AGE level is associated with the 
glycation gap status and showed that positive G-gap group patients with low FN3K 
activity have a high level of AGE and negative G-gap group patients with high FN3K 
activity has a low level of AGE. To further investigate this, plasma sRAGE level was 
measured in negative and positive G-gap groups. Result obtained in this study 
showed that patients from negative G-gap group have slightly higher plasma sRAGE 
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concentrations (mean Rank 77.34). However, in comparison with the value obtained 
for positive G-gap group, this increase is not statistically significant (U = 2343, p = 
0.23).  
 
AGEs and other ligands bind to sRAGE. This plays an important role in the 
development of diabetic vascular complications (Bucciarelli et al., 2002, Goldin et 
al., 2006 and Selvin et al., 2013). sRAGE is well expressed at vascular injury sites 
as in diabetic kidney disease (Goldin et al., 2006). Interpreting the sRAGE level is 
controversial because previous studies reported an inverse relationship between 
sRAGE and poor health issues (Falcone et al., 2005 and Lindsey et al., 2009) like 
hyperglycemia and obesity. Other studies indicated that diabetic individuals, 
especially those with microvascular and/or macrovascular complications, have high 
circulating levels of sRAGE (Thomas et al., 2011 and Colhoun et al., 2011). Thomas 
et al. (2015) reported an independent association between sRAGE levels and new-
onset/worsening renal disease as well as all-cause mortality in a type 2 diabetic 
cohort.  Thomas et al. (2011) also found consistency in the results with their previous 
study in type 1 diabetic individuals (Thomas et al., 2011). The study reported a 
positive correlation between sRAGE and mortality. The results of their study 
highlighted the AGE/RAGE axis is potentially important in the pathogenesis of 
diabetic complications and associated outcomes.  
 
In this study the association between sRAGE levels and FN3K genotypes was also 
investigated. Skrha et al. (2014) previously reported a link between FN3K SNPs (rs 
3848403, rs1056534) with soluble RAGE (sRAGE). However, the present study 
observed no association between sRAGE level, glycation status and genotypes of 
FN3K SNPs (rs3848403 and rs1056534) in negative and positive G-gap patients. 
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These SNPs do not appear to have any impact on sRAGE level. Results of this 
study indicated that sRAGE levels did not differ by G-gap status, suggesting that 
sRAGE may not be as specific to the G-gap as AGE level and sRAGE may be a 
generalised marker of ill health.  
 
Overall, the glycation gap could be developed due to the production of transcript 
splice variants that encode products of differing activity. It might be possible that 
during alternative splicing or the presence of SNPs in exon/intron boundaries could 
lead to intron retention or exon skipping at the mRNA processing stage. These 
events would significantly change the structure of the resulting protein.
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Chapter 4 
 
 
 
Investigation of relative telomere length by quantitative real-time 
PCR in G-gap negative and G-gap positive patients. 
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4.1. Introduction 
Many factors, including lack of telomerase activity, cell division, and oxidative stress, 
contribute to telomere shortening (Saretzki and Von, 2002). With each replication 
cycle, telomeric DNA gradually shortens and can lead to replicative senescence or 
apoptosis (Teixeira, 2013). Cell senescence contributes to T1D and T2D 
pathogenesis and plays an important role in the associated complications of the 
disease (Sampson et al., 2006). High levels of oxidative stress, and consequently 
increased oxidative DNA damage have been identified in prediabetes, metabolic 
syndrome (Hansel et al., 2004 & Su et al., 2008), and in T2D (Sampson et al., 2006). 
Reactive oxygen species (ROS) levels rise in hyperglycaemia because of high 
incorporation of reducing equivalents into the mitochondrial electron transport chain 
(Brownlee, 2001). Glucose is highly catabolised in hyperglycaemia, resulting in the 
high production of reducing equivalents and rise in NADPH-to-NADP ratio. This ratio 
stimulates the NADPH oxidases activity and results in increased ROS formation 
(Raddatz et al., 2011). The combination of above scenarios and reduced antioxidant 
cell defence mechanism (superoxide dismutase and/or glutathione peroxidase 
activity is low) could contribute to high ROS levels in prediabetes, metabolic 
syndrome or diabetes.  
 
Special deoxyribonucleic acid (DNA) structures “telomeres” protects the 
chromosomes from end-to-end fusion in conjunction with specialised proteins called 
shelterin. The human telomere sequence consists of TTAGGG repeats (Lee et al., 
2018) which facilitates telomere recognition and quantification. In somatic cells, 
telomeres shorten with age. The telomeric DNA is susceptible to oxidative DNA 
damage, so the high ROS levels in diabetes presumably lead to accelerated 
telomere erosion (Petersen, Saretzki and von, 1998 & Serra et al., 2000).  Various 
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cell types, including beta cells, may undergo vast and premature senescence 
because of the above processes and consequently, apoptosis occurs which if 
affecting the secretion or action of insulin could cause the onset of diabetes.  
Previously, shorter telomeres have been reported in patients with type 1 diabetes 
(Jeanclos et al.,1998) and type 2 diabetes compared with healthy individuals 
(Adaikalakoteswari, Balasubramanyam, and Mohan, 2005, Sampson et al., 2006 & 
Uziel et al., 2007). Although shortened telomeres were shown to be associated with 
diabetes, and a significant negative correlation has been reported between glycated 
haemoglobin (HbA1c) and β-cell telomere length (Tamura et al., 2016), there are no 
data available on such a relationship with the G-gap. Therefore, this study 
investigated the relationship between relative telomere to single copy gene ratio 
(T/S) and the G-gap in patients who are G-gap negative and G-gap positive. 
 
4.2. Material and Methods 
 
4.2.1. DNA source 
DNA was extracted from whole blood from patients with diabetes using the QIAamp 
DNA Blood Mini Kit (QIAGEN, # 51104). (“DNA extraction” in Chapter 2). 
 
4.2.2. Methods for quantitative analysis of mean telomere length in the studied 
cohort 
 
4.2.2.1. Terminal restriction fragment (TRF) length analysis via Southern 
blotting 
Southern blotting was used to estimate the mean terminal restriction fragment (TRF) 
length. This is the traditional method for measuring telomere length in total human 
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genomic DNA samples. Briefly, this method uses restriction enzymes that cleave 
DNA in the subtelomeric regions in order to produce TRF. Electrophoresis was used 
to separate the cleaved DNA before being transferred to a membrane where 
hybridisation takes place with a labelled telomere-specific probe. Different 
algorithms are used to convert the signals to calculate the actual telomere length, 
described in kilobase pairs. 
 
This method is inappropriate where an available amount of DNA was restricted. TRF 
also gives false positive results in the mean telomere length estimation by 
measuring highly variable sub-telomeric regions. These regions include restriction 
site polymorphisms or length polymorphisms, that create confusion in the 
identification of primary factors responsible for inter-individual variation in the mean 
length of the true telomeric repeat sequence. 
 
4.2.2.2. Standard PCR vs quantitative polymerase chain reaction (qPCR) for 
telomere 
Recently, PCR based methods allow multiple samples to be compared for their 
relative content of pure telomeric repeats with low amounts of DNA. The technique 
also reduces the time required for analysis. Quantitative PCR (qPCR) estimates only 
average telomere length and does not give any information about the shortest 
telomere or the distribution of telomere lengths within the cell (Baird, 2005). 
Cawthon (2002), introduced the simplest quantitative PCR-based method that 
solves the amplification problem due to the repetitive nature of telomeric sequences 
by designing a set of primers which bind specifically to human telomere regions and 
lead to the amplification of only telomeric (TTAGGG) repeats. Prior to this 
development, the repetitive telomeric sequence used primers that were 
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complementary, leading to the formation of primer dimers, where two primers bind 
to one another, resulting in the amplification of the primer sequence, rather than 
amplification of the target DNA from the patient. In Cawthon’s method (Cawthon, 
2002) specifically designed telomere primers anneal to genomic DNA during 
hybridisation in a way that only four consecutive out of six base pairs are hybridised, 
followed by two mismatched bases and preventing DNA polymerase to extend from 
the 3’-end of each primer, thus eliminating the possibility for primer-dimer formation. 
 
The principle for quantification of telomere repeats is that there will be an increase 
in fluorescence with more potential primer- annealing sites when there are longer 
telomeres, and hence decrease in the cycle numbers to reach a given threshold, 
and vice versa with shorter telomeres. Cawthon (2002) indicates that a factor that is 
used to determine the relative telomere length for each DNA sample, by which the 
sample differed from a reference DNA sample, is its ratio of telomere repeat number 
to single gene copy (SCG) number. Two quantitative PCRs for each sample, one 
for the telomere repeats (T) and one for an SCG (S), were performed (Figure 4.1) 
and Ct values were calculated respectively. The use of SCG (Rplp0) helps to 
normalise DNA loading and control variation in initial DNA quantity, the ratio of these 
two Ct values is used to calculate relative average telomere length. The T/S ratio of 
125 of the samples was calculated. PCRs were performed in a 7500 FAST qPCR 
(Applied Biosystems) (refer Chapter 2 for detail). The melting curve produced for 
telomere assays suggested that only TTAGGG/SCG was amplified (Figure 4.2). On 
both telomere and SCG plates, all samples were run in triplicate. Each 96-well plate 
contained 15ng of DNA per well, from G-gap negative and G-gap positive patients. 
The Ct value represents, where a number of PCR cycles is required to amplify the 
telomeric DNA TTAGGG sequence in a given DNA sample to accumulate enough 
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product to pass a set threshold level. Small Ct values indicate that samples have 
more of the TTAGGG sequence and have longer telomeres as compared to 
samples with larger Ct values. This method provides the mean relative telomere 
content instead of actual telomere length. 
 
 
 
Figure 4. 1 Figure showing an amplification plot of telomere (A) and 
amplification plot of Single Copy Gene (SCG) (B) 
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Figure 4. 2 Figure showing the melting curve of telomere (A) and melting curve 
of Single Copy Gene (SCG) (B) 
 
4.2.3. Rationale behind the cycle threshold (Ct) value  
In real-time PCR, at the crossing point (cycle threshold (Ct)), the fluorescence of a 
sample is detectable because it exceeds above the background fluorescence. This 
crossing point is very much dependent on the initial concentration of DNA. More 
amplification cycles are needed if there is a lower initial DNA concentration present 
in samples than with initial high DNA concentrations. Previous studies showed that 
with 35 ng/μl (Cawthon, 2002 & Gil and Coetzer, 2004) of the initial concentration of 
DNA the number of cycles used was 20 for telomere repeats and 30 for Rplp0 gene 
when quantitative real-time PCR was used for analysis of telomere length. The initial 
concentration of genomic DNA extracted from the whole blood of G-gap negative 
and G-gap positive patients was 15ng/μl and the number of cycles increased to 40 
for both telomere length amplification and Rplp0 amplification. Rplp0 was a 
A)  Melting curve of 
telomeric DNA  
B) Melting curve of  
SCG  
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“housekeeping” gene and this gene has constant expression levels amongst the 
samples cohort compared (Wang et al., 2012). To monitor the amplification 
efficiency, a second primer pair was included that was specific for a “housekeeping” 
gene in the reaction. Acceptable quality of target nucleic acid and reaction 
components was verified by the amplification of the housekeeping gene. 
 
4.3. Calculation and statistical analysis 
Statistical analysis were performed with SPSS. The sample means (T/S) of the 2 
groups of different G-gap groups were compared using an independent samples t-
test with equal variances not assumed and the criteria for significance has been set 
≤ 0.05 and the test is two-tailed. Descriptive statistics were calculated (the mean 
and standard deviation (SD)). Univariate analysis was used to compare the 
association of continuous variables with other factors i.e. age, gender, ethnicity, 
BMI, type of diabetes or G-gap status. 
 
4.4. Results 
After running the qPCR, for each sample with negative (<-0.5%, n=73) and positive 
(>+0.5%, n=52) G-gaps, mean Ct values were calculated by taking an average of 
triplet values. Subsequently, for each sample a mean T/S ratio (T stands for 
telomere, S stands for the single-copy gene) was calculated (Figure 4.3). Levene`s 
test for equality of variances showed no violations (p=0.116) whilst mean±SD in 
negative and positive G-gap groups were 1.097±0.009 and 1.075±0.010 
respectively. Normality test was non-significant in the negative g-gap group 
(Kolmogorov-Smirnov; p =0.2) whilst it was found significant in the positive g-gap 
group (Kolmogorov-Smirnov; p =0.004). Non-parametric Mann Whitney U test was 
performed on SPSS, showed a non-significant difference (P = 0.17). These results 
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showed that the distribution of the T/S ratio is the same across negative and positive 
G-gap groups. In univariate analysis telomere length with duration of diabetes 
(p=0.029) was significantly associated but not with age, gender, ethnicity, BMI, type 
of diabetes or G-gap status (p>0.05).  
  
  
   
Figure 4. 3 Relative average telomere length. Data are shown as telomere to 
single-copy gene (T/S) ratio, G-gap negative (n=73) vs G-gap positive (n=52). 
 
4.5. Discussion 
Telomeres consist of TTAGGG tandem repeats (Stohr and Blackburn, 2010). The 
length of telomere of somatic cells is progressively shortened with each cycle of cell 
division as a function of the donor's age (Hornsby, 2007) because of the end-
replication problem. In the end-replication problem, the DNA replication machinery 
is unable to synthesise the very end of the 3′ strand (Kim et al., 2003).  In vitro 
studies indicated that the telomere length predicts the replicative history of cells 
(Hills et al., 2009), because with a continuous replication process the telomere 
length progressively shortens, and cells undergo permanent cell cycle arrest and 
become senescent. This happens when telomere length reaches a critical length 
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(Mollano, Martin and Buckwalter, 2002). The "end replication problem”, leads to the 
attrition in telomeres length.  
 
The "end replication problem” involves the incomplete replication of the ends of 
linear chromosomes (Maestroni, Matmati and Coulon, 2017). Telomerase, a 
ribonucleoprotein complex counteracts telomeric attrition. This enzyme uses its 
RNA component as a template to add telomeric repeats onto the ends of 
chromosomes (Lindstrom et al., 2002). Telomerase expression is very low in 
somatic cells. Therefore, the activity of the telomerase enzyme is insufficient to 
counterbalance the progressive attrition in the telomere length. Telomere length has 
therefore been considered an indicator of the replicative potential of cells in vitro as 
well as in vivo. Research reports demonstrated an association between telomere 
shortening in white blood cells (WBCs) of Type 1 (Jeanclos et al., 1998) and Asian 
Indian Type 2 diabetic patients (Adaikalakoteswari, Balasubramanyam, and Mohan, 
2005). Telomere shortening might be a long-term risk marker of macro-vascular 
complications in negative and positive G-gap diabetic patients. This assumption was 
supported because Adaikalakoteswari et al. (2007) demonstrated that type 2 
diabetic patients with atherosclerotic plaques had significantly shorter telomeres 
length and shorter telomere was associated with increased markers of systemic 
inflammation and oxidative stress (Adaikalakoteswari et al., 2007).  
 
To understand normal cellular biology, telomere biology and function is of great 
significance. For understanding telomere biology, variation in telomere length and 
biological controls that control this length are of greater importance. Traditionally 
different methods were used to determine the telomere lengths, that were costly in 
terms of money and time. Usage of a standard PCR method for amplification was 
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limited because of the repetitive nature of telomeric DNA sequence, but this issue 
was resolved with the development of primers for the human telomere assay. The 
DNA used was extracted from whole human blood. Telomere length varies between 
various tissues (Campisi et al., 2001), therefore measuring telomere length in blood 
equates with telomere length in other tissues (Saretzki and Von, 2002). Previous 
study found a strong correlation between telomere length in leukocytes and the 
telomere length in skeletal muscle, skin, and subcutaneous fat (Daniali et al., 2013). 
Telomere length shorten at different rate in muscles and heart as their replication 
activities are low. In blood cells or skin, where the replication activities are higher, 
telomere length shortening rate is different. In addition to this, different 
pathophysiological condition associated with ageing also affect the rate of telomere 
length shorten in various tissues. Therefore, telomere length study in peripheral 
leukocytes is more common (Wang, 2018). Although short length telomeres have 
been reported in T1D and T2D, no difference between the studied groups G-gap 
negative and G-gap positive was observed and no relationship was found between 
telomere and glycation gap in this study. 
 
The T/S data were normally distributed in negative G-gap (Kolmogorov-Smirnov; p 
= 0.2) but abnormal distribution was found in positive G-gap (Kolmogorov-Smirnov; 
p =0.004) (Figure 4.3). The observed abnormal distribution may be due to one 
anomaly/abnormality (Figure 4.3). When this anomaly was removed, still data were 
not normally distributed (Kolmogorov-Smirnov; p =0.001) in positive G-gap. 
Abnormal distribution of T/S data between studied groups could be due to the 
unequal sample sizes (G-gap negative; n=73 and G-gap positive; n=52). The data 
were not normally distributed between the groups. Therefore, the normality test is 
no longer valid. A non-parametric Mann–Whitney U test on SPSS was conducted, 
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which showed a non-significant difference (P = 0.17). These results showed that the 
distribution of the T/S ratio is the same across negative and positive G-gap groups.  
 
The qPCR assay may produce different results if there are differences in the initial 
sample DNA concentrations. This was addressed by measuring the concentration 
of DNA in the samples shortly before qPCR analysis and preparing 125 samples 
with the same DNA concentrations (15ng/µl). Additional care was taken during 
pipetting to avoid any uncertainty for sample preparation before the qPCR run. For 
the present study, it is potentially impossible to completely exclude the impact of 
different sampling dates in individual telomere length but as the T/S data were 
normally distributed any such impact was minimal, if it exists. T/S data were not 
related to age as it might be linked with the biological age rather than chronological 
age. 
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Chapter 5 
 
 
RNA-Seq from peripheral blood for the study of differential gene 
expression and transcript variants in G-gap negative and G-gap 
positive groups 
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5.1. Introduction  
Nucleated, enucleated cells and cell-free ribonucleoproteins contain RNA within 
peripheral blood. Alongside this blood contains cell-free RNA that circulates in 
membrane vesicles i.e. apoptotic bodies, microvesicles, and exosomes. 
Physiological and pathological processes taking place in different cells and tissues 
of human cause specific changes in the RNA profile of whole peripheral blood 
(Yanez et al., 2015 & Mohr and Liew, 2007). Consistently, it was found by comparing 
the transcriptome of peripheral blood with the genes expressed in nine different 
human tissues such as brain, colon, heart, kidney, liver, lung, prostate, spleen, and 
stomach that more than 80% expression was shared with any given tissue (Liew et 
al., 2006). Peripheral blood is an ideal surrogate tissue because it continuously 
interacts with the whole body. This interaction may trigger specific changes in the 
gene expression in blood as a result of subtle changes within cell and tissue that 
occur in association with the disease.  
 
Gene expression is critical in the understanding of cellular phenotypes and how it 
affects phenotypic demonstrations for the characterisation of disease risk genes 
(Altshuler, Daly and Lander, 2008 & Manolio et al., 2009). It is well understood that 
most part of the genome is transcribed into RNA and only a small proportion (1-2%) 
codes for a protein (ENCODE Project Consortium, 2012). Messenger RNA (mRNA) 
not only consists of the coding region but also contains untranslated sequences at 
both it's 5’ and 3’ ends that are important in regulatory function (Hinnebusch, Ivanov 
and Sonenberg, 2016). There are also many non-coding RNAs that play an 
important role in intracellular signalling and transcriptional modification (Cech and 
Steitz, 2014). It appears that the correlation of mRNA with its downstream protein-
coding counterpart is weak which suggests that post-transcriptional regulation takes 
139 
 
place before translation occurs (Albert and Kruglyak, 2015). In the past, for gene 
expression studies, the widely recognised method was hybridisation-based 
microarray (DeRisi et al.,1996; Fodor et al.,1993). The technique was able to probe 
thousands of transcripts simultaneously, but its dependence on existing gene 
models and potential cross-hybridisation to probes with similar sequences could 
produce bias results. 
 
Sequencing-based method i.e. RNA-sequencing (RNA-Seq) is another approach for 
accurately quantifying gene expression via transcriptome. This technique provides 
digital readouts for depicting and quantification of transcriptomes (Bentley et al., 
2008; Lister et al., 2008; Mortazavi et al., 2008; Nagalakshmi et al., 2008; Wilhelm 
et al., 2008). RNA-Seq technology is based on deep sequencing that ensures each 
genomic region in the samples is sequenced repeatedly (Meyerson, Gabriel, and 
Getz, 2010). In this study, RNA-Seq involved the investigation of the complex 
aspects of transcriptomics, e.g. transcript variants, identification of differentially 
expressed genes and to investigate their association with disease, pathways and 
gene ontology and the putative mechanisms to explain observed gene expression 
changes between G-gap negative and G-gap positive groups.  
 
RNA extraction, Selection/depletion of RNA (i.e. filtration of RNA with 3' poly(A) tails 
as these are mature, processed, coding sequences or depletion of ribosomal RNA 
(rRNA) because it is over 90% of the RNA in a cell, which if not removed would 
submerge other data in the transcriptome), cDNA synthesis with adaptors attached, 
and cDNA pair-end sequencing  in a high-throughput manner to get short sequences 
typically 30 to 400 nucleotides in length. After sequencing the short sequences are 
then aligned to a reference genome and reference transcriptome. These sequences 
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help in the identification of exon regions from which the reads are generated or 
assembled de novo where genomic sequence does not exist. Counting the number 
of reads aligned to each locus in the transcriptome assembly step provides the 
quantification for the expression level for exons or gene. Nearly 95% of human’s 
multi-exon genes are produced via alternatively spliced events and are reported in 
global surveys of alternative splicing (Pan et al., 2008). There is no genomic 
information regarding gene expression differences and transcript variants at the 
whole blood transcriptome level of negative and positive G-gap patients with 
diabetes. To solve this, the characterisation of specific gene expression related to 
the G-gap was performed in the whole blood of the studied cohort using RNA-Seq 
(RNA sequencing) technology. RNA was extracted from whole blood. The blood 
cells not only act as the first line of defence of the immune system and flow through 
the whole body (Chaussabel, Pascual and Banchereau, 2010) but the transcriptome 
extracted had a great resemblance with various tissues (Mohr and Liew, 2007). 
Thus, changes in gene expression in those tissues as well as in pre-erythrocytes 
(normoblasts) and other pathways constituting the G-gap might give a clear view via 
whole blood gene expression. RNA sequencing is one of the next generation 
sequencing (NGS) technology that made it possible to explore differentially 
expressed genes (Wilhelm and Landry, 2009) alongside assessing mRNA 
transcription patterns for all the genes in G-gap negative and G-gap positive group. 
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5.2. Materials and Methods 
 
5.2.1. Sample collection and processing 
RNA extraction and removal of chromosomal DNA were performed as reported in 
Chapter 2. RNA concentration and purity were assessed using a NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific). Samples were sent to Oxford 
Genomic Centre for library preparation (refer to chapter 2) and sequencing, where 
RNA was quantified using RiboGreen assay and the size profile and integrity 
analysed on the 2200 TapeStation (Agilent, RNA ScreenTape) (details are in 
Chapter 2). Cytoplasmic ribosomal RNA depleted using Ribo-Zero rRNA removal 
kit and library preparation was completed using TruSeq Stranded Total RNA 
Human kit (See Chapter 2). Sequencing was performed in the same facility (Oxford 
Genomic Centre).  
 
5.2.2. Illumina sequencing Hi-Seq 4000 platform 
Each sample was sequenced to a target depth of >45 million paired-ended 75 bp 
reads using a multiplex strategy on an Illumina Hi-Seq 4000 (Illumina, San Diego, 
CA, USA) by using PE Cluster kit and 150 cycle SBS kit. Illumina sequencing 
machine workflow consists of 4 stages: Preparing sample, cluster formation, 
sequencing of sample and data analysis. Sample preparation (Total RNA) 
comprises of series of stages to the RNA fragmentation, cDNA conversion, and 
formation of cDNA library (refer to Chap 2). cDNA library was loaded to six-lane flow 
cell where cDNA fragments hybridised to oligonucleotide primers that are 
complementary to adapters attached to cDNA. Clusters formed via bridge 
amplification. Illumina sequencing technology for RNA-Seq based on the standard 
dideoxy method (Lasken and McLean, 2014). During the assay for the sequencing 
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of each cluster flow cell inside the sequencing machine was flooded with DNA 
polymerase and nucleotides. These nucleotides were fluorescently labelled (the 
colour corresponding to the nucleotide base) and attached to a terminator at the 3’-
end. The different fluorescent molecules emit four different wavelengths of light 
whilst the terminator inhibits elongation reaction. The sequencing cycle continues 
where only complementary nucleotides in the template strand added and the 
remaining i.e. terminator and fluorescent molecule washed away after fluorescent 
signals read correctly. This process is repeated i.e. adding one nucleotide at a time 
and imaging in between with high-resolution camera. The base-calls represented by 
the fluorescence intensity whilst the length of the reads indicated by cycle number 
and number of reads by clusters numbers (Bullard et al., 2010). 
 
Sequencing billions of reactions are possible with the Illumina system at the same 
time. It produces approximately 200 nucleotides long individual sequencing read 
which is shorter though as compared to sequencing reads produced from other 
sequencing instruments but parallel sequencing in vast amount is possible by it. All 
sequencing data in this thesis are paired-end as pair end data provides accurate 
mapping and can quantify duplication rate with reasonable reliability.  
 
5.2.3. Processing of RNAseq Data  
Raw data from RNA sequencing experiment in FASTQ format was post-processed 
into Nottingham’s Advanced Data Analysis Centre (ADAC). FastQC version 0.11.5 
was used to display the quality of reads. After that raw reads were aligned to a 
reference using HISAT2 v 2.1.0. HISAT2 mapped the reads to a reference with the 
use of one global FM index and numerous small local FM indexes and identified 
transcript splice sites. HISAT2 stored the output as SAM files format. The reference 
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was downloaded from ENSEMBL 
(ftp://ftp.ensembl.org/pub/release95/fasta/homo_sapiens/dna/Homo_sapiens.GRC
h38.dna.primary_assembly.fa.gz). StringTie v 1.2.3 program was used for the 
assembly of alignments into transcripts with human genome annotation. The human 
genome annotation was downloaded in the form of a GTF file from the web address 
(ftp://ftp.ensembl.org/pub/release-
95/gtf/homo_sapiens/Homo_sapiens.GRCh38.95.gtf.gz). This assembly step 
generated an estimated transcript length that was stored in the form of GTF file for 
each of the 32 samples. Transcript assemblies were merged from all G-gap negative 
and G-gap positive samples by StringTie-merger in GTF format. Estimation of 
assembled transcripts abundance in each sample on the basis of gene expression 
values, the principal component analysis was done using ‘cmdscale’ (Classical 
multidimensional scaling) function. Differential expression analysis of gene, as well 
as a transcript, was performed using the Ballgown v 2.14.1 program. The statistical 
significance of fold changes was calculated by comparison of the read values of G-
gap negative and G-gap positive groups. The normalisation of the data to correct 
distributional differences within the read counts, i.e. differences in total counts 
(sequencing depths), and within sample gene-specific effects i.e. gene length was 
performed using the FPKM function of Ballgown program.  
 
5.2.4. Statistical analysis 
Differential expression analysis was performed by using the stattest function of 
Ballgown. This is an open-source software based on FPKM values in a linear model 
(Pertea et al., 2016). The log in the model converts the count data and uses linear 
models for the testing of differential expression at the gene, transcript, exon or 
junction level. Contrasts between negative and positive G-gaps were performed. 
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The adjusted p-value <0.05 considered statistically significant. Differentially 
expressed genes (DEGs) and transcript variants with p-value <0.05 and fold change 
>1.5 were identified and submitted for gene enrichment to R Bioconductor package 
Ballgown. Downstream pathway analysis was performed using the DAVID software. 
 
5.2.5. Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) 
DAVID is a bioinformatic tool that performs functional and pathway enrichment 
analysis of DEGs (refer to 2.1.8.7). DAVID identifies the molecular functions, 
biological processes and associated diseases amongst differentially expressed 
genes. The program not only calculates the enrichment of a gene associated with a 
specific pathway but also provide a statistical significance value of this enrichment. 
Enrichment will be considered statistical valuable when more genes in the list 
associated with a specific pathway. This statistical significance also depends on how 
many genes in total are in a pathway for e.g. having 5 differentially expressed genes 
in a pathway of 200 genes might have a lower significance than 5 genes in a 
pathway of only 50 genes. 
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5.3. Results  
 
5.3.1. RNA quality analysis 
 
5.3.1.1. Nanodrop 
Downstream analysis requires intact and pure RNA.  The purity of RNA control 
samples was analysed by NanoDrop. The absorbance at 260 nm (A260) provided 
yield and concentration of RNA. The average concentration of RNA samples was 
approximately 186.53ng/µl and 195.78ng/µl in G-gap negative and G-gap positive 
groups respectively. Absorbance ratio 260/280 was used to assess the purity of the 
samples. A range between 1.8 and 2.0 indicated adequate purity and is generally 
acceptable (Desjardins and Conklin, 2010). Contamination with proteins or phenol 
reduces this ratio because they absorb strongly near 280nm whilst alkaline 
conditions increase this ratio to over 2. The 260/280 ratio for all studied RNA 
samples in this study was in between 1.97-2.23 in both G-gaps groups. Another 
measure of nucleic acid purity is represented by the ratio 260/230 with a range of 
2.0- 2.2. A lower 260/230 ratio could be due to the presence of 
ethylenediaminetetraacetic acid (EDTA), carbohydrates or phenol, which absorb 
near 230nm. In the present study, the RNA samples had desirable 260/280 ratios 
but 260/230 was lower (0.81-2.23) in both groups. An elution buffer and a phenol-
based reagent were used to extract RNA from whole blood samples, the low 
260/230 might be due to the contamination from salt or phenol reagent. To increase 
this ratio and to get the RNA of sufficient quality sodium acetate precipitation of small 
nucleic acids can be used. 
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5.3.1.2. Agilent 2200 TapeStation system 
RNA samples need to be structurally intact to produce reliable results (Schroeder et 
al., 2006) in RNA sequencing. Otherwise, full-length cDNA could not be produced 
with the degraded RNA. Previous studies used 28S:18S ribosomal RNA ratio to 
determine the level of degradation, but due to the subjective nature of this method 
that produces discrepant results (Schroeder et al., 2006) a reliable method was 
introduced to detect the integrity of RNA samples by using the automated quality 
control instrumentation (Agilent 2200 Tape system). The tape station analyses the 
whole electrophoretic trace of the RNA and uses an algorithm to report on the 
integrity of each sample (Mueller, Lightfoot and Schroeder, 2004). The algorithm 
classifies RNA based on a scale of 1 to 10, where 1 indicates an extremely degraded 
sample whilst 10 represents perfectly intact RNA. RNA samples in this study had 
values ranging between 2.6- 6.0 RIN. RNA samples were then used in cDNA 
synthesis. 
 
5.3.2. RNA sequencing (RNA-Seq) of G-gap patients’ transcriptomes 
RNA showed variable quality. Therefore, the proper library preparation kit was used 
to compensate for the low-input samples (see “TruSeq Stranded total RNA (Illumina) 
library preparation” section in chapter 2). After quality control checks, an average of 
over 45 million paired-end reads was obtained from each sample (n = 32). 
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5.3.3. FastQC report of RNA sequencing 
ADAC bioinformatics unit of Nottingham University checked the quality of the RNA 
sequencing data using FastQC software. Per base, sequence quality is based on 
Phred quality scores. Sequencer uses Phred quality scores estimations for the 
quality of a base-call. Quality score (Q) of each given base was calculated on the 
basis of the probability of the base call being wrong. A sequencing quality score 10 
(Q10) shows an error rate of 1 in 10 and inferred base call accuracy is 90%, Q20 
represents an error rate of 1 in 100 and the base call accuracy is 99% whilst Q30 
represents an error rate of 1 in 1000 and the corresponding base call accuracy 
99.9%. The FastQC plots for forward (Figure 5.1) and reverse (Figure 5.2) reads 
represent the highest and lowest quality. Reads indicated consistent high-quality 
sequencing, with Q scores approaching 40. This indicated that the sequencing of 
cDNA libraries was highly accurate. 
 
Overall quality of the reads was very good. Therefore, no trimming was done. 
Paired-end reads had a uniform length of 75bp and were not overlapping. The GC 
content was 45%. The range of average GC-content in human genomes is 35% to 
60% across 100-Kb fragments, with a mean of 46.1 (Romiguier et al., 2010).  
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Figure 5. 1: Per base sequence quality of forward reads produced by FastQC 
(version 0.11.5). The quality scores are on the y-axis. The higher score indicates 
the better the base call. The y-axis has three parts on the basis of the background 
of the graph i.e. very good quality calls (green), calls of reasonable quality (orange), 
and calls of poor quality (red).  
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Figure 5. 2: Per base sequence quality of reverse reads produced by FastQC 
(version 0.11.5). The quality scores are on the y-axis. The higher score indicates 
the better the base call. The y-axis has three parts on the basis of the background 
of the graph i.e. very good quality calls (green), calls of reasonable quality (orange), 
and calls of poor quality (red).  
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5.3.4. Principal component analysis (PCA) 
PCA was conducted to determine whether samples in each G-gap group clustered 
with each other or other groups. First, HISAT2 was used to count reads that uniquely 
mapped to one gene, and the data were then imported into StringTie to generate 
PCA plots. The PCA results demonstrated that most samples clustered together, 
regardless of the G-gap grouping Figure 5.3. 
 
    
 
Figure 5.3: Principal component analysis (PCA) for all samples in G-gap 
groups. (Black: negative G-gap group; Red: positive G-gap group). 
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5.3.5. Transcript length and differential expression analysis of genes and 
transcripts 
 
StringTie assembled the mapped reads into transcripts. These transcripts were of 
various lengths. The average length of the transcript was 2741.82 bp whilst the 
longest transcript consists of 205012 bp. The distribution of transcript length is 
shown in Figure 5.4. Overall, 64451 genes mapped to the human genome. Amongst 
them 103 genes and 342 transcripts were differentially expressed (p < 0.05, > 1.5-
fold change). Of 103 DEGs 61 were upregulated in G-gap negative and 42 were 
upregulated in G-gap positive figure 5.5. Out of 103 DEGs 14 produced alternatively 
spliced transcript variants. On average 1 splice variant was encoded by a single 
gene whilst on higher side eight splice variants expressed from a single gene 
(EPB41). Out of 8 transcripts, 6 were upregulated in negative G-gap whilst 2 
transcripts were upregulated in positive G-gap.  
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Figure 5. 4: Distribution of transcript length and number of sequences from 
G-gap negative and G-gap positive samples. The longest transcript consisted of 
205012 bp and the average transcript length was 2741.82 bp. StringTie (v1.2.3) was 
used to assemble the mapped reads into transcripts. 
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Figure 5.5: Distribution of differentially expressed genes between G-gap 
negative and G-gap positive groups. Overall, 103 genes were differentially 
expressed. Of these 61 were upregulated in negative G-gap whilst 42 were 
upregulated in G-gap positive samples. 
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5.3.6. Screening of differentially expressed genes using DAVID 
Disease analysis demonstrated the DEGs from G-gap groups were enriched in 
seven diseases including blood pressure, glycated haemoglobin, erythrocytes 
indices, mean corpuscular volume, carotid stenosis, mean corpuscular haemoglobin 
and posttransplantation diabetes mellitus (PTDM) (Table 5.1), Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway analysis demonstrated that the DEGs 
were enriched in four key pathways including viral carcinogenesis, ribosome, 
phagosome and dorso-ventral axis formation table (Table 5.2) while gene ontology 
showed biological processes that were enriched in the identified DEGs. In the 
biological process group, DEGs were mainly enriched in metabolic process, cellular 
component analysis and developmental process (Table 5.3). 
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Disease Count P value Genes 
Blood pressure 8 9.1E-1 CITED2, PHF11, RAP1A, 
TBC1D4, CPVL, 
CCDC71L, EPB41L3 and 
GLRX5 
Glycated haemoglobin  5 9.2E-1 CD44, CPVL, CDC123, 
SCAMP2 and SYNE2 
Erythrocytes indices 4 8.9E-1 CITED2, MAX, TYMP and 
TFRC 
Mean corpuscular volume 3 9.0E-1 CITED2, TYMP and TFRC 
Carotid stenosis 3 7.8E1 CX3CR1, TBC1D4 and 
EPB41L3 
Mean corpuscular haemoglobin 2 9.8E-1 CITED2 and TFRC 
Post transplantation diabetes 
mellitus (PTDM) 
2 9.9E-1 CDC123 and GCLC 
 
Table 5.1: Enriched disease association of differentially expressed genes 
(DEGs). Eight genes were associated with blood pressure whilst in 
posttransplantation diabetes mellitus, two genes were enriched (P≤0.05). 
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Pathway Count P value Genes 
Viral carcinogenesis 7 1.8E-2 LYN, ACTN1, GRB2, HNRNPK, 
RHOA, ATAT5A and YWHAB 
Ribosome 5 4.9E-2 RPL37, RPL41, RPS20, RPS26 and 
RPSA 
Phagosome 5 6.6E-2 CLEC7A, CTSS, CORO1A, NCF4 
and TFRC 
Dorso-ventral axis 3 3.0E-2 ETS1, GRB2 and NOTCH2 
 
Table 5.2: Enriched pathways of differentially expressed genes. In Viral 
carcinogenesis, seven genes were enriched whilst in Dorso-ventral axis, three 
genes were enriched (P≤ 0.05). 
 
 
Biological processes Gene count P value 
Metabolic process 88 9.7E-2 
Cellular component analysis 60 6.4E-3 
Developmental process 55 1.7E-2 
Immune system process 32 2.9E-2 
Multi organism process 28 8.1E-2 
Biological adhesion 25 1.0E-3 
 
Table 5.3: Gene ontology analysis of DEGs in different biological processes.  
A large number of DEGs genes were enriched in the metabolic process (88) whilst 
biological adhesion was enriched with 25 DEGs. 
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5.4. Results validation 
Verifying the data from RNA sequencing analysis is of major concern (Zheng, Chung 
and Zhao, 2011).  Possibilities that might influence the results include technical error 
during the blood collection phase or correct nucleotide quantification during RNA 
sequencing. The second possibility might arise during analysis whilst a third 
possibility could be the misinterpretation of the results.  
 
To overcome these situations, the blood collection from patients was done by a 
professional and all the information and procedures were well documented. To 
overcome the second possibility obvious variations were eliminated whilst minor 
variations that could ± 0-10 % change the results (Rapaport et al., 2013) were 
ignored. However, no possible sources of error were noticed for the validation of 
results. RTqPCR could be employed by using the specific primers for the gene that 
were identified in RNA-sequencing in the remaining RNA extracted samples from 
patients and it would be possible to get the results that were nearly similar. However, 
RNA-Seq uses different algorithms and is more sensitive therefore this partly explain 
the difference between the results from two methods.  
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5.5. Discussion 
The G-gap is common in patients with diabetes, However, the cause and underlying 
molecular events of G-gap are not clear. However, the study of transcriptome may 
contribute to understanding the underlying mechanism of G-gap occurrence and 
consistency. In this study, differentially expressed genes were enriched mainly in 
blood pressure and glycated haemoglobin A. These conditions coexist with 
diabetes.  Studies showed that up to 75% of patients with diabetes suffer high blood 
pressure (Campbell et al., 2009). Amongst DEGs linked to blood pressure and 
glycalated haemoglobin A, the CPVL gene was common to both diseases. This 
gene was upregulated in negative G-gap group. Hu et al. (2011) investigated that 
CPVL variant was associated with diabetic retinopathy.  
 
According to GO and KEGG pathway enrichment analysis, various pathways were 
significantly downregulated in G-gap groups. Four pathways (Viral carcinogenesis, 
Ribosome, Phagosome and Dorso-ventral axis) came out top in the bioinformatic 
analysis in which DEGs were enriched. The identified pathways are important but 
the statistical significance of them appears quite small. These pathways are 
important because of their link with RBCs level (which could be affected by 
infection), ribosome (involves in the translation process) and Phagosome (involved 
in normal homeostasis of the immune system). These pathways are based purely 
on the difference between negative and positive G-gap groups. However, if the 
pathway analysis is performed based on gene expression profiles of the samples 
that cluster together under the PCA then the pathways that come out may be very 
different. Obviously, there is still the issue of what might be a more significant driver 
of gene expression leading to G-gap in these patients e.g. sex, age or ethnicity that 
is making them cluster other than G-gap basis. This requires further investigation.  
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5.4. Conclusion 
In this study, RNA sequencing was performed for G-gap groups. Amongst a total of 
64451 genes that were identified, 103 genes were differentially expressed in a 
significant manner whilst 342 differentially expressed transcripts were identified 
between negative and positive G-gap groups. It is important to understand the 
mechanism for the differences in diabetes complications by identifying the relevant 
pathway in which these genes play an important role. This would improve diabetes 
control and associated complications as well as enlightens the effective and specific 
ways for the prediction of diabetic complications in G-gap groups and to cure these. 
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Chapter 6 
 
 
 
Final discussion, conclusion, limitation of the study and future 
study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
6.1. Final Discussion 
End-stage renal damage, blindness, neuropathies and cardiovascular disease 
(CVD), are vascular complications in diabetes. These complications result in 
disabilities and high mortality rates in patients with diabetes mellitus (Brownlee, 
2001). Non-enzymatic glycation of proteins is an important process for patients with 
diabetes with regards of the development of diabetic complications through the 
generation of Advanced Glycated End-products (AGE) and in respect of the 
methodology for diagnosing and monitoring diabetes through measurement of 
glycated haemoglobin or other glycated blood proteins which are widely used as a 
sign of average glycaemia. Glycation is a non-enzymatic process mainly indicated 
by the glucose concentration, while deglycation is an enzyme-mediated pathway, 
one of the major enzymes of which is thought to be fructosamine-3-kinase (FN3K) 
(Van Schaftingen et al., 2012). FN3K gene knock-out mice studies demonstrated 
that glycation of proteins increases (Veiga et al., 2006), highlighting the role of the 
enzyme in physiological deglycation. The gene that encodes FN3K is located on 
chromosome 17q25. Research studies demonstrated various polymorphisms of the 
FN3K gene, some SNPs from them alter FN3K activity in human erythrocytes 
(Delpierre et al., 2006) and some are responsible for variations in glycated 
haemoglobin levels (Mohás et al., 2010) and some diabetic complications (Škrha et 
al., 2014).   
 
Non-enzymatic glycation and modification of proteins through Schiff base, Amadori, 
and Maillard reactions form AGEs that cross-link with extracellular matrix materials 
such as collagen and cause vascular stiffness (Goldin et al., 2006 and Semba et al., 
2015) and vascular complications of diabetes (Genuth et al., 2005 and Nin et al., 
2011). These AGEs accumulate in tissue and plasma during ageing and diabetes 
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(Meerwaldt et al., 2008) and contribute to age-related and diabetes-related 
pathologies, including atherosclerosis, cataract, nephropathy, retinopathy, and 
Alzheimer’s disease (Roriz et al., 2009). Thus, FN3K provides a protective 
mechanism against non-enzymatic glycation by decomposing fructosamine 3-
phosphates to 3-deoxyglucosone, inorganic phosphate and an amine (Collard et al., 
2003). Studies in animal models proved that circulating sRAGE neutralises the 
adverse effects of cellular RAGE by binding with serum AGEs (Wautier et al., 1996 
and Park et al.,1998) through the mechanisms that promote cleavage and shedding 
of full-length RAGE to develop sRAGE. But as previously discussed (section 3.5) 
that interpretation of sRAGE is controversial as different studies had different results 
depending on the disease type.  
 
This study found a non- significant difference in sRAGE levels between two groups 
with negative and positive glycation gaps whereas Dunmore et al. (2018) 
demonstrated that the AGE level was higher.  So, the finding of this study is 
consistent with the concept that AGEs act via receptor-dependent and receptor-
independent ways (Goh and Cooper, 2008). When the AGEs act in a receptor-
dependent manner this produces oxidative stress and increased inflammation as a 
of result immune cells proliferate. During this proliferation, telomere length shortens 
with each cycle of cell division. The present study found no difference in telomere 
length ratio between negative and positive G-gap indicating a potential low 
inflammatory response in those patients. This study did not observe any genotypic 
association between FN3K SNPs (rs3848403 and rs1056534) and sRAGE 
concentration among those groups so the AGE concentration is a more likely link 
between excessive glycation in subjects with a positive G-gap which is likely to be 
a consequence of lower FN3K activity. Since sRAGE levels could reflect the 
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expression of RAGE in a tissue but in reality, the sRAGE level is 1,000 times lower 
in humans than the level that is actually and efficiently needed to capture the 
circulating AGEs (Yamagishi and Matsui, 2010) and this supports the hypothesis 
that sRAGE is not acting as a decoy receptor for AGEs.  
 
HbA1c values vary among individuals, despite the similar preceding levels of blood 
glucose or fructosamine concentration. Dunmore et al. (2018) correlated the FN3K 
activity with the glycation gap and the development of diabetic complications. The 
non-enzymatic glycation links between an elevated level of blood glucose 
concentration and the development of diabetic complications, as evidenced from 
various research studies. Therefore, FN3K deglycating/protein repairing enzyme 
activity is of greater importance and various research studies proved the association 
of SNPs in FN3K gene with typical aspects of diabetes. FN3K SNPs and the 
ferroportin1 SNP were not responsible for functional alterations in the studied cohort 
indicating the potential involvement of DEGs and transcript variants. These could 
be enriched in various disease states, involving pathways and biological processes 
in the underlying mechanism of G-gap. The transcriptome study was conducted to 
check the hypothesis that DEGs and transcript variants in G-gap groups could 
collectively enhance or reduce the expression of other enzymes, the activity of 
enzymes and regulatory factors that take part in the deglycation reaction. This study 
identified 103 DEGs and 342 differentially expressed transcripts in G-gap groups. 
This study also found 14 DEGs that encoded various alternatively spliced transcript 
variants. These DEGs were mainly associated with blood pressure, glycated 
haemoglobin and erythrocyte indices, and they were enriched in various pathways 
(viral carcinogenesis, ribosome and phagosome) and biological processes 
(metabolic process, cellular component analysis, developmental process and 
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immune system process). This is the initial finding. Therefore, protein-protein 
interaction (PPI) analysis in STRING (Search tool for the Retrieval of Interacting 
Genes/Proteins) can be performed to find putative partners that affect the gene 
expression and provide an understanding for the mechanisms associated with G-
gap.  
 
6.2. Conclusion 
The prime objective of the present thesis was to explore the findings via research 
related to the questions presented in Chapter 1. These questions were developed 
based on gaps from previous studies. In this study the role of SNPs was assessed 
for the differences of FN3K activity in G-gap negative and positive groups. This was 
explored by TaqMan genotyping assay on Real-time qPCR. Results demonstrated 
novel findings that studied SNPs were not involved in the mechanism related to 
higher and lower FN3K activity in the studied cohort. The sRAGE level was not 
different in both groups and this study confirmed direct (receptor-independent) and 
indirect (receptor-dependent) roles of AGEs in diabetic complications. The lack of 
differences in telomere length between group within the studied cohort, indicated a 
potentially low inflammatory response. The transcriptome study in this thesis 
identified various DEGs, differentially expressed transcripts and alternatively spliced 
variants and their association with various disease, pathways and biological 
processes which has opened up new ways of thinking about the underlying 
mechanism of the G-gap in patients with diabetes. 
  
6.3. Limitations  
Working with a small sample size of different ethnic groups reduces the possibility 
of accounting for genetic and lifestyle factors that are more important when 
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considering a wider population during multicentre research. The studied cohort had 
a limited ethnic background including mainly white population and without 
considering the relatively specific ethnic background and the country of origin. The 
limitation of this research including participant’s involvement from only a single NHS 
trust hospital in Wolverhampton which might not reflect the country’s overall ethnic 
diversity and thus makes it difficult to interpret the impact of genetic variability on 
the medical conditions of patients with diabetes. Ethnicity might have an impact on 
the variable expression of genes under different medical conditions alongside 
responding to antidiabetic drug management. It has been reported that Asian 
ethnicities are more vulnerable to develop diabetes and they are 60% of the global 
diabetic population (Guariguata et al., 2014). 
 
In this study, there is an unequal percentage of males and females (77% vs 23% 
respectively in negative G-gap group whilst 61% vs 39% respectively in positive G-
gap group). Consequently, the analyses are not generally applicable to both 
genders because there might be gender specific variation. The lack of diversity in 
ethnicity and gender bias may affect variations in G-gap values. Research studies 
demonstrated that gender and ethnicity might be associated with potential variation 
in G-gap values (Cohen et al., 2006 and Nayak et al., 2011).  This makes it 
questionable to represent the global population based on the studied cohort in this 
study.  Another potential limitation is several freeze-thaw cycles that might affect the 
sRAGE level in relation to G-gap values over time.  
 
6.4. Future study 
Detailed studies are important to understand the difference in the glycation gap 
between individuals including epigenomics, involving reversible heritable changes 
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in actual DNA sequence. These epigenetic changes take place via DNA methylation 
and histone modification which affect gene expression via potential hindrance in the 
availability of DNA sequence for transcriptome formation. 
 
Study of the glycation gap in a mouse with FN3K knock-out of the gene. In the 
absence of FN3K gene glycation of HbA1c is increased. Glycation gap study will 
help to identify and confirm whether there any other mechanism exists to control 
diabetic complications. 
 
WDRG studied the glycation level in positive and negative G-gap groups in human 
with diabetes. In the future, this study could be conducted in normal individuals 
without diabetes as well as in other mammals such as a chimpanzee.    
 
Validation study for differentially expressed genes identified by RNA-Seq can be 
conducted through RTqPCR. This will contribute to the analysis of the measured 
transcript abundance of selected genes that were involved in diabetes pathways 
and showed levels of differential expression.   
 
Bioinformatic data from RNA-Seq study should be analysed further for the 
identification of the generic organisational principle of functional networks and for 
the investigation of novel protein function. 
 
  
167 
 
 
 
 
 
 
 
Chapter 7 
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
Abreu, E., Aritonovska, E., Reichenbach, P., Cristofari, G., Culp, B., Terns, R.M., 
Lingner, J. and Terns, M.P. (2010) TIN2-tethered TPP1 recruits human telomerase 
to telomeres in vivo. Molecular and cellular biology, 30(12), pp. 2971-2982. 
 
Adaikalakoteswari, A., Balasubramanyam, M. and Mohan, V. (2005) Telomere 
shortening occurs in Asian Indian Type 2 diabetic patients. Diabetic Medicine, 22(9), 
pp. 1151-1156. 
 
Adaikalakoteswari, A., Balasubramanyam, M., Ravikumar, R., Deepa, R. and 
Mohan, V. (2007) Association of telomere shortening with impaired glucose 
tolerance and diabetic macroangiopathy. Atherosclerosis, 195(1), pp. 83-89. 
 
Ahmad, S., Khan, M.S., Akhter, F., Khan, M.S., Khan, A., Ashraf, J.M., Pandey, R.P. 
and Shahab, U. (2014). Glycoxidation of biological macromolecules: a critical 
approach to halt the menace of glycation. Glycobiology, 24(11), pp.979-990. 
 
Ahmed, N. and Thornalley, P. (2007). Advanced glycation endproducts: what is their 
relevance to diabetic complications? Diabetes, Obesity and Metabolism, 9(3), 
pp.233-245. 
 
Albert, F.W. and Kruglyak, L. (2015) The role of regulatory variation in complex traits 
and disease. Nature Reviews Genetics, 16(4), pp. 197-212. 
  
 
 
169 
 
Albuquerque, D., Manco, L., Loua, K.M., Arez, A.P., Trovoada, M.d.J., Relvas, L., 
Millimono, T.S., Rath, S.L., Lopes, D. and Nogueira, F. (2011) SLC40A1 Q248H 
allele frequencies and associated SLC40A1 haplotypes in three West African 
population samples. Annals of Human Biology, 38(3), pp. 378-381.  
 
Altshuler, D., Daly, M.J. and Lander, E.S. (2008) Genetic mapping in human 
disease. Science (New York, N.Y.), 322(5903), pp. 881-888.  
 
American Diabetes Association (2010) Standards of medical care in diabetes--2010. 
Diabetes Care, 33 Suppl 1pp. S11-61.  
 
American Diabetes Association (2010). Diagnosis and classification of diabetes 
mellitus. Diabetes Care, 33 suppl 1pp. S62-69. 
 
American Diabetes Association (2014) Diagnosis and classification of diabetes 
mellitus. Diabetes care, 37 Suppl 1pp. S81-90.  
 
Amore, A., Cirina, P., Conti, G., Cerutti, F., Bagheri, N., Emancipator, S.N. and 
Coppo, R. (2004) Amadori-configurated albumin induces nitric oxide-dependent 
apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. 
Nephrology Dialysis Transplantation, 19(1), pp. 53-60.  
 
Anders, S., Pyl, P.T. and Huber, W. (2015) HTSeq—a Python framework to work 
with high-throughput sequencing data. Bioinformatics, 31(2), pp. 166-169. 
 
170 
 
Anders, S., Reyes, A. and Huber, W. (2012) Detecting differential usage of exons 
from RNA-seq data. Genome research, 22(10), pp. 2008-2017.  
 
Andrews, S. (2010) FastQC: a quality control tool for high throughput sequence 
data.  
 
Applied Biosystems., 2010a. Custom TaqMan® SNP Genotyping Assays: Protocol. 
Foster City, CA, USA: Applied Biosystems. 
 
Armanios, M. (2013). Telomeres and age-related disease: how telomere biology 
informs clinical paradigms. The Journal of clinical investigation, 123(3), pp.996-
1002. 
 
Arvan, P., Pietropaolo, M., Ostrov, D. and Rhodes, C.J. (2012) Islet autoantigens: 
structure, function, localization, and regulation. Cold Spring Harbor perspectives in 
medicine, 2(8), pp. 10.1101. 
 
Atkinson, M. and Eisenbarth, G. (2015). Type 1 diabetes. Lancet, pp.383:69-82. 
 
Atkinson, M.A., Eisenbarth, G.S. and Michels, A.W. (2014) Type 1 diabetes. The 
Lancet, 383(9911), pp. 69-82.  
 
Avemaria, F., Carrera, P., Lapolla, A., Sartore, G., Chilelli, N.C., Paleari, R., 
Ambrosi, A., Ferrari, M. and Mosca, A. (2015) Possible role of fructosamine 3-kinase 
genotyping for the management of diabetic patients. Clinical Chemistry and 
Laboratory Medicine (CCLM), 53(9), pp. 1315-1320. 
171 
 
Bailes, B.K, (2002). Diabetes mellitus and its chronic complications. AORN journal, 
76(2), pp.265-282. 
 
Baird, D.M. (2005) New developments in telomere length analysis. Experimental 
Gerontology, 40(5), pp. 363-368. 
 
Baker, D., Wijshake, T., Tchkonia, T., LeBrasseur, N., Childs, B., van de Sluis, B., 
Kirkland, J. and van Deursen, J. (2011). Clearance of p16Ink4a-positive senescent 
cells delays ageing-associated disorders. Nature, 479(7372), pp.232-236. 
 
Bandaria, J., Qin, P., Berk, V., Chu, S. and Yildiz, A. (2016). Shelterin Protects 
Chromosome Ends by Compacting Telomeric Chromatin. Cell, 164(4), pp.735-746. 
 
Barton, J.C., Acton, R.T., Lee, P.L. and West, C. (2007) SLC40A1 Q248H allele 
frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-
Saharan African descent. Blood Cells, Molecules, and Diseases, 39(2), pp. 206-
211.  
 
Beltran del Rio, M., Tiwari, M., Amodu, L.I., Cagliani, J. and Rodriguez Rilo, H.L, 
(2016). Glycated hemoglobin, plasma glucose, and erythrocyte aging. Journal of 
diabetes science and technology, 10(6), pp.1303-1307. 
 
Benjamini, Y. and Speed, T.P. (2012) Summarizing and correcting the GC content 
bias in high-throughput sequencing. Nucleic acids research, 40(10), pp. e72-e72.  
Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., Smith, G.P., Milton, J., Brown, 
C.G., Hall, K.P., Evers, D.J., Barnes, C.L. and Bignell, H.R. (2008) Accurate whole 
172 
 
human genome sequencing using reversible terminator chemistry. Nature, 
456(7218), pp. 53- 59.  
 
Beutler, E., Barton, J.C., Felitti, V.J., Gelbart, T., West, C., Lee, P.L., Waalen, J. and 
Vulpe, C. (2003) Ferroportin 1 (SCL40A1) variant associated with iron overload in 
African-Americans. Blood Cells, Molecules, and Diseases, 31(3), pp. 305-309. 
 
Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P., Chen, J., 
Hong, M., Luther, T., Henle, T., Kloting, I., Morcos, M., Hofmann, M., Tritschler, H., 
Weigle, B., Kasper, M., Smith, M., Perry, G., Schmidt, A., Stern, D., Haring, H., 
Schleicher, E. and Nawroth, P. (2001). Diabetes-Associated Sustained Activation of 
the Transcription Factor Nuclear Factor- B. Diabetes, 50(12), pp.2792-2808. 
 
Blackburn, E. (2000). Telomere states and cell fates. Nature, pp.408:53–56. 
 
Blackburn, E. (2001). Switching and Signaling at the Telomere. Cell, 106(6), pp.661-
673. 
 
Blackburn, E., Greider, C. and Szostak, J. (2006). Telomeres and telomerase: the 
path from maize, Tetrahymena, and yeast to human cancer and ageing. Nature 
Medicine, 12(10), pp.1133-1138. 
 
Blencowe, B.J. (2006) Alternative splicing: new insights from global analyses. Cell, 
126(1), pp. 37-47.  
 
173 
 
Borodina, T., Adjaye, J. and Sultan, M. (2011) A strand-specific library preparation 
protocol for RNA sequencing. in Methods in Enzymology, 500, pp. 79-98. 
 
Boteva, E. and Mironova, R. (2019) Maillard reaction and aging: can bacteria shed 
light on the link? Biotechnology & Biotechnological Equipment, pp. 1-17.  
 
Braasch, D.A. and Corey, D.R. (2001) Locked nucleic acid (LNA): fine-tuning the 
recognition of DNA and RNA. Chemistry & Biology, 8(1), pp. 1-7.  
 
Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic 
complications. Nature, 414(6865), pp.813-820. 
 
Brownlee, M. (2005) The pathobiology of diabetic complications: a unifying 
mechanism. Diabetes, 54(6), pp. 1615-1625.  
 
Bucciarelli, L.G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L.L., Goova, M.T., 
Moser, B., Kislinger, T., Lee, D.C., Kashyap, Y., Stern, D.M. and Schmidt, A.M. 
(2002) RAGE blockade stabilizes established atherosclerosis in diabetic 
apolipoprotein E-null mice. Circulation, 106(22), pp. 2827-2835. 
 
Buijsse, B., Feskens, E.J., Moschandreas, J., Jansen, E.H., Jacobs Jr, D.R., 
Kafatos, A., Kok, F.J. and Kromhout, D., (2007). Oxidative stress, and iron and 
antioxidant status in elderly men: differences between the Mediterranean south 
(Crete) and northern Europe (Zutphen). European Journal of Cardiovascular 
Prevention & Rehabilitation, 14(4), pp.495-500. 
 
174 
 
Bullard, J.H., Purdom, E., Hansen, K.D. and Dudoit, S. (2010) Evaluation of 
statistical methods for normalization and differential expression in mRNA-Seq 
experiments. BMC Bioinformatics, 11(1), pp. 94.  
 
Cabili, M.N., Trapnell, C., Goff, L., Koziol, M., Tazon-Vega, B., Regev, A. and Rinn, 
J.L. (2011) Integrative annotation of human large intergenic noncoding RNAs 
reveals global properties and specific subclasses. Genes & development, 25(18), 
pp. 1915-1927.  
 
Cai, W., Ramdas, M., Zhu, L., Chen, X., Striker, G.E. and Vlassara, H. (2012) Oral 
advanced glycation endproducts (AGEs) promote insulin resistance and diabetes 
by depleting the antioxidant defences AGE receptor-1 and sirtuin 1. Proceedings of 
the National Academy of Sciences, 109(39), pp. 15888-15893. 
 
Callicott, R.J. and Womack, J.E. (2006) Real-time PCR assay for measurement of 
mouse telomeres. Comparative medicine, 56(1), pp. 17-22.  
 
Campbell, N.R., Leiter, L.A., Larochelle, P., Tobe, S., Chockalingam, A., Ward, R., 
Morris, D. and Tsuyuki, R. (2009) Hypertension in diabetes: a call to action. 
Canadian Journal of Cardiology, 25(5), pp. 299-302.  
 
Campisi, J., Kim, S., Lim, C. and Rubio, M. (2001) Cellular senescence, cancer, and 
ageing: the telomere connection. Experimental Gerontology, 36(10), pp. 1619-1637.  
 
 
175 
 
Caselli, E., Rizzo, R., Ingianni, A., Contini, P., Pompei, R., and Di Luca, D. (2014) 
High prevalence of HHV8 infection and specific killer cell immunoglobulin‐like 
receptors allotypes in Sardinian patients with type 2 diabetes mellitus. Journal of 
medical virology, 86(10), pp. 1745-1751. 
 
Cawthon, R.M. (2002) Telomere measurement by quantitative PCR. Nucleic acids 
research, 30(10), pp. e47-e47.  
 
Cawthon, R.M., Smith, K.R., O'Brien, E., Sivatchenko, A. and Kerber, R.A. (2003) 
Association between telomere length in blood and mortality in people aged 60 years 
or older. The Lancet, 361(9355), pp. 393-395. 
 
Cech, T.R. and Steitz, J.A. (2014) The noncoding RNA revolution—trashing old 
rules to forge new ones. Cell, 157(1), pp. 77-94.  
 
Chakhtoura, M. and Azar, S.T. (2013) The role of vitamin d deficiency in the 
incidence, progression, and complications of type 1 diabetes mellitus. International 
journal of endocrinology, 2013pp. 148673. 
 
Chan, C.L., Hope, E., Thurston, J., Vigers, T., Pyle, L., Zeitler, P.S. and Nadeau, 
K.J. (2018). Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring–
Derived Average Glucose in Youth and Young Adults with Cystic Fibrosis. Diabetes 
care, 41(7), pp.1406-1413. 
 
Chanock, S. (2001). Candidate genes and single nucleotide polymorphisms (SNPs) 
in the study of human disease. Disease markers, 17(2), pp.89-98. 
176 
 
Chaussabel, D., Pascual, V. and Banchereau, J. (2010) Assessing the human 
immune system through blood transcriptomics. BMC biology, 8(1), pp. 80-84.  
 
Chen, L., Redon, S. and Lingner, J. (2012) The human CST complex is a terminator 
of telomerase activity. Nature, 488(7412), pp. 540-544. 
 
Chen, M. and Manley, J.L. (2009) Mechanisms of alternative splicing regulation: 
insights from molecular and genomics approaches. Nature reviews Molecular cell 
biology, 10(11), pp. 741-754.  
 
Chilelli, N., Burlina, S. and Lapolla, A. (2013) AGEs, rather than hyperglycemia, are 
responsible for microvascular complications in diabetes: a “glycoxidation-centric” 
point of view. Nutrition, Metabolism and Cardiovascular Diseases, 23(10), pp. 913-
919. 
 
Cikomola, J.C., Kishabongo, A.S., Vandepoele, K., De Mulder, M., Katchunga, P.B., 
Laukens, B., Van Schie, L., Grootaert, H., Callewaert, N. and Speeckaert, M.M. 
(2017) A simple colorimetric assay for measuring fructosamine 3 kinase activity. 
Clinical Chemistry and Laboratory Medicine (CCLM), 55(1), pp. 154-159.  
 
Classification and Diagnosis of Diabetes. (2014). Diabetes Care, 
38(Supplement_1), pp. S8-S16. 
 
Cock, P.J., Fields, C.J., Goto, N., Heuer, M.L. and Rice, P.M. (2009) The Sanger 
FASTQ file format for sequences with quality scores, and the Solexa/Illumina 
FASTQ variants. Nucleic acids research, 38(6), pp. 1767-1771. 
177 
 
Cohen, R.A., Hennekens, C.H., Christen, W.G., Krolewski, A., Nathan, D.M., 
Peterson, M.J., LaMotte, F., and Manson, J.E. (1999) Determinants of retinopathy 
progression in type 1 diabetes mellitus. The American Journal of Medicine, 107(1), 
pp. 45-51.  
  
Cohen, R.M. and Lindsell, C.J. (2012) When the blood glucose and the HbA(1c) 
don't match: turning uncertainty into opportunity. Diabetes Care, 35(12), pp. 2421-
2423.  
 
Cohen, R.M. and Smith, E.P. (2008) Frequency of HbA1c discordance in estimating 
blood glucose control. Current Opinion in Clinical Nutrition & Metabolic Care, 11(4), 
pp. 512-517.  
 
Cohen, R.M., Franco, R.S., Khera, P.K., Smith, E.P., Lindsell, C.J., Ciraolo, P.J., 
Palascak, M.B. and Joiner, C.H. (2008) Red cell life span heterogeneity in 
hematologically normal people is sufficient to alter HbA1c. Blood, 112(10), pp. 4284-
4291. 
 
Cohen, R.M., Holmes, Y.R., Chenier, T.C. and Joiner, C.H. (2003) Discordance 
between HbA1c and fructosamine: evidence for a glycosylation gap and its relation 
to diabetic nephropathy. Diabetes Care, 26(1), pp. 163-167. 
 
Cohen, R.M., Snieder, H., Lindsell, C.J., Beyan, H., Hawa, M.I., Blinko, S., Edwards, 
R., Spector, T.D. and Leslie, R.D. (2006) Evidence for independent heritability of the 
glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes 
Care, 29(8), pp. 1739-1743.  
178 
 
Colhoun, H.M., Betteridge, D.J., Durrington, P., Hitman, G., Neil, A., Livingstone, S., 
Charlton-Menys, V., Bao, W., Demicco, D.A., Preston, G.M., Deshmukh, H., Tan, K. 
and Fuller, J.H. (2011) Total soluble and endogenous secretory receptor for 
advanced glycation end products as predictive biomarkers of coronary heart disease 
risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes, 
60(9), pp. 2379-2385. 
 
Collard, F., Delpierre, G., Stroobant, V., Matthijs, G., and Van Schaftingen, E. (2003) 
A mammalian protein homologous to fructosamine-3-kinase is a ketosamine-3-
kinase acting on psicosamines and ribulosamines but not on fructosamines. 
Diabetes, 52(12), pp. 2888-2895.  
 
Conner, J.R., Beisswenger, P.J. and Szwergold, B.S. (2004) The expression of the 
genes for fructosamine-3-kinase and fructosamine-3-kinase-related protein appears 
to be constitutive and unaffected by environmental signals. Biochemical and 
biophysical research communications, 323(3), pp. 932-936.  
 
Conner, J.R., Beisswenger, P.J. and Szwergold, B.S. (2005). Some clues as to the 
regulation, expression, function, and distribution of fructosamine‐3‐kinase and 
fructosamine‐3‐kinase-related protein. Annals of the New York Academy of 
Sciences, 1043(1), pp.824-836. 
 
Consortium EP. (2012) an integrated encyclopedia of DNA elements in the human 
genome. Nature, 489 (7414), pp. 57-74. 
 
179 
 
Costes, S., Langen, R., Gurlo, T., Matveyenko, A.V. and Butler, P.C. (2013) beta-
Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes, 62(2), 
pp. 327-335. 
 
Coughlan, M.T., Thorburn, D.R., Penfold, S.A., Laskowski, A., Harcourt, B.E., 
Sourris, K.C., Tan, A.L., Fukami, K., Thallas-Bonke, V., Nawroth, P.P., Brownlee, 
M., Bierhaus, A., Cooper, M.E. and Forbes, J.M. (2009) RAGE-induced cytosolic 
ROS promote mitochondrial superoxide generation in diabetes. Journal of the 
American Society of Nephrology: JASN, 20(4), pp. 742-752. 
 
Creager, M.A., Luscher, T.F., Cosentino, F. and Beckman, J.A. (2003) Diabetes and 
vascular disease: pathophysiology, clinical consequences, and medical therapy: 
Part I. Circulation, 108(12), pp. 1527-1532. 
 
Daniali, L., Benetos, A., Susser, E., Kark, J.D., Labat, C., Kimura, M., Desai, K.K., 
Granick, M. and Aviv, A. (2013). Telomeres shorten at equivalent rates in somatic 
tissues of adults. Nature communications, 4, p.1597. 
 
Darnell, J.E., Jr (2013) Reflections on the history of pre-mRNA processing and 
highlights of current knowledge: a unified picture. RNA (New York, N.Y.), 19(4), pp. 
443-460.  
 
Das, S. and Vikalo, H. (2013) Base-calling for high-throughput short-read 
sequencing: dynamic programming solutions. BMC Bioinformatics, 14(1), pp. 129. 
 
180 
 
Davuluri, R.V., Suzuki, Y., Sugano, S., Plass, C. and Huang, T.H. (2008) The 
functional consequences of alternative promoter use in mammalian genomes. 
Trends in Genetics, 24(4), pp. 167-177.  
 
De Boeck, G., Forsyth, R.G., Praet, M., and Hogendoorn, P.C. (2009) Telomere‐
associated proteins: cross‐talk between telomere maintenance and telomere‐
lengthening mechanisms. The Journal of Pathology, 217(3), pp. 327-344.  
 
De Lange, T. (2005) Shelterin: the protein complex that shapes and safeguards 
human telomeres. Genes & development, 19(18), pp. 2100-2110. 
 
Degner, J.F., Marioni, J.C., Pai, A.A., Pickrell, J.K., Nkadori, E., Gilad, Y. and 
Pritchard, J.K. (2009) Effect of read-mapping biases on detecting allele-specific 
expression from RNA-sequencing data. Bioinformatics, 25(24), pp. 3207-3212. 
 
Delpierre, G., Collard, F., Fortpied, J., and Van Schaftingen, E. (2002) Fructosamine 
3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. 
The Biochemical journal, 365(Pt 3), pp. 801-808. 
 
Delpierre, G., Rider, M.H., Collard, F. and Stoobant, V. (2000) Identification, cloning, 
and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes, 
49(10), pp. 1627-1634.  
 
Delpierre, G., Veiga-da-Cunha, M., Vertommen, D., Buysschaert, M., and Van 
Schaftingen, E. (2006) Variability in erythrocyte fructosamine 3-kinase activity in 
181 
 
humans correlates with polymorphisms in the FN3K gene and impacts on 
haemoglobin glycation at specific sites. Diabetes & Metabolism, 32(1), pp. 31-39. 
 
Delpierrre, G., Vertommen, D., Communi, D., Rider, M.H. and Van Schaftingen, E. 
(2004) Identification of fructosamine residues deglycated by fructosamine-3-kinase 
in human hemoglobin. The Journal of biological chemistry, 279(26), pp. 27613-
27620. 
 
Delplanque, J., Delpierre, G., Opperdoes, F.R., and Van Schaftingen, E. (2004) 
Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-
kinase-related protein. The Journal of biological chemistry, 279(45), pp. 46606-
46613. 
 
Desjardins, P. and Conklin, D. (2010). NanoDrop microvolume quantitation of 
nucleic acids. JoVE (Journal of Visualized Experiments), (45), p.e2565. 
 
Di Bella, J.M., Bao, Y., Gloor, G.B., Burton, J.P. and Reid, G. (2013) High throughput 
sequencing methods and analysis for microbiome research. Journal of 
microbiological methods, 95(3), pp. 401-414. 
 
Di Giammartino, D.C., Nishida, K. and Manley, J.L. (2011) Mechanisms and 
consequences of alternative polyadenylation. Molecular Cell, 43(6), pp. 853-866. 
 
Diotti, R. and Loayza, D. (2011). Shelterin complex and associated factors at human 
telomeres. Nucleus, 2(2), pp.119-135. 
 
182 
 
Djebali, S., Davis, C.A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, 
A., Lagarde, J., Lin, W. and Schlesinger, F. (2012) Landscape of transcription in 
human cells. Nature, 489(7414), pp. 101-108. 
 
Drosten, C., Seifried, E. and Roth, W.K. (2001). TaqMan 5′-nuclease human 
immunodeficiency virus type 1 PCR assay with phage-packaged competitive 
internal control for high-throughput blood donor screening. Journal of clinical 
microbiology, 39(12), pp.4302-4308. 
 
Dunmore, S.J., Al-Derawi, A.S., Nayak, A.U., Narshi, A., Nevill, A.M., Hellwig, A., 
Majebi, A., Kirkham, P., Brown, J.E. and Singh, B.M. (2018) Evidence That 
Differences in Fructosamine-3-Kinase Activity May Be Associated with the Glycation 
Gap in Human Diabetes. Diabetes, 67(1), pp. 131-136. 
 
 
Duran, L., Rodriguez, C., Drozd, D., Nance, R.M., Delaney, J.A., Burkholder, G., 
Mugavero, M.J., Willig, J.H., Warriner, A.H., Crane, P.K. and Atkinson, B.E. (2015). 
Fructosamine and hemoglobin A1c correlations in HIV-infected adults in routine 
clinical care: impact of Anemia and albumin levels. AIDS research and treatment, 
2015. 
 
Edgren, H., Murumagi, A., Kangaspeska, S., Nicorici, D., Hongisto, V., Kleivi, K., 
Rye, I.H., Nyberg, S., Wolf, M. and Borresen-Dale, A. (2011) Identification of fusion 
genes in breast cancer by paired-end RNA-sequencing. Genome biology, 12(1), pp. 
R6.  
 
183 
 
Elgar, G. and Vavouri, T. (2008) Tuning into the signals: noncoding sequence 
conservation in vertebrate genomes. Trends in genetics, 24(7), pp. 344-352.  
 
ENCODE Project Consortium (2012) An integrated encyclopedia of DNA elements 
in the human genome. Nature, 489(7414), pp. 57-74.  
 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) 
Report of the expert committee on the diagnosis and classification of diabetes 
mellitus. Diabetes Care, 26 Suppl 1pp. S5-20. 
 
Falcone, C., Emanuele, E., D'Angelo, A., Buzzi, M.P., Belvito, C., Cuccia, M. and 
Geroldi, D. (2005) Plasma levels of soluble receptor for advanced glycation end 
products and coronary artery disease in nondiabetic men. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 25(5), pp. 1032-1037.  
 
Farajollahi, S. and Maas, S. (2010) Molecular diversity through RNA editing: a 
balancing act. Trends in Genetics, 26(5), pp. 221-230.  
 
Farmer, A. (2012) Use of HbA1c in the diagnosis of diabetes. BMJ (Clinical research 
ed.), 345pp. e7293 .  
 
Fleming, A.M. and Burrows, C.J. (2013) G-quadruplex folds of the human telomere 
sequence alter the site reactivity and reaction pathway of guanine oxidation 
compared to duplex DNA. Chemical research in toxicology, 26(4), pp. 593-607. 
 
184 
 
Florez, J.C., and Barroso, I. (2014) Genome-Wide Association Studies of Glycaemic 
Traits: A Magical Journey. in Genetics in Diabetes. Karger Publishers, 23, pp. 42-
57. 
 
Fournet, M., Bonte, F. and Desmouliere, A. (2018) Glycation damage: A possible 
hub for major pathophysiological disorders and aging. Aging and disease, 9(5), pp. 
880-900.  
 
Francisco, M., Lazaruk, K.D., Rhodes, M.D. and Wenz, M.H. (2005) Assessment of 
two flexible and compatible SNP genotyping platforms: TaqMan® SNP Genotyping 
Assays and the SNPlex™ Genotyping System. Mutation Research/Fundamental 
and Molecular Mechanisms of Mutagenesis, 573(1), pp. 111-135.  
 
Fraser, C.G. (2001) Biological variation: from principles to practice. Amer. Assoc. 
for Clinical Chemistry. 
 
Fuda, N.J., Ardehali, M.B. and Lis, J.T. (2009) Defining mechanisms that regulate 
RNA polymerase II transcription in vivo. Nature, 461(7261), pp. 186-192. 
 
Garber, M., Grabherr, M.G., Guttman, M. and Trapnell, C. (2011) Computational 
methods for transcriptome annotation and quantification using RNA-seq. Nature 
methods, 8(6), pp. 469-477.  
 
 
 
185 
 
Genuth, S., Sun, W., Cleary, P., Sell, D., Dahms, W., Malone, J., Sivitz, W. and 
Monnier, V. (2005) DCCT Skin Collagen Ancillary Study Group: Glycation and 
carboxymethyllysine levels in skin collagen predict the risk of future 10-year 
progression of diabetic retinopathy and nephropathy in the diabetes control and 
complications trial and epidemiology of diabetes interventions and complications 
participants with type 1 diabetes. Diabetes, 54(11), pp. 3103-3111. 
 
Georgin-Lavialle, S., Aouba, A., Mouthon, L., Londono-Vallejo, J.A., Lepelletier, Y., 
Gabet, A. and Hermine, O. (2010) The telomere/telomerase system in autoimmune 
and systemic immune-mediated diseases. Autoimmunity reviews, 9(10), pp. 646-
651.  
 
Gil, M.E. and Coetzer, T.L. (2004) Real-time quantitative PCR of telomere length. 
Molecular biotechnology, 27(2), pp. 169-172. 
 
Girelli, D., De Domenico, I., Bozzini, C., Campostrini, N., Busti, F., Castagna, A., 
Soriani, N., Cremonesi, L., Ferrari, M. and Colombari, R. (2008) Clinical, 
pathological, and molecular correlates in ferroportin disease: a study of two novel 
mutations. Journal of hepatology, 49(4), pp. 664-671. 
 
Gkogkolou, P. and Bohm, M. (2012). Advanced glycation end products: key players 
in skin aging? Dermato-endocrinology, 4(3), pp.259-270. 
 
Goh, S. and Cooper, M.E. (2008) The role of advanced glycation end products in 
progression and complications of diabetes. The Journal of Clinical Endocrinology & 
Metabolism, 93(4), pp. 1143-1152.  
186 
 
Goldin, A., Beckman, J.A., Schmidt, A.M. and Creager, M.A. (2006) Advanced 
glycation end products: sparking the development of diabetic vascular injury. 
Circulation, 114(6), pp. 597-605.  
 
Goldstein, D.E., Little, R.R., Lorenz, R.A., Malone, J.I., Nathan, D., Peterson, C.M. 
and Sacks, D.B. (2004) Tests of glycemia in diabetes. Diabetes care, 27(7), pp. 
1761-1773.  
 
Gordeuk, V., Mukiibi, J., Hasstedt, S.J., Samowitz, W., Edwards, C.Q., West, G., 
Ndambire, S., Emmanual, J., Nkanza, N. and Chapanduka, Z. (1992) Iron overload 
in Africa. New England Journal of Medicine, 326(2), pp. 95-100.  
 
Gordeuk, V.R., Caleffi, A., Corradini, E., Ferrara, F., Jones, R.A., Castro, O., 
Onyekwere, O., Kittles, R., Pignatti, E. and Montosi, G. (2003) Iron overload in 
Africans and African-Americans and a common mutation in the SCL40A1 
(ferroportin 1) gene☆. Blood Cells, Molecules, and Diseases, 31(3), pp. 299-304.  
 
Gott, J.M. and Emeson, R.B. (2000) Functions and mechanisms of RNA editing. 
Annual Review of Genetics, 34(1), pp. 499-531. 
 
Graham, K.L., Sutherland, R.M., Mannering, S.I., Zhao, Y., Chee, J., Krishnamurthy, 
B., Thomas, H.E., Lew, A.M. and Kay, T.W. (2012). Pathogenic mechanisms in type 
1 diabetes: the islet is both target and driver of disease. The review of diabetic 
studies: RDS, 9(4), p.148-168. 
 
187 
 
Grant, P. (2007) Diabetes mellitus as a prothrombotic condition. Journal of internal 
medicine, 262(2), pp. 157-172.  
 
Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U. and Shaw, 
J.E. (2014) Global estimates of diabetes prevalence for 2013 and projections for 
2035. Diabetes research and clinical practice, 103(2), pp. 137-149. 
 
Guimarães, E.L., Empsen, C., Geerts, A., and van Grunsven, L.A. (2010) Advanced 
glycation end products induce production of reactive oxygen species via the 
activation of NADPH oxidase in murine hepatic stellate cells. Journal of Hepatology, 
52(3), pp. 389-397.  
 
Guo, N., Parry, E.M., Li, L., Kembou, F., Lauder, N., Hussain, M.A., Berggren, P. 
and Armanios, M. (2011) Short telomeres compromise β-cell signaling and survival. 
PloS one, 6(3), pp. e17858. 
 
Guttman, M., Garber, M., Levin, J.Z., Donaghey, J., Robinson, J., Adiconis, X., Fan, 
L., Koziol, M.J., Gnirke, A. and Nusbaum, C. (2010) Ab initio reconstruction of cell 
type-specific transcriptomes in the mouse reveals the conserved multi-exonic 
structure of lincRNAs. Nature Biotechnology, 28(5), pp. 503-510.  
 
Hajjawi, O.S. (2013) Glucose transport in human red blood cells. Am J Biomed Life 
Sci, 1(3), pp. 44-52.  
 
 
188 
 
Hansel, B., Giral, P., Nobecourt, E., Chantepie, S., Bruckert, E., Chapman, M.J. and 
Kontush, A. (2004) Metabolic syndrome is associated with elevated oxidative stress 
and dysfunctional dense high-density lipoprotein particles displaying impaired 
antioxidative activity. The Journal of Clinical Endocrinology & Metabolism, 89(10), 
pp. 4963-4971. 
 
Hansen, K.D., Brenner, S.E. and Dudoit, S. (2010) Biases in Illumina transcriptome 
sequencing caused by random hexamer priming. Nucleic acids research, 38(12), 
pp. e131-e131.  
 
Hansen, K.D., Irizarry, R.A. and Wu, Z. (2012) Removing technical variability in 
RNA-seq data using conditional quantile normalization. Biostatistics, 13(2), pp. 204-
216.  
 
Hare, M.J., Shaw, J.E. and Zimmet, P.Z. (2012). Current controversies in the use of 
haemoglobin A1c. Journal of internal medicine, 271(3), pp.227-236. 
 
Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocinski, F., 
Aken, B.L., Barrell, D., Zadissa, A., Searle, S., Barnes, I., Bignell, A., Boychenko, 
V., Hunt, T., Kay, M., Mukherjee, G., Rajan, J., Despacio-Reyes, G., Saunders, G., 
Steward, C., Harte, R., Lin, M., Howald, C., Tanzer, A., Derrien, T., Chrast, J., 
Walters, N., Balasubramanian, S., Pei, B., Tress, M., Rodriguez, J.M., Ezkurdia, I., 
van Baren, J., Brent, M., Haussler, D., Kellis, M., Valencia, A., Reymond, A., 
Gerstein, M., Guigo, R. and Hubbard, T.J. (2012) GENCODE: the reference human 
genome annotation for The ENCODE Project. Genome research, 22(9), pp. 1760-
1774.  
189 
 
Hempe, J.M., Gomez, R., McCarter, R.J. and Chalew, S.A. (2002) High and low 
hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation 
of glycemic control. Journal of diabetes and its complications, 16(5), pp. 313-320. 
 
Herbert, B.S. (2011). The impact of telomeres and telomerase in cellular biology and 
medicine: it’s not the end of the story. Journal of cellular and molecular medicine, 
15(1), p.1-2. 
 
Herman, W.H. and Cohen, R.M. (2012) Racial and ethnic differences in the 
relationship between HbA1c and blood glucose: implications for the diagnosis of 
diabetes. The Journal of Clinical Endocrinology & Metabolism, 97(4), pp. 1067-
1072. 
 
Hex, N., Bartlett, C., Wright, D., Taylor, M. and Varley, D. (2012) Estimating the 
current and future costs of Type 1 and Type 2 diabetes in the UK, including direct 
health costs and indirect societal and productivity costs. Diabetic Medicine, 29(7), 
pp. 855-862. 
 
Hills, M., Lücke, K., Chavez, E.A., Eaves, C.J. and Lansdorp, P.M. (2009). Probing 
the mitotic history and developmental stage of hematopoietic cells using single 
telomere length analysis (STELA). Blood, 113(23), pp.5765-5775. 
 
Hinnebusch, A.G., Ivanov, I.P. and Sonenberg, N. (2016) Translational control by 
5'-untranslated regions of eukaryotic mRNAs. Science (New York, N.Y.), 352(6292), 
pp. 1413-1416.  
 
190 
 
Hockemeyer, D., Daniels, J., Takai, H. and de Lange, T. (2006) Recent expansion 
of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse 
telomeres. Cell, 126(1), pp. 63-77. 
 
Hornsby, P.J. (2007). Telomerase and the aging process. Experimental 
gerontology, 42(7), pp.575-581. 
 
Horvath, S. (2013) DNA methylation age of human tissues and cell types. Genome 
biology, 14(10), pp. 3156.  
 
Hu, C., Zhang, R., Yu, W., Wang, J., Wang, C., Pang, C., Ma, X., Bao, Y., Xiang, K. 
and Jia, W. (2011). CPVL/CHN2 genetic variant is associated with diabetic 
retinopathy in Chinese type 2 diabetic patients. Diabetes, 60(11), pp.3085-3089. 
 
Hudson, B.I., Carter, A.M., Harja, E., Kalea, A.Z., Arriero, M., Yang, H., Grant, P.J. 
and Schmidt, A.M. (2008) Identification, classification, and expression of RAGE 
gene splice variants. The FASEB Journal, 22(5), pp. 1572-1580.  
 
Hudson, P.R., Child, D.F., Jones, H. and Williams, C.P. (1999) Differences in rates 
of glycation (glycation index) may significantly affect individual HbA1c results in type 
1 diabetes. Annals of Clinical Biochemistry, 36(4), pp. 451-459. 
 
Humpert, P.M., Kopf, S., Djuric, Z., Wendt, T., Morcos, M., Nawroth, P.P. and 
Bierhaus, A. (2006) Plasma sRAGE is independently associated with urinary 
albumin excretion in type 2 diabetes. Diabetes Care, 29(5), pp. 1111-1113.  
 
191 
 
International Expert Committee (2009) International Expert Committee report on the 
role of the A1C assay in the diagnosis of diabetes. Diabetes Care, 32(7), pp. 1327-
1334. 
 
International Human Genome Sequencing Consortium (2004) Finishing the 
euchromatic sequence of the human genome. Nature, 431(7011), pp. 931-945. 
 
Jeffcoate, S. (2004) Diabetes control and complications: the role of glycated 
haemoglobin, 25 years on. Diabetic Medicine, 21(7), pp. 657-665.  
 
Kalisky, T., Blainey, P. and Quake, S.R. (2011) Genomic analysis at the single-cell 
level. Annual Review of Genetics, 45pp. 431-445.  
 
Kallio, M.A., Tuimala, J.T., Hupponen, T., Klemelä, P., Gentile, M., Scheinin, I., 
Koski, M., Käki, J. and Korpelainen, E.I. (2011) Chipster: user-friendly analysis 
software for microarray and other high-throughput data. BMC Genomics, 12(1), pp. 
507.  
 
Karijolich, J. and Yu, Y. (2011) Converting nonsense codons into sense codons by 
targeted pseudouridylation. Nature, 474(7351), pp. 395-398. 
 
Karki, R., Pandya, D., Elston, R.C. and Ferlini, C. (2015). Defining “mutation” and 
“polymorphism” in the era of personal genomics. BMC medical genomics, 8(1), p.37. 
 
Karlseder, J. (2003) Telomere repeat binding factors: keeping the ends in check. 
Cancer letters, 194(2), pp. 189-197. 
192 
 
Kasvosve, I., Gomo, Z.A., Nathoo, K.J., Matibe, P., Mudenge, B., Loyevsky, M. and 
Gordeuk, V.R. (2005) Effect of ferroportin Q248H polymorphism on iron status in 
African children–. The American Journal of Clinical Nutrition, 82(5), pp. 1102-1106. 
 
Kasvosve, I., Tshwenyego, U., Phuthego, T., Koto, G., Zachariah, M., Nyepetsi, 
N.G. and Motswaledi, M.S. (2015) Serum ferritin concentration is affected by 
ferroportin Q248H mutation in Africans. Clinica Chimica Acta, 444pp. 257-259. 
 
Kaszubowska, L. (2008) Telomere shortening and ageing of the immune system. J 
Physiol Pharmacol, 59(Suppl 9), pp. 169-186.  
 
Katchunga, P.B., Baguma, M., Jean-René, M., Philippé, J., Hermans, M.P. and 
Delanghe, J. (2013) Ferroportin Q248H mutation, hyperferritinemia and atypical 
type 2 diabetes mellitus in South Kivu. Diabetes & Metabolic Syndrome: Clinical 
Research & Reviews, 7(2), pp. 112-115.  
 
Kato, H., van Chuyen, N., Shinoda, T., Sekiya, F. and Hayase, F. (1990) Metabolism 
of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, 
administered orally or intravenously to rats. Biochimica et Biophysica Acta (BBA)-
General Subjects, 1035(1), pp. 71-76.  
 
Katz, Y., Wang, E.T., Airoldi, E.M. and Burge, C.B. (2010) Analysis and design of 
RNA sequencing experiments for identifying isoform regulation. Nature methods, 
7(12), pp. 1009.  
 
193 
 
Kent, W.J., Sugnet, C.W., Furey, T.S., Roskin, K.M., Pringle, T.H., Zahler, A.M. and 
Haussler, D. (2002) The human genome browser at UCSC. Genome research, 
12(6), pp. 996-1006.  
 
Kilpatrick, E.S., Rigby, A.S. and Atkin, S.L. (2008) A1C variability and the risk of 
microvascular complications in type 1 diabetes: data from the Diabetes Control and 
Complications Trial. Diabetes Care, 31(11), pp. 2198-2202.  
 
Kim, D., Langmead, B. and Salzberg, S.L. (2015) HISAT: a fast-spliced aligner with 
low memory requirements. Nature methods, 12(4), pp. 357-360.  
 
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R. and Salzberg, S.L. (2013) 
TopHat2: accurate alignment of transcriptomes in the presence of insertions, 
deletions and gene fusions. Genome biology, 14(4), pp. R36. 
 
Kim, J., Lim, J. and Lee, C. (2013) Quantitative real-time PCR approaches for 
microbial community studies in wastewater treatment systems: applications and 
considerations. Biotechnology Advances, 31(8), pp. 1358-1373. 
  
Kim, S., Parrinello, S., Kim, J. and Campisi, J. (2003) Mus musculus and Mus 
spretus homologues of the human telomere-associated protein TIN2. Genomics, 
81(4), pp. 422-432.  
 
Kirchner, H., Shaheen, F., Kalscheuer, H., Schmid, S., Oster, H. and Lehnert, H. 
(2017). The telomeric complex and metabolic disease. Genes, 8(7), p.176. 
 
194 
 
Knoop, V. (2011) When you can’t trust the DNA: RNA editing changes transcript 
sequences. Cellular and Molecular Life Sciences, 68(4), pp. 567-586.  
 
Krause, R., Oehme, A., Wolf, K., and Henle, T. (2006) A convenient HPLC assay 
for the determination of fructosamine-3-kinase activity in erythrocytes. Analytical 
and bioanalytical chemistry, 386(7-8), pp. 2019-2025. 
 
Krentz, A.J., Clough, G. and Byrne, C.D. (2007). Interactions between microvascular 
and macrovascular disease in diabetes: pathophysiology and therapeutic 
implications. Diabetes, Obesity and Metabolism, 9(6), pp.781-791. 
 
Krueger, F. (2015) Trim galore. A wrapper tool around Cutadapt and FastQC to 
consistently apply quality and adapter trimming to FastQ files.  
 
Kulis, M. and Esteller, M.  (2010) DNA methylation and cancer. In Advances in 
genetics, 70 pp. 27-56.  
 
Kumar, R., Nandhini, L.P., Kamalanathan, S., Sahoo, J. and Vivekanadan, M. 
(2016) Evidence for current diagnostic criteria of diabetes mellitus. World journal of 
diabetes, 7(17), pp. 396-405.  
 
Kwak, H. and Lis, J.T. (2013) Control of transcriptional elongation. Annual Review 
of Genetics, 47pp. 483-508.  
 
195 
 
Lal, S., Szwergold, B.S., Walker, M., Randall, W., Kappler, F., Brown, T. and 
Beisswenger, P.J. (2005). Production and metabolism of 3-deoxyglucosone in 
humans. In the Maillard reaction in foods and medicine, pp. 291-297.  
 
Lamble, S., Batty, E., Attar, M., Buck, D., Bowden, R., Lunter, G., Crook, D., El-
Fahmawi, B. and Piazza, P. (2013) Improved workflows for high throughput library 
preparation using the transposome-based Nextera system. BMC Biotechnology, 
13(1), pp. 104.  
 
Langmead, B. and Salzberg, S.L. (2012) Fast gapped-read alignment with Bowtie 
2. Nature methods, 9(4), pp. 357-359.  
 
Lapolla, A., Traldi, P. and Fedele, D. (2005) Importance of measuring products of 
non-enzymatic glycation of proteins. Clinical biochemistry, 38(2), pp. 103-115. 
 
Lasken, R.S. and McLean, J.S. (2014) Recent advances in genomic DNA 
sequencing of microbial species from single cells. Nature Reviews Genetics, 15(9), 
pp. 577-584.  
 
Lee, M., Teber, E.T., Holmes, O., Nones, K., Patch, A.M., Dagg, R.A., Lau, L.M.S., 
Lee, J.H., Napier, C.E., Arthur, J.W. and Grimmond, S.M. (2018). Telomere 
sequence content can be used to determine ALT activity in tumours. Nucleic acids 
research, 46(10), pp.4903-4918. 
 
196 
 
Lei, M., Zaug, A.J., Podell, E.R. and Cech, T.R. (2005) Switching human telomerase 
on and off with hPOT1 protein in vitro. The Journal of biological chemistry, 280(21), 
pp. 20449-20456. 
 
Leong, A. and Wheeler, E. (2018) Genetics of HbA1c: a case study in clinical 
translation. Current opinion in genetics & development, 50pp. 79-85.  
 
Leslie, R.D.G. and Cohen, R.M. (2009) Biologic variability in plasma glucose, 
hemoglobin A1c, and advanced glycation end products associated with diabetes 
complications, J Diabetes Sci Technol, 3, pp. 635– 643.  
 
Li, B., Ruotti, V., Stewart, R.M., Thomson, J.A. and Dewey, C.N. (2009) RNA-Seq 
gene expression estimation with read mapping uncertainty. Bioinformatics, 26(4), 
pp. 493-500.  
 
Li, H. and Durbin, R. (2009) Fast and accurate short read alignment with Burrows-
Wheeler transform. bioinformatics, 25(14), pp. 1754-1760.  
 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., 
Abecasis, G. and Durbin, R. (2009) The sequence alignment/map format and 
SAMtools. Bioinformatics, 25(16), pp. 2078-2079. 
 
Li, S., Tighe, S.W., Nicolet, C.M., Grove, D., Levy, S., Farmerie, W., Viale, A., 
Wright, C., Schweitzer, P.A. and Gao, Y. (2014) Multi-platform assessment of 
transcriptome profiling using RNA-seq in the ABRF next-generation sequencing 
study. Nature Biotechnology, 32(9), pp. 915-925.  
197 
 
Liew, C.C., Ma, J., Tang, H.C., Zheng, R. and Dempsey, A.A. (2006). The peripheral 
blood transcriptome dynamically reflects system wide biology: a potential diagnostic 
tool. Journal of Laboratory and Clinical Medicine, 147(3), pp.126-132. 
 
Lindsey, J.B., Cipollone, F., Abdullah, S.M. and Mcguire, D.K. (2009) Receptor for 
advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): 
cardiovascular implications. Diabetes and Vascular Disease Research, 6(1), pp. 7-
14.  
 
Lindsey, J.B., de Lemos, J.A., Cipollone, F., Ayers, C.R., Rohatgi, A., Morrow, D.A., 
Khera, A. and McGuire, D.K. (2009) Association between circulating soluble 
receptor for advanced glycation end products and atherosclerosis: observations 
from the Dallas Heart Study. Diabetes Care, 32(7), pp. 1218-1220.  
 
Lindström, U.M., Chandrasekaran, R.A., Orbai, L., Helquist, S.A., Miller, G.P., 
Oroudjev, E., Hansma, H.G. and Kool, E.T. (2002). Artificial human telomeres from 
DNA nanocircle templates. Proceedings of the National Academy of Sciences, 
99(25), pp.15953-15958. 
 
Liton, P.B., Challa, P., Stinnett, S., Luna, C., Epstein, D.L. and Gonzalez, P. (2005) 
Cellular senescence in the glaucomatous outflow pathway. Experimental 
Gerontology, 40(8), pp. 745-748. 
 
Little, R.R. and Rohlfing, C.L. (2013) The long and winding road to optimal HbA1c 
measurement. Clinica Chimica Acta, 418pp. 63-71.  
 
198 
 
Love, M.I., Huber, W. and Anders, S. (2014) Moderated estimation of fold change 
and dispersion for RNA-seq data with DESeq2. Genome biology, 15(12), pp. 550.  
 
Lowe, R., Shirley, N., Bleackley, M., Dolan, S. and Shafee, T. (2017). 
Transcriptomics technologies. PLoS computational biology, 13(5), p. e1005457. 
 
Lu, W., Zhang, Y., Liu, D., Songyang, Z. and Wan, M. (2013). Telomeres—structure, 
function, and regulation. Experimental cell research, 319(2), pp.133-141. 
 
Luscombe, N.M., Greenbaum, D. and Gerstein, M. (2001) What is bioinformatics? 
A proposed definition and overview of the field. Methods of information in medicine, 
40(04), pp. 346-358.  
 
Lutz, C.S. (2008) Alternative polyadenylation: a twist on mRNA 3′ end formation. 
ACS chemical biology, 3(10), pp. 609-617. 
 
Macdonald, D.R., Hanson, A.M., Holland, M.R. and Singh, B.M. (2008) Clinical 
impact of variability in HbA1c as assessed by simultaneously measuring 
fructosamine and use of error grid analysis. Annals of Clinical Biochemistry, 45(4), 
pp. 421-425.  
 
Maestroni, L., Matmati, S. and Coulon, S. (2017). Solving the telomere replication 
problem. Genes, 8(2), pp.55. 
 
 
199 
 
Magalhaes, P.M., Appell, H. and Duarte, J.A. (2008) Involvement of advanced 
glycation end products in the pathogenesis of diabetic complications: the protective 
role of regular physical activity. European Review of Aging and Physical Activity, 
5(1), pp. 17.  
 
Makris, K. and Spanou, L. (2011) Is there a relationship between mean blood 
glucose and glycated hemoglobin? Journal of diabetes science and technology, 
5(6), pp. 1572-1583.  
 
Malkki, M. and Petersdorf, E.W. (2012). Genotyping of single nucleotide 
polymorphisms by 5′ nuclease allelic discrimination. In Immunogenetics pp. 173-
182.  
 
Maniatis, T. and Reed, R. (2002) An extensive network of coupling among gene 
expression machines. Nature, 416(6880), pp. 499-506.  
 
Maniatis, T. and Tasic, B. (2002) Alternative pre-mRNA splicing and proteome 
expansion in metazoans. Nature, 418(6894), pp. 236-243.  
 
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., 
McCarthy, M.I., Ramos, E.M., Cardon, L.R. and Chakravarti, A. (2009) Finding the 
missing heritability of complex diseases. Nature, 461(7265), pp. 747-753. 
 
Mardis, E.R. (2013) Next-generation sequencing platforms. Annual review of 
analytical chemistry, 6pp. 287-303. 
 
200 
 
Marioni, J.C., Mason, C.E., Mane, S.M., Stephens, M. and Gilad, Y. (2008) RNA-
Seq: an assessment of technical reproducibility and comparison with gene 
expression arrays. Genome research, 18(9), pp. 1509-1517.  
 
Martin, A.R., Costa, H.A., Lappalainen, T., Henn, B.M., Kidd, J.M., Yee, M.C., 
Grubert, F., Cann, H.M., Snyder, M., Montgomery, S.B. and Bustamante, C.D. 
(2014). Transcriptome sequencing from diverse human populations reveals 
differentiated regulatory architecture. PLoS genetics, 10(8), p.e1004549. 
 
Martin, G. and Keller, W. (2007) RNA-specific ribonucleotidyl transferases. RNA 
(New York, N.Y.), 13(11), pp. 1834-1849.  
 
Martin, J.A., Brown, T.D., Heiner, A.D. and Buckwalter, J.A. (2004) Chondrocyte 
senescence, joint loading, and osteoarthritis. Clinical orthopaedics and related 
research, 427pp. S96-S103. 
 
Martino, A., Mancuso, T. and Rossi, A.M. (2010). Application of high-resolution 
melting to large-scale, high-throughput SNP genotyping: a comparison with the 
TaqMan® method. Journal of biomolecular screening, 15(6), pp.623-629. 
 
McCarter, R.J., Hempe, J.M., Gomez, R. and Chalew, S.A. (2004) Biological 
variation in HbA1c predicts the risk of retinopathy and nephropathy in type 1 
diabetes. Diabetes Care, 27(6), pp. 1259-1264. 
 
201 
 
McKiernan, P., Lynch, P., Ramsey, J., Cryan, S. and Greene, C. (2018). Knockdown 
of Gene Expression in Macrophages by microRNA Mimic-Containing Poly (Lactic-
co-glycolic Acid) Microparticles. Medicines, 5(4), p.133. 
 
Mcnamara, L., Gordeuk, V.R. and Macphail, A.P. (2005) Ferroportin (Q248H) 
mutations in African families with dietary iron overload. Journal of gastroenterology 
and hepatology, 20(12), pp. 1855-1858. 
 
Meerwaldt, R., Links, T., Zeebregts, C., Tio, R., Hillebrands, J. and Smit, A. (2008) 
The clinical relevance of assessing advanced glycation endproducts accumulation 
in diabetes. Cardiovascular Diabetology, 7(1), pp. 29. 
 
Meier, J.J., Butler, A.E., Saisho, Y., Monchamp, T., Galasso, R., Bhushan, A., Rizza, 
R.A. and Butler, P.C. (2008) Beta-cell replication is the primary mechanism 
subserving the postnatal expansion of beta-cell mass in humans. Diabetes, 57(6), 
pp. 1584-1594.  
 
Metzker, M.L. (2005) Emerging technologies in DNA sequencing. Genome 
research, 15(12), pp. 1767-1776.  
 
Metzker, M.L. (2010) Sequencing technologies—the next generation. Nature 
reviews genetics, 11(1), pp. 31-46. 
 
Meyerson, M., Gabriel, S. and Getz, G. (2010) Advances in understanding cancer 
genomes through second-generation sequencing. Nature Reviews Genetics, 
11(10), pp. 685-696.  
202 
 
Minamino, T., Orimo, M., Shimizu, I., Kunieda, T., Yokoyama, M., Ito, T., Nojima, A., 
Nabetani, A., Oike, Y. and Matsubara, H. (2009) A crucial role for adipose tissue 
p53 in the regulation of insulin resistance. Nature medicine, 15(9), pp. 1082-1087. 
 
Miyake, Y., Nakamura, M., Nabetani, A., Shimamura, S., Tamura, M., Yonehara, S., 
Saito, M. and Ishikawa, F. (2009). RPA-like Mammalian Ctc1-Stn1-Ten1 Complex 
Binds to Single-Stranded DNA and Protects Telomeres Independently of the Pot1 
Pathway. Molecular Cell, 36(2), pp.193-206.  
 
Mizukami, H., Takahashi, K., Inaba, W., Osonoi, S., Kamata, K., Tsuboi, K. and 
Yagihashi, S. (2014) Age‐associated changes of islet endocrine cells and the effects 
of body mass index in Japanese. Journal of diabetes investigation, 5(1), pp. 38-47. 
 
Mohás, M., Kisfali, P., Baricza, E., Mérei, A., Maász, A., Cseh, J., Mikolás, E., 
Szijártó, I., Melegh, B. and Wittmann, I. (2010) A polymorphism within the 
fructosamine-3-kinase gene is associated with HbA1c Levels and the onset of type 
2 diabetes mellitus. Experimental and clinical endocrinology & diabetes, 118(03), 
pp. 209-212.  
 
Mohr, S. and Liew, C. (2007) The peripheral-blood transcriptome: new insights into 
disease and risk assessment. Trends in molecular medicine, 13(10), pp. 422-432.  
 
Mollano, A.V., Martin, J.A. and Buckwalter, J.A. (2002). Chondrocyte senescence 
and telomere regulation: implications in cartilage aging and cancer (a brief review). 
The Iowa orthopaedic journal, 22, p.1-7. 
 
203 
 
Monnier, L., Lapinski, H. and Colette, C. (2003). Contributions of fasting and 
postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 
2 diabetic patients: variations with increasing levels of HbA1c. Diabetes care, 26(3), 
pp.881-885. 
 
Monnier, V.M. (2006) The fructosamine 3-kinase knockout mouse: a tool for testing 
the glycation hypothesis of intracellular protein damage in diabetes and aging. The 
Biochemical journal, 399(2), pp. e11-3. 
 
Monnier, V.M. and Wu, X. (2003) Enzymatic deglycation with amadoriase enzymes 
from Aspergillus sp. as a potential strategy against the complications of diabetes 
and aging. Biochemical Society Transactions, 31(Pt 6), pp. 1349-1353.  
 
Monnier, V.M., Mustata, G.T., Biemel, K.L., Reihl, O., Lederer, M.O., Zhenyu, D. 
and Sell, D.R. (2005) Cross‐linking of the extracellular matrix by the Maillard 
reaction in aging and diabetes: an update on “a puzzle nearing resolution”. Annals 
of the New York Academy of Sciences, 1043(1), pp. 533-544.  
 
Monnier, V.M., Sell, D.R. and Genuth, S. (2005) Glycation products as markers and 
predictors of the progression of diabetic complications. Annals of the New York 
Academy of Sciences, 1043(1), pp. 567-581. 
 
Moore, M.J. and Proudfoot, N.J. (2009) Pre-mRNA processing reaches back to 
transcription and ahead to translation. Cell, 136(4), pp. 688-700. 
 
204 
 
Morgan, P.E., Dean, R.T. and Davies, M.J. (2002) Inactivation of cellular enzymes 
by carbonyls and protein-bound glycation/glycoxidation products. Archives of 
Biochemistry and Biophysics, 403(2), pp. 259-269. 
 
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. and Wold, B. (2008) Mapping 
and quantifying mammalian transcriptomes by RNA-Seq. Nature methods, 5(7), pp. 
621-628. 
 
Mueller, O., Lightfoot, S., and Schroeder, A. (2004) RNA integrity number (RIN)–
standardization of RNA quality control. Agilent application note, publication pp. 1-8.  
 
Muoio, D.M., and Newgard, C.B. (2008) Mechanisms of disease: molecular and 
metabolic mechanisms of insulin resistance and [beta]-cell failure in type 2 diabetes. 
Nature reviews. Molecular cell biology, 9(3), pp. 193-205.  
 
Mutz, K., Heilkenbrinker, A., Lönne, M., Walter, J. and Stahl, F. (2013) 
Transcriptome analysis using next-generation sequencing. Current opinion in 
biotechnology, 24(1), pp. 22-30.  
 
Naess, S., Eriksen, J., Midthjell, K. and Tambs, K. (2003) Diabetes mellitus and 
comorbidity. Change between 1984–1986 and 1995–1997: Results of the Nord-
Trøndelag Health Study. Journal of diabetes and its complications, 17(6), pp. 323-
330.  
 
205 
 
Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M. and 
Snyder, M. (2008) The transcriptional landscape of the yeast genome defined by 
RNA sequencing. Science (New York, N.Y.), 320(5881), pp. 1344-1349. 
 
Nandakumar, D., Pandey, M. and Patel, S.S. (2015). Cooperative base pair melting 
by helicase and polymerase positioned one nucleotide from each other. Elife, 4, p. 
e06562. 
 
Nasir, N.M., Thevarajah, M. and Yean, C.Y. (2010) Hemoglobin variants detected 
by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements. 
International journal of diabetes in developing countries, 30(2), pp. 86-90.  
 
Nayak, A.U., Holland, M.R., Macdonald, D.R., Nevill, A. and Singh, B.M. (2011) 
Evidence for consistency of the glycation gap in diabetes. Diabetes Care, 34(8), pp. 
1712-1716.  
 
Nayak, A.U., Nevill, A.M., Bassett, P. and Singh, B.M. (2013) Association of 
glycation gap with mortality and vascular complications in diabetes. Diabetes Care, 
36(10), pp. 3247-3253.  
 
Nemet, I., Varga‐Defterdarovic, L. and Turk, Z. (2006) Methylglyoxal in food and 
living organisms. Molecular nutrition & food research, 50(12), pp. 1105-1117.  
 
 
 
206 
 
Nin, J.W., Jorsal, A., Ferreira, I., Schalkwijk, C.G., Prins, M.H., Parving, H.H., 
Tarnow, L., Rossing, P. and Stehouwer, C.D. (2011) Higher plasma levels of 
advanced glycation end products are associated with incident cardiovascular 
disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. 
Diabetes Care, 34(2), pp. 442-447.  
 
O'Callaghan, N.J., Dhillon, V.S., Thomas, P. and Fenech, M. (2008) A quantitative 
real-time PCR method for absolute telomere length. BioTechniques, 44(6), pp. 807-
809.  
 
Ogurtsova, K., da Rocha Fernandes, J., Huang, Y., Linnenkamp, U., Guariguata, L., 
Cho, N., Cavan, D., Shaw, J. and Makaroff, L. (2017) IDF Diabetes Atlas: Global 
estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and 
clinical practice, 128pp. 40-50. 
 
Okoniewski, M.J. and Miller, C.J. (2006) Hybridization interactions between 
probesets in short oligo microarrays lead to spurious correlations. BMC 
Bioinformatics, 7(1), pp. 276. 
 
Olivieri, F., Lorenzi, M., Antonicelli, R., Testa, R., Sirolla, C., Cardelli, M., Mariotti, 
S., Marchegiani, F., Marra, M. and Spazzafumo, L. (2009) Leukocyte telomere 
shortening in elderly Type2DM patients with previous myocardial infarction. 
Atherosclerosis, 206(2), pp. 588-593. 
 
Oshlack, A. and Wakefield, M.J. (2009) Transcript length bias in RNA-Seq data 
confounds systems biology. Biology direct, 4(1), pp. 14.  
207 
 
Ott, C., Jacobs, K., Haucke, E., Santos, A.N., Grune, T. and Simm, A. (2014) Role 
of advanced glycation end products in cellular signaling. Redox biology, 2pp. 411-
429 .  
 
Pachter, L. (2011) Models for transcript quantification from RNA-Seq. arXiv preprint 
arXiv:1104.3889.  
 
Palm, W. and de Lange, T. (2008) How shelterin protects mammalian telomeres. 
Annual Review of Genetics, 42pp. 301-334.  
 
Pan, Q., Shai, O., Lee, L.J., Frey, B.J. and Blencowe, B.J. (2008) Deep surveying 
of alternative splicing complexity in the human transcriptome by high-throughput 
sequencing. Nature Genetics, 40(12), pp. 1413-1415. 
 
Pan, Q., Shai, O., Misquitta, C., Zhang, W., Saltzman, A.L., Mohammad, N., Babak, 
T., Siu, H., Hughes, T.R. and Morris, Q.D. (2004) Revealing global regulatory 
features of mammalian alternative splicing using a quantitative microarray platform. 
Molecular Cell, 16(6), pp. 929-941. 
 
Peppa, M. and Vlassara, H. (2005) Advanced glycation end products and diabetic 
complications: a general overview. Hormones (Athens), 4(1), pp. 28-37. 
 
Peppa, M., Uribarri, J. and Vlassara, H. (2008) Aging and glycoxidant stress. 
HORMONES-ATHENS-, 7(2), pp. 123-132.  
 
208 
 
Pertea, M. (2012) The human transcriptome: an unfinished story. Genes, 3(3), pp. 
344-360. 
 
Pertea, M., Kim, D., Pertea, G.M., Leek, J.T. and Salzberg, S.L. (2016). Transcript-
level expression analysis of RNA-seq experiments with HISAT, StringTie and 
Ballgown. Nature protocols, 11(9), p.1650. 
 
Pertea, M., Kim, D., Pertea, G.M., Leek, J.T. and Salzberg, S.L. (2016) Transcript-
level expression analysis of RNA-seq experiments with HISAT, StringTie, and 
Ballgown. Nature protocols, 11(9), pp. 1650-1667. 
 
Pertea, M., Pertea, G.M., Antonescu, C.M., Chang, T., Mendell, J.T. and Salzberg, 
S.L. (2015) StringTie enables improved reconstruction of transcriptome from RNA-
Seq reads. Nature Biotechnology, 33(3), pp. 290-295. 
Pickrell, J.K., Marioni, J.C., Pai, A.A., Degner, J.F., Engelhardt, B.E., Nkadori, E., 
Veyrieras, J., Stephens, M., Gilad, Y. and Pritchard, J.K. (2010) Understanding 
mechanisms underlying human gene expression variation with RNA sequencing. 
Nature, 464(7289), pp. 768-772. 
 
Poitout, V., Amyot, J., Semache, M., Zarrouki, B., Hagman, D. and Fontés, G. (2010) 
Glucolipotoxicity of the pancreatic beta cell. Biochimica et Biophysica Acta (BBA)-
Molecular and Cell Biology of Lipids, 1801(3), pp. 289-298.  
 
Pop, M. and Salzberg, S.L. (2008) Bioinformatics challenges of new sequencing 
technology. Trends in Genetics, 24(3), pp. 142-149.  
 
209 
 
Price, L.H., Kao, H., Burgers, D.E., Carpenter, L.L. and Tyrka, A.R. (2013) 
Telomeres and early-life stress: an overview. Biological Psychiatry, 73(1), pp. 15-
23.  
 
Raddatz, E., Thomas, A.C., Sarre, A. and Benathan, M. (2011) Differential 
contribution of mitochondria, NADPH oxidases, and glycolysis to region-specific 
oxidant stress in the anoxic-reoxygenated embryonic heart. American journal of 
physiology.Heart and circulatory physiology, 300(3), pp. H820-35.  
 
Radobuljac, M.D., Bratina, N., Tomori, M. and Battelino, T. (2012) Type 1 diabetes 
and psychosocial risk factors in adolescence. Zdravniski Vestnik, 81(9), pp.664-675.  
 
Rains, J.L. and Jain, S.K. (2011) Oxidative stress, insulin signaling, and diabetes. 
Free Radical Biology and Medicine, 50(5), pp. 567-575. 
 
Ramasamy, R., Vannucci, S.J., Yan, S.S.D., Herold, K., Yan, S.F. and Schmidt, 
A.M. (2005) Advanced glycation end products and RAGE: a common thread in 
aging, diabetes, neurodegeneration, and inflammation. Glycobiology, 15(7), pp. 
16R-28R. 
 
Ramasamy, R., Yan, S.F., D'Agati, V. and Schmidt, A.M. (2007) Receptor for 
Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis 
of the cardiovascular complications of diabetes & aging. Current Molecular 
Medicine, 7(8), pp. 699-710.  
 
210 
 
Rapaport, F., Khanin, R., Liang, Y., Pirun, M., Krek, A., Zumbo, P., Mason, C.E., 
Socci, N.D. and Betel, D. (2013) Comprehensive evaluation of differential gene 
expression analysis methods for RNA-seq data. Genome biology, 14(9), pp. 3158. 
 
Rhee, S.Y. and Kim, Y.S. (2018). The role of advanced glycation end products in 
diabetic vascular complications. Diabetes & metabolism journal, 42(3), pp.188-195. 
 
Richter, T. and von Zglinicki, T. (2007) A continuous correlation between oxidative 
stress and telomere shortening in fibroblasts. Experimental Gerontology, 42(11), pp. 
1039-1042. 
 
Risso, D., Ngai, J., Speed, T.P. and Dudoit, S. (2014) Normalization of RNA-seq 
data using factor analysis of control genes or samples. Nature Biotechnology, 32(9), 
pp. 896-902.  
 
Ruckriemen, J., Hellwig, A., Schultes, S., Hellwig, M., Hahne, F. and Henle, T. 
(2018). Studies on the influence of dietary 3-deoxyglucosone on the urinary 
excretion of 2-keto-3-deoxygluconic acid. European Food Research and 
Technology, 244(8), pp.1389-1396. 
 
Risso, D., Schwartz, K., Sherlock, G. and Dudoit, S. (2011) GC-content 
normalization for RNA-Seq data. BMC Bioinformatics, 12(1), pp. 480.  
 
Rivers, C.A., Barton, J.C., Gordeuk, V.R., Acton, R.T., Speechley, M.R., Snively, 
B.M., Leiendecker-Foster, C., Press, R.D., Adams, P.C. and McLaren, G.D. (2007) 
Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin 
211 
 
in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) 
Study. Blood Cells, Molecules, and Diseases, 38(3), pp. 247-252. 
 
Roberts, A., Trapnell, C., Donaghey, J., Rinn, J.L. and Pachter, L. (2011) Improving 
RNA-Seq expression estimates by correcting for fragment bias. Genome biology, 
12(3), pp. R22.  
 
Robinson, M.D. and Oshlack, A. (2010) A scaling normalization method for 
differential expression analysis of RNA-seq data. Genome biology, 11(3), pp. R25.  
 
Robinson, M.D., McCarthy, D.J. and Smyth, G.K. (2010) edgeR: a Bioconductor 
package for differential expression analysis of digital gene expression data. 
Bioinformatics, 26(1), pp. 139-140.  
 
Rohlfing, C., Wiedmeyer, H.M., Little, R., Grotz, V.L., Tennill, A., England, J., 
Madsen, R. and Goldstein, D. (2002) Biological variation of glycoheamoglobin. 
Clinical chemistry, 48(7), pp. 1116-1118. 
 
Romiguier, J., Ranwez, V., Douzery, E.J. and Galtier, N. (2010) Contrasting GC-
content dynamics across 33 mammalian genomes: relationship with life-history 
traits and chromosome sizes. Genome research, 20(8), pp. 1001-1009.  
 
Roriz-Filho, J.S., Sá-Roriz, T.M., Rosset, I., Camozzato, A.L., Santos, A.C., Chaves, 
M.L., Moriguti, J.C. and Roriz-Cruz, M. (2009). (Pre) diabetes, brain aging, and 
cognition. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 
1792(5), pp.432-443. 
212 
 
Rosenbloom, K.R., Armstrong, J., Barber, G.P., Casper, J., Clawson, H., Diekhans, 
M., Dreszer, T.R., Fujita, P.A., Guruvadoo, L. and Haeussler, M. (2014) The UCSC 
genome browser database: 2015 update. Nucleic acids research, 43(D1), pp. D670-
D681. 
 
Saaddine, J.B., Fagot-Campagna, A., Rolka, D., Narayan, K.M., Geiss, L., 
Eberhardt, M. and Flegal, K.M. (2002) Distribution of HbA(1c) levels for children and 
young adults in the U.S.: Third National Health and Nutrition Examination Survey. 
Diabetes Care, 25(8), pp. 1326-1330. 
 
Sampson, M. and Hughes, D. (2006) Chromosomal telomere attrition as a 
mechanism for the increased risk of epithelial cancers and senescent phenotypes 
in type 2 diabetes. Diabetologia, 49(8), pp. 1726-1731. 
 
Sampson, M.J., Winterbone, M.S., Hughes, J.C., Dozio, N., and Hughes, D.A. 
(2006) Monocyte telomere shortening and oxidative DNA damage in type 2 
diabetes. Diabetes Care, 29(2), pp. 283-289. 
 
Saretzki, G. and Von Zglinicki, T. (2002) Replicative aging, telomeres, and oxidative 
stress. Annals of the New York Academy of Sciences, 959(1), pp. 24-29.  
 
Schmidt, A.M. and Stern, D.M. (2000) RAGE: a new target for the prevention and 
treatment of the vascular and inflammatory complications of diabetes. Trends in 
Endocrinology & Metabolism, 11(9), pp. 368-375.  
 
213 
 
Schmidt, A.M., Du Yan, S., Yan, S.F. and Stern, D.M. (2000) The biology of the 
receptor for advanced glycation end products and its ligands. Biochimica et 
Biophysica Acta (BBA)-Molecular Cell Research, 1498(2), pp. 99-111. 
 
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., 
Lightfoot, S., Menzel, W., Granzow, M. and Ragg, T. (2006) The RIN: an RNA 
integrity number for assigning integrity values to RNA measurements. BMC 
molecular biology, 7(1), pp. 3.  
 
Selvin, E., Halushka, M.K., Rawlings, A.M., Hoogeveen, R.C., Ballantyne, C.M., 
Coresh, J. and Astor, B.C. (2013) sRAGE and risk of diabetes, cardiovascular 
disease, and death. Diabetes, 62(6), pp. 2116-2121. 
 
Sakiyama, H., Takahashi, M., Yamamoto, T., Teshima, T., Lee, S.H., Miyamoto, Y., 
Misonou, Y. and Taniguchi, N. (2006). The internalization and metabolism of 3-
deoxyglucosone in human umbilical vein endothelial cells. Journal of biochemistry, 
139(2), pp.245-253.  
 
Semba, R.D., Sun, K., Schwartz, A.V., Varadhan, R., Harris, T.B., Satterfield, S., 
Garcia, M., Ferrucci, L., Newman, A.B. and Health ABC Study (2015) Serum 
carboxymethyl-lysine, an advanced glycation end product, is associated with arterial 
stiffness in older adults. Journal of hypertension, 33(4), pp. 797-803;  
 
Serra, V., Grune, T., Sitte, N., Saretzki, G. and Von Zglinicki, T. (2000) Telomere 
length as a marker of oxidative stress in primary human fibroblast cultures. Annals 
of the New York Academy of Sciences, 908(1), pp. 327-330. 
214 
 
 
Sessa, L., Gatti, E., Zeni, F., Antonelli, A., Catucci, A., Koch, M., Pompilio, G., Fritz, 
G., Raucci, A. and Bianchi, M.E. (2014). The receptor for advanced glycation end-
products (RAGE) is only present in mammals and belongs to a family of cell 
adhesion molecules (CAMs). PloS one, 9(1), p. e86903. 
 
Sexton, A.N., Youmans, D.T. and Collins, K. (2012) Specificity requirements for 
human telomere protein interaction with telomerase holoenzyme. The Journal of 
biological chemistry, 287(41), pp. 34455-34464. 
 
Shabalina, S.A. and Spiridonov, N.A. (2004) The mammalian transcriptome and the 
function of non-coding DNA sequences. Genome biology, 5(4), pp. 105.  
 
Shalev, I. (2012) Early life stress and telomere length: investigating the connection 
and possible mechanisms. Bioessays, 34(11), pp. 943-952.  
 
Shimizu, I., Yoshida, Y., Katsuno, T., Tateno, K., Okada, S., Moriya, J., Yokoyama, 
M., Nojima, A., Ito, T. and Zechner, R. (2012) p53-induced adipose tissue 
inflammation is critically involved in the development of insulin resistance in heart 
failure. Cell Metabolism, 15(1), pp. 51-64.  
 
Shiroguchi, K., Jia, T.Z., Sims, P.A. and Xie, X.S. (2012) Digital RNA sequencing 
minimizes sequence-dependent bias and amplification noise with optimized single-
molecule barcodes. Proceedings of the National Academy of Sciences of the United 
States of America, 109(4), pp. 1347-1352.  
 
215 
 
Singh, R., Barden, A., Mori, T. and Beilin, L. (2001) Advanced glycation end-
products: a review. Diabetologia, 44(2), pp. 129-146.  
 
Singh, V.P., Bali, A., Singh, N. and Jaggi, A.S. (2014). Advanced glycation end 
products and diabetic complications. The Korean Journal of Physiology & 
Pharmacology, 18(1), pp.1-14. 
 
Škrha Jr, J., Kalousová, M., Švarcová, J., Muravska, A., Kvasnička, J., Landova, L., 
Zima, T. and Škrha, J. (2012) Relationship of soluble RAGE and RAGE ligands 
HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes 
mellitus. Experimental and clinical endocrinology & diabetes, 120(05), pp. 277-281.  
 
Skrha Jr, J., Muravska, A., Flekac, M., Horova, E., Novak, J., Novotný, A., Prázný, 
M., Skrha, J., Kvasnicka, J. and Landová, L. (2014) Fructosamine 3-kinase and 
glyoxalase I polymorphisms and their association with soluble RAGE and adhesion 
molecules in diabetes. Physiological research, 63pp. S283-S291.  
 
Skyler, J.S. and Oddo, C. (2002) Diabetes trends in the USA. Diabetes/metabolism 
research and reviews, 18(3). S21-S26. 
 
Smart, M., Ehnholm, C., Jauhiainen, M., Robciuc, M., Cooper, J., Drenos, F., 
Humphries, S. and Talmud, P. (2009) Association of telomere length with type 2 
diabetes, oxidative stress, and UCP2 gene variation. Atherosclerosis, 207(1), pp. 
e6. 
 
216 
 
Smith, Z.D. and Meissner, A. (2013) DNA methylation: roles in mammalian 
development. Nature Reviews Genetics, 14(3), pp. 204-220. 
 
Smogorzewska, A. and de Lange, T. (2002) Different telomere damage signaling 
pathways in human and mouse cells. The EMBO journal, 21(16), pp. 4338-4348. 
 
Smogorzewska, A., Karlseder, J., Holtgreve-Grez, H., Jauch, A., and de Lange, T. 
(2002) DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 
and G2. Current Biology, 12(19), pp. 1635-1644. 
 
Smucker, E.J. and Turchi, J.J. (2001) TRF1 inhibits telomere C-strand DNA 
synthesis in vitro. Biochemistry, 40(8), pp. 2426-2432.  
 
Sodi, R., McKay, K., Dampetla, S., and Pappachan, J.M. (2018) Monitoring 
glycaemic control in patients with diabetes mellitus. BMJ (Clinical research ed.), 
363pp. k4723.  
 
Soleimanpour, S.A. and Stoffers, D.A. (2013) The pancreatic β cell and type 1 
diabetes: innocent bystander or active participant? Trends in Endocrinology & 
Metabolism, 24(7), pp. 324-331 .  
 
Sone, H. and Kagawa, Y. (2005) Pancreatic beta cell senescence contributes to the 
pathogenesis of type 2 diabetes in high-fat-diet-induced diabetic mice. Diabetologia, 
48(1), pp. 58-67. 
 
217 
 
Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, 
Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, 
Reilly MP, Ricketts SL, et al. (2010) Common variants at 10 genomic loci influence 
hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 59(12), 
pp.3229-3239. 
 
Sozou, P.D. and Kirkwood, T.B. (2001) A stochastic model of cell replicative 
senescence based on telomere shortening, oxidative stress, and somatic mutations 
in nuclear and mitochondrial DNA. Journal of theoretical biology, 213(4), pp. 573-
586. 
 
Speeckaert, M., Van Biesen, W., Delanghe, J., Slingerland, R., Wiecek, A., Heaf, J., 
Drechsler, C., Lacatus, R., Vanholder, R., Nistor, I. and Bilo, H. (2014). Are there 
better alternatives than haemoglobin A1c to estimate glycaemic control in the 
chronic kidney disease population? Nephrology Dialysis Transplantation, 29(12), 
pp.2167-2177. 
 
Stern, D., Yan, S. D., Yan, S. F., and Schmidt, A. M. (2002) Receptor for advanced 
glycation endproducts: a multiligand receptor magnifying cell stress in diverse 
pathologic settings. Adv Drug Deliv Rev 54, 1615-1625. 
 
Stern, D.L. and Orgogozo, V. (2008) The loci of evolution: how predictable is genetic 
evolution? Evolution, 62(9), pp. 2155-2177.  
 
218 
 
Stitt, A.W., Jenkins, A.J. and Cooper, M.E. (2002) Advanced glycation end products 
and diabetic complications. Expert opinion on investigational drugs, 11(9), pp. 1205-
1223. 
 
Stohr, B.A., Xu, L. and Blackburn, E.H. (2010). The terminal telomeric DNA 
sequence determines the mechanism of dysfunctional telomere fusion. Molecular 
cell, 39(2), pp.307-314. 
 
Su, Y., Liu, X., Sun, Y., Jin, H., Fu, R., Wang, Y., Wu, Y. and Luan, Y. (2008) The 
relationship between endothelial dysfunction and oxidative stress in diabetes and 
prediabetes. International journal of clinical practice, 62(6), pp. 877-882.  
 
Sun, L., Franco, O.H., Hu, F.B., Cai, L., Yu, Z., Li, H., Ye, X., Qi, Q., Wang, J. and 
Pan, A. (2008) Ferritin concentrations, metabolic syndrome, and type 2 diabetes in 
middle-aged and elderly Chinese. The Journal of Clinical Endocrinology & 
Metabolism, 93(12), pp. 4690-4696.  
 
Szwergold, B., Manevich, Y., Payne, L. and Loomes, K. (2007). Fructosamine-3-
kinase-related-protein phosphorylates glucitolamines on the C-4 hydroxyl: novel 
substrate specificity of an enigmatic enzyme. Biochemical and biophysical research 
communications, 361(4), pp.870-875. 
 
Szwergold, B.S. and Beisswenger, P.J. (2003) Enzymatic deglycation--a new 
paradigm or an epiphenomenon? Biochemical Society Transactions, 31(Pt 6), pp. 
1428-1432. 
 
219 
 
Szwergold, B.S., Howell, S. and Beisswenger, P.J. (2001) Human fructosamine-3-
kinase: purification, sequencing, substrate specificity, and evidence of activity in 
vivo. Diabetes, 50(9), pp. 2139-2147. 
 
Tamura, Y., Takubo, K., Aida, J., Araki, A. and Ito, H. (2016) Telomere attrition and 
diabetes mellitus. Geriatrics & gerontology international, 16pp. 66-74.  
 
Tang, F., Barbacioru, C., Nordman, E., Li, B., Xu, N., Bashkirov, V.I., Lao, K. and 
Surani, M.A. (2010) RNA-Seq analysis to capture the transcriptome landscape of a 
single cell. Nature protocols, 5(3), pp. 516-535. 
 
Tang, F., K. Lao, and M.A. Surani. (2011). Development and applications of single-
cell transcriptome analysis. Nature methods. 8pp.S6-11. 
 
Tanhäuserová, V., Kuricová, K., Pácal, L., Bartáková, V., Řehořová, J., 
Svojanovský, J., Olšovský, J., Bělobrádková, J. and Kaňková, K. (2014) Genetic 
variability in enzymes of metabolic pathways conferring protection against non-
enzymatic glycation versus diabetes-related morbidity and mortality. Clinical 
chemistry and laboratory medicine, 52(1), pp. 77-83. 
 
Teixeira, M.T. (2013). Saccharomyces cerevisiae as a model to study replicative 
senescence triggered by telomere shortening. Frontiers in oncology, 3pp.101. 
 
Thomas, C.C. and Philipson, L.H. (2015) Update on diabetes classification. The 
Medical clinics of North America, 99(1), pp. 1-16.  
 
220 
 
Thomas, M., Söderlund, J., Lehto, M., Mäkinen, V., Moran, J., Cooper, M., 
Forsblom, C., Groop, P., and FinnDiane Study Group (2011) Soluble receptor for 
AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular 
mortality in type 1 diabetes. Diabetologia, 54(10), pp. 2669-2677.  
 
Thomas, M.C., Woodward, M., Neal, B., Li, Q., Pickering, R., Marre, M., Williams, 
B., Perkovic, V., Cooper, M.E., Zoungas, S., Chalmers, J., Hillis, G.S. and 
ADVANCE Collaborative Group (2015) Relationship between levels of advanced 
glycation end products and their soluble receptor and adverse outcomes in adults 
with type 2 diabetes. Diabetes Care, 38(10), pp. 1891-1897.  
 
Thomas, P., O’Callaghan, N.J. and Fenech, M. (2008) Telomere length in white 
blood cells, buccal cells and brain tissue and its variation with ageing and 
Alzheimer's disease. Mechanisms of ageing and development, 129(4), pp. 183-190. 
 
Thornalley, P.J., Langborg, A. and Minhas, H.S. (1999) Formation of glyoxal, 
methylglyoxal, and 3-deoxyglucosone in the glycation of proteins by glucose. The 
Biochemical journal, 344 Pt 1pp. 109-116. 
 
Tian, B. and Manley, J.L. (2013) Alternative cleavage and polyadenylation: the long 
and short of it. Trends in biochemical sciences, 38(6), pp. 312-320.  
 
Tobon-Velasco, J., Cuevas, E. and A Torres-Ramos, M. (2014). Receptor for AGEs 
(RAGE) as mediator of NF-kB pathway activation in neuroinflammation and 
oxidative stress. CNS & Neurological Disorders-Drug Targets (Formerly Current 
Drug Targets-CNS & Neurological Disorders), 13(9), pp.1615-1626. 
221 
 
Trapnell, C. and Salzberg, S.L. (2009). How to map billions of short reads onto 
genomes. Nature biotechnology, 27(5), p.455-457. 
 
Trapnell, C., Pachter, L. and Salzberg, S.L. (2009) TopHat: discovering splice 
junctions with RNA-Seq. Bioinformatics, 25(9), pp. 1105-1111.  
 
Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., Van Baren, M.J., 
Salzberg, S.L., Wold, B.J. and Pachter, L. (2010) Transcript assembly and 
quantification by RNA-Seq reveals unannotated transcripts and isoform switching 
during cell differentiation. Nature Biotechnology, 28(5), pp. 511-515. 
 
Turro, E., Su, S., Gonçalves, Â., Coin, L.J., Richardson, S. and Lewin, A. (2011) 
Haplotype and isoform specific expression estimation using multi-mapping RNA-seq 
reads. Genome biology, 12(2), pp. R13. 
 
Ulrich, P. and Cerami, A. (2001) Protein glycation, diabetes, and aging. Recent 
progress in hormone research, 56pp. 1-21.  
 
Uppu, S., Krishna, A. and Gopalan, R.P. (2016). A review on methods for detecting 
SNP interactions in high-dimensional genomic data. IEEE/ACM transactions on 
computational biology and bioinformatics, 15(2), pp.599-612. 
 
Uziel, O., Singer, J.A., Danicek, V., Sahar, G., Berkov, E., Luchansky, M., Fraser, 
A., Ram, R. and Lahav, M. (2007) Telomere dynamics in arteries and mononuclear 
cells of diabetic patients: effect of diabetes and of glycemic control. Experimental 
Gerontology, 42(10), pp. 971-978.  
222 
 
Valente, L. and Nishikura, K. (2005) ADAR gene family and A-to-I RNA editing: 
diverse roles in posttranscriptional gene regulation. Progress in nucleic acid 
research and molecular biology, 79pp. 299-338. 
 
Van Schaftingen, E., Collard, F., Wiame, E. and Veiga-da-Cunha, M. (2012) 
Enzymatic repair of Amadori products. Amino acids, 42(4), pp. 1143-1150.   
 
Veiga da-Cunha, M., Jacquemin, P., Delpierre, G., Godfraind, C., Theate, I., 
Vertommen, D., Clotman, F., Lemaigre, F., Devuyst, O. and Van Schaftingen, E. 
(2006) Increased protein glycation in fructosamine 3-kinase-deficient mice. The 
Biochemical journal, 399(2), pp. 257-264. 
 
Vlassara, H. and Striker, G.E. (2013) Advanced glycation endproducts in diabetes 
and diabetic complications. Endocrinology and metabolism clinics of North America, 
42(4), pp. 697-719.  
 
Vlassara, H., Cai, W., Crandall, J., Goldberg, T., Oberstein, R., Dardaine, V., Peppa, 
M. and Rayfield, E.J. (2002) Inflammatory mediators are induced by dietary 
glycotoxins, a major risk factor for diabetic angiopathy. Proceedings of the National 
Academy of Sciences of the United States of America, 99(24), pp. 15596-15601.  
 
Vogel, C. and Marcotte, E.M. (2012) Insights into the regulation of protein 
abundance from proteomic and transcriptomic analyses. Nature Reviews Genetics, 
13(4), pp. 227-232.  
 
223 
 
Von Zglinicki, T. (2000) Role of oxidative stress in telomere length regulation and 
replicative senescence. Annals of the New York Academy of Sciences, 908(1), pp. 
99-110.  
 
Von Zglinicki, T. (2002) Oxidative stress shortens telomeres. Trends in biochemical 
sciences, 27(7), pp. 339-344.  
 
von Zglinicki, T., Martin‐Ruiz, C.M. and Saretzki, G. (2005) Telomeres, cell 
senescence, and human ageing. Signal Transduction, 5(3), pp. 103-114. 
 
Vos, F.E., Schollum, J.B. and Walker, R.J. (2011) Glycated albumin is the preferred 
marker for assessing glycaemic control in advanced chronic kidney disease. 
Nephrology Dialysis Transplantation Plus, 4(6), pp. 368-375.  
 
Wagner, G.P., Kin, K. and Lynch, V.J. (2012) Measurement of mRNA abundance 
using RNA-seq data: RPKM measure is inconsistent among samples. Theory in 
biosciences, 131(4), pp. 281-285.  
 
Wai, L.K. (2004). Telomeres, telomerase, and tumorigenesis--a review. Medscape 
General Medicine, 6(3), pp. 19. 
 
Wajid, B. and Serpedin, E. (2012) Review of general algorithmic features for 
genome assemblers for next-generation sequencers. Genomics, proteomics & 
bioinformatics, 10(2), pp. 58-73.  
 
224 
 
Wang, C.Y. (2018). Asynchronous Shortening of Telomere Length and 
Cardiovascular Outcomes. JACC: Basic to Translational Science, 3(5), pp. 601-603. 
 
Wang, E.T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, 
S.F., Schroth, G.P. and Burge, C.B. (2008) Alternative isoform regulation in human 
tissue transcriptomes. Nature, 456(7221), pp. 470-476. 
 
Wang, F., Podell, E.R., Zaug, A.J., Yang, Y., Baciu, P., Cech, T.R. and Lei, M. 
(2007) The POT1-TPP1 telomere complex is a telomerase processivity factor. 
Nature, 445(7127), pp. 506-510. 
 
Wang, J., Dong, X., Cao, L., Sun, Y., Qiu, Y., Zhang, Y., Cao, R., Covasa, M. and 
Zhong, L. (2016). Association between telomere length and diabetes mellitus: A 
meta-analysis. Journal of International Medical Research, 44(6), pp.1156-1173. 
 
Wang, T., Liang, Z.A., Sandford, A.J., Xiong, X.Y., Yang, Y.Y., Ji, Y.L. and He, J.Q. 
(2012). Selection of suitable housekeeping genes for real-time quantitative PCR in 
CD4+ lymphocytes from asthmatics with or without depression. PloS one, 7(10), 
p.e48367. 
 
Wang, Z., Gerstein, M., and Snyder, M. (2009) RNA-Seq: a revolutionary tool for 
transcriptomics. Nature reviews genetics, 10(1), pp. 57-63. 
 
 
 
225 
 
Wautier, M.P., Chappey, O., Corda, S., Stern, D.M., Schmidt, A.M. and Wautier, J.L. 
(2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene 
expression via RAGE. American journal of physiology.Endocrinology and 
metabolism, 280(5), pp. E685-694. 
 
Wei, N., Zheng, H. and Nathan, D.M. (2014). Empirically establishing blood glucose 
targets to achieve HbA1c goals. Diabetes Care, 37(4), pp.1048-1051. 
 
Wesche, B., Jaeckel, E., Trautwein, C., Wedemeyer, H., Falorni, A., Frank, H., von 
zur Muhlen, A., Manns, M.P. and Brabant, G. (2001) Induction of autoantibodies to 
the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic 
hepatitis C. Gut, 48(3), pp. 378-383.  
 
Weykamp, C., John, W.G. and Mosca, A. (2009) A review of the challenge in 
measuring hemoglobin A1c. Journal of diabetes science and technology, 3(3), 
pp.439-445. 
 
Wheeler, E., Leong, A., Liu, C., Hivert, M., Strawbridge, R.J., Podmore, C., Li, M., 
Yao, J., Sim, X. and Hong, J. (2017) Impact of common genetic determinants of 
Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse 
populations: A transethnic genome-wide meta-analysis. PLoS medicine, 14(9), pp. 
e1002383.  
 
Wiame, E., Delpierre, G., Collard, F., and Van Schaftingen, E. (2002) Identification 
of a pathway for the utilization of the Amadori product fructoselysine in Escherichia 
coli. The Journal of biological chemistry, 277(45), pp. 42523-42529. 
226 
 
Wilcox, G. (2005) Insulin and insulin resistance. The Clinical Biochemist.Reviews, 
26(2), pp. 19-39.  
 
Wild, S.H., Roglic, G., Green, A., and Sicree, R. (2004) Global prevalence of 
diabetes: estimates for the year 2030 and projections for 2030: response to 
Rathman and Giani. Diabetes Care, 27(10), pp.1047-1053. 
 
Wilhelm, B.T. and Landry, J. (2009) RNA-Seq—quantitative measurement of 
expression through massively parallel RNA-sequencing. Methods, 48(3), pp. 249-
257.  
 
Wittkopp, P. (2005) Genomic sources of regulatory variation in cis and in trans. 
Cellular and Molecular Life Sciences CMLS, 62(16), pp. 1779-1783.  
 
World Health Organization (2006) Definition and diagnosis of diabetes mellitus and 
intermediate hyperglycaemia: report of a WHO/IDF consultation.  
 
Wu, L., Multani, A.S., He, H., Cosme-Blanco, W., Deng, Y., Deng, J.M., Bachilo, O., 
Pathak, S., Tahara, H. and Bailey, S.M. (2006) Pot1 deficiency initiates DNA 
damage checkpoint activation and aberrant homologous recombination at 
telomeres. Cell, 126(1), pp. 49-62. 
 
Wu, Y.Y., Xiao, E. and Graves, D.T. (2015). Diabetes mellitus related bone 
metabolism and periodontal disease. International journal of oral science, 7(2), p.63-
72. 
 
227 
 
Xin, H., Liu, D., Ma, W., Safari, A., Kim, H., Sun, W., O'connor, M.S. and Songyang, 
Z. (2007) TPP1 is a homologue of ciliate TEBP-[beta] and interacts with POT1 to 
recruit telomerase. Nature, 445(7127), pp. 559-562. 
 
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., 
Ross, J.S., Tartaglia, L.A. and Chen, H. (2003) Chronic inflammation in fat plays a 
crucial role in the development of obesity-related insulin resistance. The Journal of 
clinical investigation, 112(12), pp. 1821-1830.  
 
Yamagishi, S. and Matsui, T. (2010) Soluble form of a receptor for advanced 
glycation end products (sRAGE) as a biomarker. Frontiers in bioscience (Elite 
edition), 2pp. 1184-1195.  
 
Yan, S.F., Barile, G.R., D’Agati, V., Du Yan, S., Ramasamy, R. and Schmidt, A.M. 
(2007) The biology of RAGE and its ligands: uncovering mechanisms at the heart 
of diabetes and its complications. Current diabetes reports, 7(2), pp. 146-153.  
 
Yan, S.F., Ramasamy, R. and Schmidt, A.M. (2008) Mechanisms of disease: 
advanced glycation end-products and their receptor in inflammation and diabetes 
complications. Nature Reviews. Endocrinology, 4(5), pp. 285-293.  
 
Yan, S.F., Ramasamy, R. and Schmidt, A.M. (2009) The receptor for advanced 
glycation endproducts (RAGE) and cardiovascular disease. Expert reviews in 
molecular medicine, 11. 
 
228 
 
Yan, S.F., Ramasamy, R. and Schmidt, A.M. (2010) The RAGE axis: a fundamental 
mechanism signaling danger to the vulnerable vasculature. Circulation research, 
106(5), pp. 842-853. 
 
Yáñez-Mó, M., Siljander, P.R.M., Andreu, Z., Bedina Zavec, A., Borràs, F.E., Buzas, 
E.I., Buzas, K., Casal, E., Cappello, F., Carvalho, J. and Colás, E. (2015). Biological 
properties of extracellular vesicles and their physiological functions. Journal of 
extracellular vesicles, 4(1), p.27066. 
 
Yonekura, H., Yamamoto, Y., Sakurai, S., Petrova, R.G., Abedin, M.J., Li, H., Yasui, 
K., Takeuchi, M., Makita, Z., Takasawa, S., Okamoto, H., Watanabe, T. and 
Yamamoto, H. (2003) Novel splice variants of the receptor for advanced glycation 
end-products expressed in human vascular endothelial cells and pericytes, and their 
putative roles in diabetes-induced vascular injury. The Biochemical journal, 370(Pt 
3), pp. 1097-1109. 
 
Yu, E.Y., Wang, F., Lei, M. and Lue, N.F. (2008) A proposed OB-fold with a protein-
interaction surface in Candida albicans telomerase protein Est3. Nature structural & 
molecular biology, 15(9), pp. 985-989. 
 
Zee, R.Y., Castonguay, A.J., Barton, N.S., Germer, S. and Martin, M. (2010) Mean 
leukocyte telomere length shortening and type 2 diabetes mellitus: a case-control 
study. Translational research, 155(4), pp. 166-169.  
 
229 
 
Zemlin, A.E., Matsha, T.E., Hassan, M.S. and Erasmus, R.T. (2011) HbA1c of 6.5% 
to diagnose diabetes mellitus—does it work for us? —the Bellville South Africa 
study. PloS one, 6(8), pp. e22558. 
 
Zeng, W. and Mortazavi, A. (2012) Technical considerations for functional 
sequencing assays. Nature Immunology, 13(9), pp. 802-807.  
 
Zglinicki, T.v. and Martin-Ruiz, C. (2005) Telomeres as biomarkers for aging and 
age-related diseases. Current Molecular Medicine, 5(2), pp. 197-203.  
 
Zhang, L., Postina, R. and Wang, Y. (2009) Ectodomain shedding of the receptor 
for advanced glycation end products: a novel therapeutic target for Alzheimer’s 
disease. Cellular and molecular life sciences, 66(24), pp. 3923-3935.  
 
Zhang, M., Kho, A.L., Anilkumar, N., Chibber, R., Pagano, P.J., Shah, A.M. and 
Cave, A.C. (2006) Glycated proteins stimulate reactive oxygen species production 
in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. 
Circulation, 113(9), pp. 1235-1243. 
 
Zhang, Y., Sturgill, D., Parisi, M., Kumar, S. and Oliver, B. (2007) Constraint and 
turnover in sex-biased gene expression in the genus Drosophila. Nature, 450(7167), 
pp. 233-237. 
 
Zhao, S. (2014). Assessment of the impact of using a reference transcriptome in 
mapping short RNA-Seq reads. PLoS One, 9(7), p.e101374. 
 
230 
 
Zheng, F., He, C., Cai, W., Hattori, M., Steffes, M. and Vlassara, H. (2002) 
Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. 
Diabetes/metabolism research and reviews, 18(3), pp. 224-237. 
 
Zheng, W., Chung, L.M. and Zhao, H. (2011) Bias detection and correction in RNA-
Sequencing data. BMC Bioinformatics, 12(1), pp. 290.  
 
Zhu, H., Belcher, M. and van der Harst, P. (2011) Healthy aging and disease: a role 
for telomere biology? Clinical science (London, England: 1979), 120(10), pp. 427-
440.  
 
Zieman, S.J., Melenovsky, V., Clattenburg, L., Corretti, M.C., Capriotti, A., 
Gerstenblith, G., and Kass, D.A. (2007) Advanced glycation end-product cross-link 
breaker (alagebrium) improves endothelial function in patients with isolated systolic 
hypertension. Journal of hypertension, 25(3), pp. 577-583.  
 
 
 
231 
 
Appendices 
 
 
Appendix 1  
  
1.1. Specialised kit, chemical, and reagents for clinical research  
 
1.1.1.  The specialised kits for clinical research  
 
Duoset Elisa kit for Human sRAGE                       R&D systems Europe Ltd  
                                                                                       Abingdon Science Park, UK  
 
QIAamp DNA Blood Mini Kit     QIAGEN Lloyd Street North  
Manchester, UK 
 
TaqMan Gene Expression Assay     ThermoFisher Scientific  
 
 
Norgen Bioteck RNA purification kit   Norgen, Thorold, On, 
Canada 
 
 
RNase-Free DNase 1 kit     Norgen, Thorold, On, 
Canada 
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RiboGreen RNA assay kit (Invitrogen)   ThermoFisher Scientific 
Ribo-Zero rRNA removal kit Epicentre an Illumina 
Biotechnology Company, 
Research Park, Madison, 
USA 
 
TruSeq standard total RNA kit Illumina Madison 
Epicentre, USA 
 
   
1.1.2. Reagents and Chemicals for clinical research  
  
PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 - 7.4, 
0.2 µm filtered 
 
Wash Buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4  
  
Reagent Diluent: 1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered. Quality of BSA is 
critical.  
 
Substrate Solution: 1:1 mixture of Color Reagent A (H2O2) and Color Reagent B 
(Tetramethylbenzidine).  
 
Stop Solution - 2 N H2SO4  
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Appendix 2 
 
 
Table: Serial dilution of the standard stock solution 
 
Standard No. Standard Volume 2 X Assay Buffer Concentrations 
Stock 500 µl ------- 4000 pg/ml 
# 1 500 µl of stock 500 µl 2000 pg/ml 
# 2 500 µl of # 1 500 µl 1000 pg/ml 
# 3 500 µl of # 2 500 µl 500 pg/ml 
# 4 500 µl of # 3  500 µl 250 pg/ml 
# 5 500 µl of # 4 500 µl 125 pg/ml 
# 6 500 µl of # 5 500 µl 62.5 pg/ml 
# 7 ------- 500 µl 0 pg/ml 
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Appendix 3  
 
Consent form 
 
Study Title: The enzymatic deglycation pathway may be an explanation for the 
variation in glycated HbA1c - Exploring the glycation gap 
 
Name of Researcher:  
Telephone:  (Office),  (mobile) 
E-mail:  
    
              Please initial box 
 
1. I confirm that I have read and understand the information sheet 
dated……(version 1.2 dated5/5/2011………) for the above study 
and have had the opportunity to ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time; without giving a reason, without effecting my 
treatment or my legal rights. 
  
3. I understand that relevant section of my medical notes and data collected during 
the study, may be looked at by the researcher and supervisor(s) at 
New cross hospital, from regulatory authorities or from the NHS trust, 
where it is relevant to my taking in his research. I give permission for 
these individuals to have access to my records.  
 
4. I understand that the project using the sample I give will include DNA 
extraction and genetic research aimed at understanding the genetic 
influences on factors that may influence variation in HbA1c levels but 
that the results of these investigations may be unlikely to have any implications 
for me personally.  
 
 
5. I agree that samples (genetic or otherwise) I have given, and the 
information gathered about me can be stored and possibly used for 
future projects in diabetes, if these projects are approved by local research ethics 
committee. 
 
6. I understand that I will not benefit financially if this research leads to 
the development of a new treatment or medical test 
 
7. I agree to take part in the above study. 
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Thank you for agreeing to participate in this research 
 
 
 
Name of patient  Date  Signature 
Name of person taking consent  
(if different from researcher) 
 Date  Signature 
 
 
Each individual who signs this document must PERSONALLY date his or her 
signature. 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in 
medical notes  
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Appendix 4 
 
Conference presentations 
 
1. Abstract: 468-P 08 June 2017; Simon J. Dunmore, Amr S. Alderawi, Aruna 
Narshi, Fakhra Naseem, James E.P Brown, Alan Nevill, Ananth Nayak, 
Baldev M Singh: Evidence of the Role of Fructosamine-3-Kinase in the 
Glycation Gap and in Protection against Complications in Patients with 
Diabetes.   
 
2. Abstract: 0494-P 06 December 2017; Simon J. Dunmore, Fakhra Naseem, 
James E.P Brown, Adam Watkins, Paul Kirkham, Ananth Nayak, Baldev M 
Singh: Single Nucleotide Polymorphisms (SNPs) in the Fructosamine-3-
Kinase gene as a possible explanation of variation in the glycation gap 
between individuals. 
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